Datasets:
ChatDOC
/
OCRFlux-pubtabnet-cross

Dataset card Data Studio Files Community
1
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
table_fragment_1
stringlengths
43
8.42k
table_fragment_2
stringlengths
39
8.21k
72afa18de3fd3ef5c5918be6d1af39d8cdcb4ac09f2b9260438a3122266c0d9c.png
complex
<table><tr><td>miRNA Migr. / Inv. / Met.</td><td>Targets</td><td>Cells / Tissue</td><td>Expression</td><td>Function</td><td>Reference</td></tr><tr><td>miR-17 family (20a, 20b)</td><td>TGF&#223;R2</td><td>A549/CDDP</td><td>down</td><td>TGF&#223;R2 suppressor, reverses CDDP-resistance and suppresses metastases</td><td>[81]</td></tr><tr><td>miR-21</td><td>PTEN</td><td>Serum, NSCLC cells</td><td>up</td><td>Promotes migration, invasion and metastasis</td><td>[9]</td></tr><tr><td>mir-26b</td><td>PTEN</td><td>NSCLC tissue, NSCLC cells</td><td>down</td><td>Regulates NSCLC migration and CDDP-chemosensitivity</td><td>[78]</td></tr><tr><td>miR-27a</td><td>RKIP</td><td>A549/CDDP</td><td>up</td><td>Regulates EM-transition and CDDP-resistance</td><td>[82]</td></tr><tr><td>miR-98</td><td>PAK1</td><td>NSCLC tissue, A549/PAR</td><td>down</td><td>Inversely regulates PAK1, inhibits migration and invasion</td><td>[51]</td></tr><tr><td>miR-182</td><td>PDCD4</td><td>A549 cells</td><td>up</td><td>Induces resistance to CDDP by targeting PDCD4</td><td>[84]</td></tr><tr><td>miR-200c</td><td>n. d.</td><td>NSCLC cell lines (n=9)</td><td>down</td><td>Inversely correlates with aggressive, invasive and chemoresistant phenotype</td><td>[8]</td></tr><tr><td>miR-206</td><td>MET</td><td>NSCLC tissue, A549/CDDP, H1299/CDDP</td><td>down</td><td>Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways</td><td>[80]</td></tr><tr><td>miR-217</td><td>KRAS</td><td>NSCLC tissue, A549/PAR</td><td>down</td><td>Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP</td><td>[79]</td></tr><tr><td colspan="6">DNA damage response</td></tr><tr><td>miR-17/miR-92 families</td><td>TGF&#223;R2, CDKN1A, RAD21</td><td>A549/CDDP</td><td>down</td><td>Influence CDDP-resistance by synergistic and combined regulation of their target genes</td><td>[127]</td></tr><tr><td>miR-33b-3p</td><td>P21WAF1</td><td>A549/CDDP</td><td>up</td><td>Impairs the DNA damage response</td><td>[128]</td></tr><tr><td colspan="6">miR-92</td></tr><tr><td>miR-138</td><td>ERCC1</td><td>A549/CDDP</td><td>up</td><td>Negatively regulates ERCC1 expression</td><td>[38]</td></tr><tr><td>miR-155</td><td>APAF-1</td><td>NSCLC tissue, A549/PAR</td><td>up</td><td>Inhibits sensitivity to CDDP via negative regulation of Apaf-1</td><td>[37]</td></tr><tr><td>miR-509-3-5p</td><td>PLK1</td><td>CDDP-treated A549/PAR</td><td>down</td><td>Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1</td><td>[20]</td></tr><tr><td>miR-630</td><td>ATM, H2AX, p53</td><td>A549/PAR CDDP-treated</td><td>up</td><td>Blocks DNA-damage response</td><td>[13]</td></tr><tr><td colspan="6">Drug uptake</td></tr><tr><td>miR-15b</td><td>PEBP4</td><td>A549/CDDP, NSCLC tissue</td><td>up</td><td>Suppresses PEBP4 expression and contribute to CDDP-resistance</td><td>[129]</td></tr><tr><td>miR-31-p</td><td>Dicer</td><td>A549 cells</td><td>n. d.</td><td>Enhances sensitivity to CDDP by repressing Dicer</td><td>[130]</td></tr><tr><td>miR-34a</td><td>PEBP4, MYCN</td><td>A549/PAR</td><td>up</td><td>Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression</td><td>[131]</td></tr><tr><td>miR-106a</td><td>ABCA1</td><td>A549/CDDP</td><td>up</td><td>Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis</td><td>[68]</td></tr><tr><td>miR-148b</td><td>DNMT1</td><td>A549/CDDP, SPC-A1/CDDP</td><td>down</td><td>Influence CDDP-sensitivity, cell viability and apoptosis</td><td>[57]</td></tr><tr><td>miR-181a</td><td>PTEN</td><td>A549/CDDP</td><td>up</td><td>Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells</td><td>[46]</td></tr><tr><td>miR-185-5p</td><td>ABCC1</td><td>A549/CDDP</td><td>down</td><td>Promotes CDDP-induced apoptosis by suppressing ABCC1</td><td>[69]</td></tr><tr><td>miR-495</td><td>ATP7A</td><td>NSCLC tissue, A549/CDDP</td><td>down</td><td>Negatively regulates ATP7A and modulates CDDP-induced apoptosis</td><td>[70]</td></tr><tr><td>miR-503</td><td>FANCA</td><td>NSCLC tissue, A549/CDDP</td><td>down</td><td>Regulates CDDP-resistance by targeting FANCA</td><td>[102]</td></tr></table>
<table><tr><td>miRNA Migr. / Inv. / Met.</td><td>Targets</td><td>Cells / Tissue</td></tr><tr><td>miR-17 family (20a, 20b)</td><td>TGFßR2</td><td>A549/CDDP</td></tr><tr><td>miR-21</td><td>PTEN</td><td>Serum, NSCLC cells</td></tr><tr><td>mir-26b</td><td>PTEN</td><td>NSCLC tissue, NSCLC cells</td></tr><tr><td>miR-27a</td><td>RKIP</td><td>A549/CDDP</td></tr><tr><td>miR-98</td><td>PAK1</td><td>NSCLC tissue, A549/PAR</td></tr><tr><td>miR-182</td><td>PDCD4</td><td>A549 cells</td></tr><tr><td>miR-200c</td><td>n. d.</td><td>NSCLC cell lines (n=9)</td></tr><tr><td>miR-206</td><td>MET</td><td>NSCLC tissue, A549/CDDP, H1299/CDDP</td></tr><tr><td>miR-217</td><td>KRAS</td><td>NSCLC tissue, A549/PAR</td></tr><tr><td colspan="3">DNA damage response</td></tr><tr><td>miR-17/miR-92 families</td><td>TGFßR2, CDKN1A, RAD21</td><td>A549/CDDP</td></tr><tr><td>miR-33b-3p</td><td>P21WAF1</td><td>A549/CDDP</td></tr><tr><td colspan="3">miR-92</td></tr><tr><td>miR-138</td><td>ERCC1</td><td>A549/CDDP</td></tr><tr><td>miR-155</td><td>APAF-1</td><td>NSCLC tissue, A549/PAR</td></tr><tr><td>miR-509-3-5p</td><td>PLK1</td><td>CDDP-treated A549/PAR</td></tr><tr><td>miR-630</td><td>ATM, H2AX, p53</td><td>A549/PAR CDDP-treated</td></tr><tr><td colspan="3">Drug uptake</td></tr><tr><td>miR-15b</td><td>PEBP4</td><td>A549/CDDP, NSCLC tissue</td></tr><tr><td>miR-31-p</td><td>Dicer</td><td>A549 cells</td></tr><tr><td>miR-34a</td><td>PEBP4, MYCN</td><td>A549/PAR</td></tr><tr><td>miR-106a</td><td>ABCA1</td><td>A549/CDDP</td></tr><tr><td>miR-148b</td><td>DNMT1</td><td>A549/CDDP, SPC-A1/CDDP</td></tr><tr><td>miR-181a</td><td>PTEN</td><td>A549/CDDP</td></tr><tr><td>miR-185-5p</td><td>ABCC1</td><td>A549/CDDP</td></tr><tr><td>miR-495</td><td>ATP7A</td><td>NSCLC tissue, A549/CDDP</td></tr><tr><td>miR-503</td><td>FANCA</td><td>NSCLC tissue, A549/CDDP</td></tr></table>
<table><tr><td>Expression</td><td>Function</td><td>Reference</td></tr><tr><td>down</td><td>TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases</td><td>[81]</td></tr><tr><td>up</td><td>Promotes migration, invasion and metastasis</td><td>[9]</td></tr><tr><td>down</td><td>Regulates NSCLC migration and CDDP-chemosensitivity</td><td>[78]</td></tr><tr><td>up</td><td>Regulates EM-transition and CDDP-resistance</td><td>[82]</td></tr><tr><td>down</td><td>Inversely regulates PAK1, inhibits migration and invasion</td><td>[51]</td></tr><tr><td>up</td><td>Induces resistance to CDDP by targeting PDCD4</td><td>[84]</td></tr><tr><td>down</td><td>Inversely correlates with aggressive, invasive and chemoresistant phenotype</td><td>[8]</td></tr><tr><td>down</td><td>Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways</td><td>[80]</td></tr><tr><td>down</td><td>Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP</td><td>[79]</td></tr><tr><td colspan="3">DNA damage response</td></tr><tr><td>down</td><td>Influence CDDP-resistance by synergistic and combined regulation of their target genes</td><td>[127]</td></tr><tr><td>up</td><td>Impairs the DNA damage response</td><td>[128]</td></tr><tr><td colspan="3">miR-92</td></tr><tr><td>up</td><td>Negatively regulates ERCC1 expression</td><td>[38]</td></tr><tr><td>up</td><td>Inhibits sensitivity to CDDP via negative regulation of Apaf-1</td><td>[37]</td></tr><tr><td>down</td><td>Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1</td><td>[20]</td></tr><tr><td>up</td><td>Blocks DNA-damage response</td><td>[13]</td></tr><tr><td colspan="3">Drug uptake</td></tr><tr><td>up</td><td>Suppresses PEBP4 expression and contribute to CDDP-resistance</td><td>[129]</td></tr><tr><td>n. d.</td><td>Enhances sensitivity to CDDP by repressing Dicer</td><td>[130]</td></tr><tr><td>up</td><td>Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression</td><td>[131]</td></tr><tr><td>up</td><td>Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis</td><td>[68]</td></tr><tr><td>down</td><td>Influence CDDP-sensitivity, cell viability and apoptosis</td><td>[57]</td></tr><tr><td>up</td><td>Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells</td><td>[46]</td></tr><tr><td>down</td><td>Promotes CDDP-induced apoptosis by suppressing ABCC1</td><td>[69]</td></tr><tr><td>down</td><td>Negatively regulates ATP7A and modulates CDDP-induced apoptosis</td><td>[70]</td></tr><tr><td>down</td><td>Regulates CDDP-resistance by targeting FANCA</td><td>[102]</td></tr></table>
86819affa162f5883bd2baf27ed966441ecd2aac6efd775eb6c7ed5c01e6688b.png
simple
<table><tr><td></td><td>AC-</td><td>AC+</td></tr><tr><td>2.5 Gy/fraction</td><td>94 (A1)</td><td>83 (A3)</td></tr><tr><td>2.0 Gy/fraction</td><td>142 (A2)</td><td>114 (A4)</td></tr></table>
<table><tr><td></td></tr><tr><td>2.5 Gy/fraction</td></tr><tr><td>2.0 Gy/fraction</td></tr></table>
<table><tr><td>AC-</td><td>AC+</td></tr><tr><td>94 (A1)</td><td>83 (A3)</td></tr><tr><td>142 (A2)</td><td>114 (A4)</td></tr></table>
069b2ffed479cef0278b60a392eb3238f35b0651e83b6f772225bd5be452de33.png
complex
<table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log<sub>2</sub> (RPKM<sub>OXR</sub>/RPKM<sub>WT</sub>)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td colspan="5">Catalase (CAT)</td></tr><tr><td>Os06t0727200-01</td><td>0.79</td><td>1.36 **</td><td>0.79</td><td>catalase isozyme B (EC 1.11.1.6)</td></tr><tr><td colspan="5">Ascorbate peroxidase (APX)</td></tr><tr><td>Os04t0602100-01</td><td>&#8722;1.77 *</td><td>&#8722;2.21 *</td><td>&#8722;1.34 *</td><td>l-ascorbate peroxidase</td></tr><tr><td colspan="5">Peroxiredoxin (PrxR)</td></tr><tr><td>Os06t0196300-01</td><td>&#8722;1.64 *</td><td>&#8722;0.49</td><td>0.77</td><td>similar to peroxiredoxin Q</td></tr><tr><td colspan="5">Glutathione S-transferase (GST)</td></tr><tr><td>Os04t0435500-01</td><td>&#8722;0.72</td><td>&#8722;1.03 *</td><td>&#8722;0.15</td><td>glutathione S-transferase, c-terminal-like domain containing protein</td></tr><tr><td>Os10t0530500-01</td><td>&#8722;1.42 *</td><td>&#8722;1.78 *</td><td>&#8722;2.0 *</td><td>similar to glutathione-S-transferase</td></tr><tr><td colspan="5">Peroxidase superfamily protein</td></tr><tr><td>Os07t0677200-01</td><td>&#8722;0.04</td><td>2.81 **</td><td>0.64</td><td>peroxidase</td></tr><tr><td>Os07t0677400-00</td><td>&#8722;1.47 *</td><td>&#8722;0.28</td><td>&#8722;0.02</td><td>peroxidase.</td></tr><tr><td>Os04t0688100-01</td><td>0.45</td><td>2.21 **</td><td>0.18</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os04t0688100-02</td><td>0.79</td><td>1.87 **</td><td>0.58</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os04t0688500-01</td><td>0.9</td><td>2.72 **</td><td>1.21 **</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os10t0109300-01</td><td>0.35</td><td>1.94 **</td><td>0.17</td><td>similar to peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os01t0263300-01</td><td>0.44</td><td>1.42 **</td><td>&#8722;0.6</td><td>similar to peroxidase 72 precursor (EC 1.11.1.7)</td></tr><tr><td>Os01t0962700-01</td><td>0.47</td><td>1.11 **</td><td>&#8722;0.16</td><td>similar to peroxidase 12 precursor (EC 1.11.1.7)</td></tr><tr><td>Os01t0963000-01</td><td>1.01 **</td><td>4.55 **</td><td>1.38 **</td><td>similar to peroxidase BP 1 precursor</td></tr><tr><td>Os06t0547400-01</td><td>0.73</td><td>1.76 **</td><td>1.03 **</td><td>similar to peroxidase P7 (EC 1.11.1.7)</td></tr><tr><td>Os06t0695500-01</td><td>0.01</td><td>2.19 **</td><td>&#8722;0.44</td><td>similar to peroxidase 16 precursor (EC 1.11.1.7)</td></tr><tr><td>Os04t0688300-01</td><td>1.02 **</td><td>3.24 **</td><td>1.77 **</td><td>Haem peroxidase, plant/fungal/bacterial family protein.</td></tr><tr><td>Os01t0326300-01</td><td>&#8722;0.07</td><td>1.92**</td><td>0.24</td><td>Haem peroxidase, plant/fungal/bacterial family protein.</td></tr><tr><td>Os06t0521500-01</td><td>1.26 **</td><td>3.09 **</td><td>0.82</td><td>Haem peroxidase family protein.</td></tr><tr><td>Os06t0306300-01</td><td>0.42</td><td>1.94 **</td><td>0</td><td>Haem peroxidase domain containing protein.</td></tr><tr><td>Os02t0684400-01</td><td>0.24</td><td>1.33 **</td><td>0</td><td>similar to OXS3 (OXIDATIVE STRESS 3)</td></tr><tr><td colspan="5">Dehydrogenase/reductase</td></tr><tr><td>Os04t0531900-01</td><td>0.62</td><td>1.05 **</td><td>&#8722;0.07</td><td>short-chain dehydrogenase/reductase SDR domain-containing protein</td></tr><tr><td>Os11t0484500-01</td><td>0.31</td><td>&#8722;0.76</td><td>&#8722;1.23 *</td><td>similar to 6-phosphogluconate dehydrogenase</td></tr></table>
<table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log2 (RPKMOXR/RPKMWT)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td colspan="5">Catalase (CAT)</td></tr><tr><td>Os06t0727200-01</td><td>0.79</td><td>1.36 **</td><td>0.79</td><td>catalase isozyme B (EC 1.11.1.6)</td></tr><tr><td colspan="5">Ascorbate peroxidase (APX)</td></tr><tr><td>Os04t0602100-01</td><td>−1.77 *</td><td>−2.21 *</td><td>−1.34 *</td><td>l-ascorbate peroxidase</td></tr><tr><td colspan="5">Peroxiredoxin (PrxR)</td></tr><tr><td>Os06t0196300-01</td><td>−1.64 *</td><td>−0.49</td><td>0.77</td><td>similar to peroxiredoxin Q</td></tr><tr><td colspan="5">Glutathione S-transferase (GST)</td></tr><tr><td>Os04t0435500-01</td><td>−0.72</td><td>−1.03 *</td><td>−0.15</td><td>glutathione S-transferase, c-terminal-like domain containing protein</td></tr><tr><td>Os10t0530500-01</td><td>−1.42 *</td><td>−1.78 *</td><td>−2.0 *</td><td>similar to glutathione-S-transferase</td></tr><tr><td colspan="5">Peroxidase superfamily protein</td></tr><tr><td>Os07t0677200-01</td><td>−0.04</td><td>2.81 **</td><td>0.64</td><td>peroxidase</td></tr><tr><td>Os07t0677400-00</td><td>−1.47 *</td><td>−0.28</td><td>−0.02</td><td>peroxidase.</td></tr><tr><td>Os04t0688100-01</td><td>0.45</td><td>2.21 **</td><td>0.18</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os04t0688100-02</td><td>0.79</td><td>1.87 **</td><td>0.58</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os04t0688500-01</td><td>0.9</td><td>2.72 **</td><td>1.21 **</td><td>peroxidase (EC 1.11.1.7)</td></tr><tr><td>Os10t0109300-01</td><td>0.35</td><td>1.94 **</td><td>0.17</td><td>similar to peroxidase (EC 1.11.1.7)</td></tr></table>
<table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log2 (RPKMOXR/RPKMWT)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td>Os01t0263300-01</td><td>0.44</td><td>1.42 **</td><td>−0.6</td><td>similar to peroxidase 72 precursor (EC 1.11.1.7)</td></tr><tr><td>Os01t0962700-01</td><td>0.47</td><td>1.11 **</td><td>−0.16</td><td>similar to peroxidase 12 precursor (EC 1.11.1.7)</td></tr><tr><td>Os01t0963000-01</td><td>1.01 **</td><td>4.55 **</td><td>1.38 **</td><td>similar to peroxidase BP 1 precursor</td></tr><tr><td>Os06t0547400-01</td><td>0.73</td><td>1.76 **</td><td>1.03 **</td><td>similar to peroxidase P7 (EC 1.11.1.7)</td></tr><tr><td>Os06t0695500-01</td><td>0.01</td><td>2.19 **</td><td>−0.44</td><td>similar to peroxidase 16 precursor (EC 1.11.1.7)</td></tr><tr><td>Os04t0688300-01</td><td>1.02 **</td><td>3.24 **</td><td>1.77 **</td><td>Haem peroxidase, plant/fungal/bacterial family protein.</td></tr><tr><td>Os01t0326300-01</td><td>−0.07</td><td>1.92**</td><td>0.24</td><td>Haem peroxidase, plant/fungal/bacterial family protein.</td></tr><tr><td>Os06t0521500-01</td><td>1.26 **</td><td>3.09 **</td><td>0.82</td><td>Haem peroxidase family protein.</td></tr><tr><td>Os06t0306300-01</td><td>0.42</td><td>1.94 **</td><td>0</td><td>Haem peroxidase domain containing protein.</td></tr><tr><td>Os02t0684400-01</td><td>0.24</td><td>1.33 **</td><td>0</td><td>similar to OXS3 (OXIDATIVE STRESS 3)</td></tr><tr><td colspan="5">Dehydrogenase/reductase</td></tr><tr><td>Os04t0531900-01</td><td>0.62</td><td>1.05 **</td><td>−0.07</td><td>short-chain dehydrogenase/reductase SDR domain-containing protein</td></tr><tr><td>Os11t0484500-01</td><td>0.31</td><td>−0.76</td><td>−1.23 *</td><td>similar to 6-phosphogluconate dehydrogenase</td></tr></table>
33c414e689ec1b56672aecf6d272d53ca0e00f4ec0c1f0cfa129dddd4de9ec69.png
complex
<table><tr><td>50 years +</td><td colspan="2">Female</td><td colspan="2">Male</td><td colspan="2">Total</td></tr><tr><td></td><td>N</td><td>%</td><td>n</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Circulatory system diseases</td><td>29</td><td>27.6</td><td>19</td><td>18.6</td><td>48</td><td>23.2</td></tr><tr><td>Tuberculosis</td><td>7</td><td>6.7</td><td>10</td><td>9.8</td><td>17</td><td>8.2</td></tr><tr><td>Malaria</td><td>8</td><td>7.6</td><td>8</td><td>7.8</td><td>16</td><td>7.7</td></tr><tr><td>Intestinal infectious diseases (diarrhea)</td><td>3</td><td>2.9</td><td>6</td><td>5.9</td><td>9</td><td>4.3</td></tr><tr><td>Malignant neoplasms</td><td>5</td><td>4.8</td><td>3</td><td>2.9</td><td>8</td><td>3.9</td></tr><tr><td>Traffic accidents</td><td>2</td><td>1.9</td><td>5</td><td>4.9</td><td>7</td><td>3.4</td></tr><tr><td>Acute respiratory infections (pneumonia)</td><td>4</td><td>3.8</td><td>3</td><td>2.9</td><td>7</td><td>3.4</td></tr><tr><td>HIV</td><td>4</td><td>3.8</td><td>1</td><td>1.0</td><td>5</td><td>2.4</td></tr><tr><td>Diabetes Mellitus</td><td>1</td><td>1.0</td><td>4</td><td>3.9</td><td>5</td><td>2.4</td></tr><tr><td>Digestive system</td><td>1</td><td>1.0</td><td>3</td><td>2.9</td><td>4</td><td>1.9</td></tr><tr><td>Intentional self-harm</td><td>2</td><td>1.9</td><td>1</td><td>1.0</td><td>3</td><td>1.4</td></tr><tr><td>Accidental drowning and sub.</td><td>0</td><td>0.0</td><td>2</td><td>2.0</td><td>2</td><td>1.0</td></tr><tr><td>Rabies</td><td>1</td><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>Mental and behavioural disorders</td><td>0</td><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>Infections of the skin and subcutaneous tissue</td><td>0</td><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>Injury of unspecified body region</td><td>1</td><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>Exposure to unspecified electric current</td><td>1</td><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>Sepsis</td><td>0</td><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>Asthma</td><td>0</td><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>Unknow (R95-R99)</td><td>1</td><td>1.0</td><td>6</td><td>5.9</td><td>7</td><td>3.4</td></tr><tr><td>Indeterminate</td><td>35</td><td>33.3</td><td>27</td><td>26.5</td><td>62</td><td>30.0</td></tr><tr><td>Total</td><td>105</td><td></td><td>102</td><td></td><td>207</td><td></td></tr></table>
<table><tr><td>50 years +</td><td>Female</td></tr><tr><td></td><td>N</td></tr><tr><td>Circulatory system diseases</td><td>29</td></tr><tr><td>Tuberculosis</td><td>7</td></tr><tr><td>Malaria</td><td>8</td></tr><tr><td>Intestinal infectious diseases (diarrhea)</td><td>3</td></tr><tr><td>Malignant neoplasms</td><td>5</td></tr><tr><td>Traffic accidents</td><td>2</td></tr><tr><td>Acute respiratory infections (pneumonia)</td><td>4</td></tr><tr><td>HIV</td><td>4</td></tr><tr><td>Diabetes Mellitus</td><td>1</td></tr><tr><td>Digestive system</td><td>1</td></tr><tr><td>Intentional self-harm</td><td>2</td></tr><tr><td>Accidental drowning and sub.</td><td>0</td></tr><tr><td>Rabies</td><td>1</td></tr><tr><td>Mental and behavioural disorders</td><td>0</td></tr><tr><td>Infections of the skin and subcutaneous tissue</td><td>0</td></tr><tr><td>Injury of unspecified body region</td><td>1</td></tr><tr><td>Exposure to unspecified electric current</td><td>1</td></tr><tr><td>Sepsis</td><td>0</td></tr><tr><td>Asthma</td><td>0</td></tr><tr><td>Unknow (R95-R99)</td><td>1</td></tr><tr><td>Indeterminate</td><td>35</td></tr><tr><td>Total</td><td>105</td></tr></table>
<table><tr><td>Female</td><td colspan="2">Male</td><td colspan="2">Total</td></tr><tr><td>%</td><td>n</td><td>%</td><td>N</td><td>%</td></tr><tr><td>27.6</td><td>19</td><td>18.6</td><td>48</td><td>23.2</td></tr><tr><td>6.7</td><td>10</td><td>9.8</td><td>17</td><td>8.2</td></tr><tr><td>7.6</td><td>8</td><td>7.8</td><td>16</td><td>7.7</td></tr><tr><td>2.9</td><td>6</td><td>5.9</td><td>9</td><td>4.3</td></tr><tr><td>4.8</td><td>3</td><td>2.9</td><td>8</td><td>3.9</td></tr><tr><td>1.9</td><td>5</td><td>4.9</td><td>7</td><td>3.4</td></tr><tr><td>3.8</td><td>3</td><td>2.9</td><td>7</td><td>3.4</td></tr><tr><td>3.8</td><td>1</td><td>1.0</td><td>5</td><td>2.4</td></tr><tr><td>1.0</td><td>4</td><td>3.9</td><td>5</td><td>2.4</td></tr><tr><td>1.0</td><td>3</td><td>2.9</td><td>4</td><td>1.9</td></tr><tr><td>1.9</td><td>1</td><td>1.0</td><td>3</td><td>1.4</td></tr><tr><td>0.0</td><td>2</td><td>2.0</td><td>2</td><td>1.0</td></tr><tr><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>1.0</td><td>0</td><td>0.0</td><td>1</td><td>0.5</td></tr><tr><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>0.0</td><td>1</td><td>1.0</td><td>1</td><td>0.5</td></tr><tr><td>1.0</td><td>6</td><td>5.9</td><td>7</td><td>3.4</td></tr><tr><td>33.3</td><td>27</td><td>26.5</td><td>62</td><td>30.0</td></tr><tr><td></td><td>102</td><td></td><td>207</td><td></td></tr></table>
8d2f0fba4ded7277dc979d18dd963bdfae5e5a130385538edf293b668d77389b.png
simple
<table><tr><td>Device</td><td>Structure</td><td>Thickness (nm)</td><td><i>a</i> (nm)</td><td><i>n</i></td><td><i>&#955;</i> (nm)</td><td><i>s</i> (&#956;m)</td><td><i>&#951;</i></td></tr><tr><td>A1</td><td>YIG/Ti/Co</td><td>20/1/25</td><td>200</td><td>2, 4</td><td>100</td><td>30</td><td>95%</td></tr><tr><td>A2</td><td>YIG/Ti/Co</td><td>20/1/25</td><td>180</td><td>2, 4, 6</td><td>60</td><td>30</td><td>106%</td></tr><tr><td>A3</td><td>YIG/Ti/Co</td><td>20/1/50</td><td>180</td><td>4</td><td>90</td><td>60</td><td>61%</td></tr><tr><td>A4</td><td>YIG/Al<sub>2</sub>O<sub>3</sub>/Co</td><td>20/7/30</td><td>600</td><td>14, 16</td><td>75</td><td>30</td><td>11%<sup>a</sup></td></tr><tr><td>B1</td><td>YIG/Ti/Ni</td><td>20/2/20</td><td>600</td><td>4, 6, 8, 10</td><td>120</td><td>30</td><td>21%</td></tr><tr><td>C1</td><td>YIG/Ti/CoFe</td><td>20/1/50</td><td>200</td><td>2, 4, 6, 8</td><td>50</td><td>15</td><td>98%</td></tr><tr><td>C2</td><td>YIG/Al<sub>2</sub>O<sub>3</sub>/CoFe</td><td>20/25/50</td><td>200</td><td>2, 4</td><td>100</td><td>15</td><td>41%</td></tr></table>
<table><tr><td>Device</td><td>Structure</td></tr><tr><td>A1</td><td>YIG/Ti/Co</td></tr><tr><td>A2</td><td>YIG/Ti/Co</td></tr><tr><td>A3</td><td>YIG/Ti/Co</td></tr><tr><td>A4</td><td>YIG/Al2O3/Co</td></tr><tr><td>B1</td><td>YIG/Ti/Ni</td></tr><tr><td>C1</td><td>YIG/Ti/CoFe</td></tr><tr><td>C2</td><td>YIG/Al2O3/CoFe</td></tr></table>
<table><tr><td>Thickness (nm)</td><td>a (nm)</td><td>n</td><td>λ (nm)</td><td>s (μm)</td><td>η</td></tr><tr><td>20/1/25</td><td>200</td><td>2, 4</td><td>100</td><td>30</td><td>95%</td></tr><tr><td>20/1/25</td><td>180</td><td>2, 4, 6</td><td>60</td><td>30</td><td>106%</td></tr><tr><td>20/1/50</td><td>180</td><td>4</td><td>90</td><td>60</td><td>61%</td></tr><tr><td>20/7/30</td><td>600</td><td>14, 16</td><td>75</td><td>30</td><td>11%a</td></tr><tr><td>20/2/20</td><td>600</td><td>4, 6, 8, 10</td><td>120</td><td>30</td><td>21%</td></tr><tr><td>20/1/50</td><td>200</td><td>2, 4, 6, 8</td><td>50</td><td>15</td><td>98%</td></tr><tr><td>20/25/50</td><td>200</td><td>2, 4</td><td>100</td><td>15</td><td>41%</td></tr></table>
a7044b7715752653954a10520b1d9dc5677a00fce4369578a9ba5b6e97c28056.png
complex
<table><tr><td>Sample</td><td colspan="2">Superoxide Anion Generation (Inh %)</td><td colspan="2">Elastase Release (Inh %)</td></tr><tr><td>A-EtOH</td><td>90.1 &#177; 5.3</td><td>**</td><td>85.3 &#177; 0.8</td><td>**</td></tr><tr><td>A-BuOH</td><td>93.9 &#177; 8.3</td><td>**</td><td>77.6 &#177; 2.4</td><td>**</td></tr><tr><td>A-Water</td><td>11.4 &#177; 1.6</td><td>*</td><td>2.7 &#177; 4.1</td><td>&#8211;</td></tr><tr><td>A-EtOAc</td><td>94.8 &#177; 5.6</td><td>**</td><td>85.4 &#177; 1.8</td><td>**</td></tr><tr><td>A-Hexane</td><td>103.4 &#177; 1.8</td><td>**</td><td>80.2 &#177; 4.0</td><td>**</td></tr><tr><td>A-MeOH</td><td>96.5 &#177; 8.0</td><td>**</td><td>90.4 &#177; 6.0</td><td>**</td></tr><tr><td>AM1</td><td>54.5 &#177; 5.7</td><td>**</td><td>99.2 &#177; 2.3</td><td>**</td></tr><tr><td>AM2</td><td>68.7 &#177; 5.0</td><td>**</td><td>47.5 &#177; 5.3</td><td>**</td></tr><tr><td>AM3</td><td>105.9 &#177; 3.4</td><td>**</td><td>86.8 &#177; 2.0</td><td>**</td></tr><tr><td>AM4</td><td>100.7 &#177; 8.1</td><td>**</td><td>70.9 &#177; 1.0</td><td>**</td></tr><tr><td>AM5</td><td>102.6 &#177; 1.5</td><td>**</td><td>93.5 &#177; 3.7</td><td>**</td></tr><tr><td>AM6</td><td>102.4 &#177; 2.0</td><td>**</td><td>99.3 &#177; 2.3</td><td>**</td></tr></table>
<table><tr><td>Sample</td></tr><tr><td>A-EtOH</td></tr><tr><td>A-BuOH</td></tr><tr><td>A-Water</td></tr><tr><td>A-EtOAc</td></tr><tr><td>A-Hexane</td></tr><tr><td>A-MeOH</td></tr><tr><td>AM1</td></tr><tr><td>AM2</td></tr><tr><td>AM3</td></tr><tr><td>AM4</td></tr><tr><td>AM5</td></tr><tr><td>AM6</td></tr></table>
<table><tr><td colspan="2">Superoxide Anion Generation (Inh %)</td><td colspan="2">Elastase Release (Inh %)</td></tr><tr><td>90.1 ± 5.3</td><td>**</td><td>85.3 ± 0.8</td><td>**</td></tr><tr><td>93.9 ± 8.3</td><td>**</td><td>77.6 ± 2.4</td><td>**</td></tr><tr><td>11.4 ± 1.6</td><td>*</td><td>2.7 ± 4.1</td><td>–</td></tr><tr><td>94.8 ± 5.6</td><td>**</td><td>85.4 ± 1.8</td><td>**</td></tr><tr><td>103.4 ± 1.8</td><td>**</td><td>80.2 ± 4.0</td><td>**</td></tr><tr><td>96.5 ± 8.0</td><td>**</td><td>90.4 ± 6.0</td><td>**</td></tr><tr><td>54.5 ± 5.7</td><td>**</td><td>99.2 ± 2.3</td><td>**</td></tr><tr><td>68.7 ± 5.0</td><td>**</td><td>47.5 ± 5.3</td><td>**</td></tr><tr><td>105.9 ± 3.4</td><td>**</td><td>86.8 ± 2.0</td><td>**</td></tr><tr><td>100.7 ± 8.1</td><td>**</td><td>70.9 ± 1.0</td><td>**</td></tr><tr><td>102.6 ± 1.5</td><td>**</td><td>93.5 ± 3.7</td><td>**</td></tr><tr><td>102.4 ± 2.0</td><td>**</td><td>99.3 ± 2.3</td><td>**</td></tr></table>
b5afabe4f42bbad4cf5ce15df13037eeff8796ddf001de024bb6ee2a05a6d004.png
simple
<table><tr><td></td><td>E50</td><td>E60</td><td>E70</td></tr><tr><td>Total clean reads</td><td>57,050,205</td><td>60,029,490</td><td>61,295,544</td></tr><tr><td>Total clean nucleotides</td><td>11,410,041,000</td><td>12,005,898,000</td><td>12,259,308,800</td></tr><tr><td>Total trinity transcripts</td><td>61,057</td><td>342,255</td><td>192,448</td></tr><tr><td>Total trinity components</td><td>49,282</td><td>279,928</td><td>158,626</td></tr><tr><td>Contig N50</td><td>1379</td><td>1159</td><td>825</td></tr><tr><td>Median contig length</td><td>536</td><td>352</td><td>279</td></tr><tr><td>Average contig</td><td>909</td><td>695</td><td>536</td></tr><tr><td>Total assembled bases</td><td>55,473,630</td><td>237,734,046</td><td>103,165,360</td></tr><tr><td>Percent GC (%)</td><td>48</td><td>51</td><td>47</td></tr><tr><td>Q20 percentage (%)</td><td>98</td><td>98.4</td><td>98.6</td></tr></table>
<table><tr><td></td></tr><tr><td>Total clean reads</td></tr><tr><td>Total clean nucleotides</td></tr><tr><td>Total trinity transcripts</td></tr><tr><td>Total trinity components</td></tr><tr><td>Contig N50</td></tr><tr><td>Median contig length</td></tr><tr><td>Average contig</td></tr><tr><td>Total assembled bases</td></tr><tr><td>Percent GC (%)</td></tr><tr><td>Q20 percentage (%)</td></tr></table>
<table><tr><td>E50</td><td>E60</td><td>E70</td></tr><tr><td>57,050,205</td><td>60,029,490</td><td>61,295,544</td></tr><tr><td>11,410,041,000</td><td>12,005,898,000</td><td>12,259,308,800</td></tr><tr><td>61,057</td><td>342,255</td><td>192,448</td></tr><tr><td>49,282</td><td>279,928</td><td>158,626</td></tr><tr><td>1379</td><td>1159</td><td>825</td></tr><tr><td>536</td><td>352</td><td>279</td></tr><tr><td>909</td><td>695</td><td>536</td></tr><tr><td>55,473,630</td><td>237,734,046</td><td>103,165,360</td></tr><tr><td>48</td><td>51</td><td>47</td></tr><tr><td>98</td><td>98.4</td><td>98.6</td></tr></table>
2c2395d9674077ece93f47e1d15bc3bbf433a90396972c7b4c94e4bf60fb06a3.png
simple
<table><tr><td>OD values</td><td>Biofilm formation</td></tr><tr><td>&#8804;ODc</td><td>Non</td></tr><tr><td>2 &#215; ODc &#8804; OD &gt; ODc</td><td>Weak</td></tr><tr><td>4 &#215; ODc &#8804; OD &gt; 2 &#215; ODc</td><td>Moderate</td></tr><tr><td>&gt;4 &#215; ODc</td><td>High</td></tr></table>
<table><tr><td>OD values</td></tr><tr><td>≤ODc</td></tr><tr><td>2 × ODc ≤ OD > ODc</td></tr><tr><td>4 × ODc ≤ OD > 2 × ODc</td></tr><tr><td>>4 × ODc</td></tr></table>
<table><tr><td>Biofilm formation</td></tr><tr><td>Non</td></tr><tr><td>Weak</td></tr><tr><td>Moderate</td></tr><tr><td>High</td></tr></table>
64e25abec7ade13432c1e06de9221d66dd08c2f4cf3dea67e580cc14efde4a77.png
complex
<table><tr><td>Scale</td><td>Subscale</td><td> M</td><td> SD</td><td>Extreme negative responders (%)<sup>a</sup></td></tr><tr><td rowspan="4">Marcus</td><td>Prognosis for recovery (recovery)</td><td>3.01</td><td>1.37</td><td>&#8212;</td></tr><tr><td>Alcoholism and character defect (character defect)</td><td>2.59</td><td>1.22</td><td>&#8212;</td></tr><tr><td>Social status of the alcoholic (social status)</td><td>2.91</td><td>1.02</td><td>&#8212;</td></tr><tr><td>Alcoholism as an illness (illness)</td><td>3.13</td><td>1.67</td><td>4.2</td></tr><tr><td rowspan="3">Seaman-Mannello</td><td>Personal/professional satisfaction (satisfaction)</td><td>3.17</td><td>1.27</td><td>12.5</td></tr><tr><td>Inclination to identify (&#8220;helpable&#8221;)</td><td>4.17</td><td>.982</td><td>&#8212;</td></tr><tr><td>Personal attitudes toward drinking (personal drinking)</td><td>4.56</td><td>1.15</td><td>&#8212;</td></tr><tr><td rowspan="6">SAAPPQ</td><td>Work satisfaction (satisfaction)</td><td>3.66</td><td>1.11</td><td>8.2</td></tr><tr><td>Role adequacy</td><td>4.04</td><td>1.33</td><td>4.1</td></tr><tr><td>Role legitimacy</td><td>4.87</td><td>1.14</td><td>2.0</td></tr><tr><td>Task specific self-esteem (self-esteem)</td><td>4.96</td><td>1.22</td><td>16.7</td></tr><tr><td>I want to work with drinkers (desire)</td><td>3.40</td><td>1.23</td><td>14.3</td></tr><tr><td>Pessimism is the most attitude to take toward drinkers (pessimism)</td><td>2.85</td><td>1.40</td><td>2.0</td></tr></table>
<table><tr><td>Scale</td><td>Subscale</td><td>M</td><td>SD</td><td>Extreme negative responders (%)a</td></tr><tr><td rowspan="4">Marcus</td><td>Prognosis for recovery (recovery)</td><td>3.01</td><td>1.37</td><td>—</td></tr><tr><td>Alcoholism and character defect (character defect)</td><td>2.59</td><td>1.22</td><td>—</td></tr><tr><td>Social status of the alcoholic (social status)</td><td>2.91</td><td>1.02</td><td>—</td></tr><tr><td>Alcoholism as an illness (illness)</td><td>3.13</td><td>1.67</td><td>4.2</td></tr><tr><td rowspan="3">Seaman-Mannello</td><td>Personal/professional satisfaction (satisfaction)</td><td>3.17</td><td>1.27</td><td>12.5</td></tr><tr><td>Inclination to identify (“helpable”)</td><td>4.17</td><td>.982</td><td>—</td></tr><tr><td>Personal attitudes toward drinking (personal drinking)</td><td>4.56</td><td>1.15</td><td>—</td></tr><tr><td rowspan="5">SAAPPQ</td><td>Work satisfaction (satisfaction)</td><td>3.66</td><td>1.11</td><td>8.2</td></tr><tr><td>Role adequacy</td><td>4.04</td><td>1.33</td><td>4.1</td></tr><tr><td>Role legitimacy</td><td>4.87</td><td>1.14</td><td>2.0</td></tr><tr><td>Task specific self-esteem (self-esteem)</td><td>4.96</td><td>1.22</td><td>16.7</td></tr><tr><td>I want to work with drinkers (desire)</td><td>3.40</td><td>1.23</td><td>14.3</td></tr></table>
<table><tr><td>Scale</td><td>Subscale</td><td>M</td><td>SD</td><td>Extreme negative responders (%)a</td></tr><tr><td>SAAPPQ</td><td>Pessimism is the most attitude to take toward drinkers (pessimism)</td><td>2.85</td><td>1.40</td><td>2.0</td></tr></table>
25ae47e661d45b275e7437513f9f9c1a91f1c52f5708b7c8b7d05d15e702c4b7.png
complex
<table><tr><td></td><td colspan="4">Patients</td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Management</td><td></td><td></td><td></td><td></td></tr><tr><td>Operation</td><td>No</td><td>Resection and IVC PTFE Patch</td><td>Resection and primary repair</td><td>Resection and IVC Vein Patch</td></tr><tr><td>Chemotherapy</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Adjuvant therapy</td><td>None</td><td>Radiotherapy</td><td>None</td><td>Radiotherapy</td></tr><tr><td>Histological grade</td><td>High</td><td>High</td><td>High</td><td>High</td></tr><tr><td>Complications</td><td></td><td></td><td></td><td></td></tr><tr><td>Limb oedema</td><td>NA</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Venous insufficiency</td><td>NA</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Other</td><td>None</td><td>No</td><td>CVA</td><td>No</td></tr><tr><td>Follow-up</td><td></td><td></td><td></td><td></td></tr><tr><td>Recurrence</td><td>-</td><td>No</td><td>Yes (5 months)</td><td>No</td></tr><tr><td>Status</td><td>Dead</td><td>Dead</td><td>Dead</td><td>Alive</td></tr><tr><td>Survival</td><td>36 months</td><td>30 months</td><td>7 months</td><td>16 months</td></tr></table>
<table><tr><td></td><td colspan="3">Patients</td></tr><tr><td></td><td>1</td><td>2</td><td>3</td></tr><tr><td>Management</td><td></td><td></td><td></td></tr><tr><td>Operation</td><td>No</td><td>Resection and IVC PTFE Patch</td><td>Resection and primary repair</td></tr><tr><td>Chemotherapy</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Adjuvant therapy</td><td>None</td><td>Radiotherapy</td><td>None</td></tr><tr><td>Histological grade</td><td>High</td><td>High</td><td>High</td></tr><tr><td>Complications</td><td></td><td></td><td></td></tr><tr><td>Limb oedema</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>Venous insufficiency</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>Other</td><td>None</td><td>No</td><td>CVA</td></tr><tr><td>Follow-up</td><td></td><td></td><td></td></tr><tr><td>Recurrence</td><td>-</td><td>No</td><td>Yes (5 months)</td></tr><tr><td>Status</td><td>Dead</td><td>Dead</td><td>Dead</td></tr><tr><td>Survival</td><td>36 months</td><td>30 months</td><td>7 months</td></tr></table>
<table><tr><td>Patients</td></tr><tr><td>4</td></tr><tr><td></td></tr><tr><td>Resection and IVC Vein Patch</td></tr><tr><td>No</td></tr><tr><td>Radiotherapy</td></tr><tr><td>High</td></tr><tr><td></td></tr><tr><td>No</td></tr><tr><td>No</td></tr><tr><td>No</td></tr><tr><td></td></tr><tr><td>No</td></tr><tr><td>Alive</td></tr><tr><td>16 months</td></tr></table>
fc3f005704356b5711a1909e38424d8059caa9b22d067007f1a692ddea8edba1.png
complex
<table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months of<i>negative</i>diagnosis)</td><td>(within 3 months of<i>positive</i>diagnosis)</td><td>(3 months after treatment initiation)</td></tr><tr><td>Health literacy</td><td>Rapid Estimate of Adult Literacy in Medicine[25]</td><td>X</td><td> </td><td> </td><td> </td></tr><tr><td>Comorbid conditions that may alter risk of mortality</td><td>Charlson Comorbidity Index[24]</td><td>X</td><td> </td><td> </td><td> </td></tr><tr><td>Anxiety and stress</td><td>Perceived Stress Scale[26]</td><td>X</td><td> </td><td> </td><td> </td></tr><tr><td>Perceived functional support</td><td>Medical Outcomes Study-Social Support Survey[27]</td><td>X</td><td> </td><td> </td><td> </td></tr><tr><td>Predisposition for fatalistic attitudes directed at health</td><td>Wallston Multi-Dimensional Locus of Control[28]</td><td>X</td><td> </td><td> </td><td>X</td></tr><tr><td>Distrust towards health care system</td><td>Health Care System Distrust[29]</td><td>X</td><td>X</td><td> </td><td>X</td></tr><tr><td>Patient engagement in own health care</td><td>*Communication and Attitudinal Self-Efficacy - General[30]</td><td> </td><td>X</td><td> </td><td> </td></tr><tr><td>Patient engagement in own cancer care</td><td>*Communication and Attitudinal Self-Efficacy - Cancer[30]</td><td> </td><td> </td><td> </td><td>X</td></tr><tr><td>Subjective distress related to a specific event</td><td>*Impact of Events[31]</td><td> </td><td>X</td><td>X</td><td>X</td></tr><tr><td>Satisfaction with cancer-related care</td><td>*Patient Satisfaction with Care[32]</td><td> </td><td>X</td><td>X</td><td>X</td></tr><tr><td>Satisfaction with patient navigation services</td><td>Patient Satisfaction with Navigator[33]</td><td> </td><td>X</td><td>X</td><td>X</td></tr></table>
<table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months ofnegativediagnosis)</td><td>(within 3 months ofpositivediagnosis)</td><td>(3 months after treatment initiation)</td></tr><tr><td>Health literacy</td><td>Rapid Estimate of Adult Literacy in Medicine[25]</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Comorbid conditions that may alter risk of mortality</td><td>Charlson Comorbidity Index[24]</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Anxiety and stress</td><td>Perceived Stress Scale[26]</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Perceived functional support</td><td>Medical Outcomes Study-Social Support Survey[27]</td><td>X</td><td></td><td></td><td></td></tr><tr><td>Predisposition for fatalistic attitudes directed at health</td><td>Wallston Multi-Dimensional Locus of Control[28]</td><td>X</td><td></td><td></td><td>X</td></tr></table>
<table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months ofnegativediagnosis)</td><td>(within 3 months ofpositivediagnosis)</td><td>(3 months after treatment initiation)</td></tr><tr><td>Distrust towards health care system</td><td>Health Care System Distrust[29]</td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>Patient engagement in own health care</td><td>*Communication and Attitudinal Self-Efficacy - General[30]</td><td></td><td>X</td><td></td><td></td></tr><tr><td>Patient engagement in own cancer care</td><td>*Communication and Attitudinal Self-Efficacy - Cancer[30]</td><td></td><td></td><td></td><td>X</td></tr><tr><td>Subjective distress related to a specific event</td><td>*Impact of Events[31]</td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><td>Satisfaction with cancer-related care</td><td>*Patient Satisfaction with Care[32]</td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><td>Satisfaction with patient navigation services</td><td>Patient Satisfaction with Navigator[33]</td><td></td><td>X</td><td>X</td><td>X</td></tr></table>
dd14cd298baa5a48fe22ee76f53f48ddf9960a4401940560fcbf76dcdcf4f8f7.png
complex
<table><tr><td></td><td colspan="4">Clusters</td></tr><tr><td></td><td>The comprehensive</td><td>The theoretician</td><td>The minimalist</td><td>The structural</td></tr><tr><td>South American sample areas</td><td>14,1</td><td>7</td><td>31</td><td>47.9</td></tr><tr><td>European sample areas</td><td>24</td><td>49.5</td><td>25</td><td>1,5</td></tr><tr><td>Total</td><td>21.4</td><td>38.4</td><td>26.6</td><td>13.7</td></tr></table>
<table><tr><td></td><td colspan="4">Clusters</td></tr><tr><td></td><td>The comprehensive</td><td>The theoretician</td><td>The minimalist</td><td>The structural</td></tr></table>
<table><tr><td>South American sample areas</td><td>14,1</td><td>7</td><td>31</td><td>47.9</td></tr><tr><td>European sample areas</td><td>24</td><td>49.5</td><td>25</td><td>1,5</td></tr><tr><td>Total</td><td>21.4</td><td>38.4</td><td>26.6</td><td>13.7</td></tr></table>
e23320a09c944bd0157e5bfc81e60300e590b3a2e8bd24a44d1598721686430b.png
simple
<table><tr><td>Resection margin</td><td>Recurrence rate No. patients (%)</td><td>Surgery and radiotherapy No. (%)</td><td>Surgery alone No. (%)</td></tr><tr><td>R0</td><td>5/16 (31)</td><td>2/4 (50)</td><td>3/12 (25)</td></tr><tr><td>R1</td><td>30/47 (64)</td><td>27/36 (75)</td><td>3/11 (27)</td></tr><tr><td>R2</td><td>11/20 (55)</td><td>9/14 (64)</td><td>2/6 (33)</td></tr><tr><td>R3</td><td>7/13 (54)</td><td>5/7 (71)</td><td>2/6 (33)</td></tr><tr><td>RX</td><td>7/14 (50)</td><td>5/7 (71)</td><td>2/7 (29)</td></tr></table>
<table><tr><td>Resection margin</td><td>Recurrence rate No. patients (%)</td><td>Surgery and radiotherapy No. (%)</td><td>Surgery alone No. (%)</td></tr><tr><td>R0</td><td>5/16 (31)</td><td>2/4 (50)</td><td>3/12 (25)</td></tr><tr><td>R1</td><td>30/47 (64)</td><td>27/36 (75)</td><td>3/11 (27)</td></tr></table>
<table><tr><td>R2</td><td>11/20 (55)</td><td>9/14 (64)</td><td>2/6 (33)</td></tr><tr><td>R3</td><td>7/13 (54)</td><td>5/7 (71)</td><td>2/6 (33)</td></tr><tr><td>RX</td><td>7/14 (50)</td><td>5/7 (71)</td><td>2/7 (29)</td></tr></table>
75e467cba65d6580a1e75e87e6ee763948ebc348c58f40957c4ce29359a7ccb1.png
simple
<table><tr><td> </td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>1,098 K/8 h</td><td> </td><td> </td><td> </td></tr><tr><td> Undoped</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 0.5% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 1% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 3% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 5% Co</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td> 10% Co</td><td>Rutile</td><td>Nanoparticle + nanorod</td><td>CoTiO<sub>3</sub> (nanoflakes)</td></tr><tr><td>1% Co-doped</td><td> </td><td> </td><td> </td></tr><tr><td> 1,098 K/8 h</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 1,173 K/8 h</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 2 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 8 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 16 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>5% Co-doped</td><td> </td><td> </td><td> </td></tr><tr><td> 1,098 K/8 h</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td> 1,173 K/8 h</td><td>Rutile</td><td>Nanoparticle</td><td>-</td></tr><tr><td> 2 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td> 8 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td> 16 h/1,098 K</td><td>Rutile</td><td>Nanoparticle</td><td>Co<sub>2</sub>P<sub>4</sub>O<sub>12</sub></td></tr></table>
<table><tr><td></td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>1,098 K/8 h</td><td></td><td></td><td></td></tr><tr><td>Undoped</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>0.5% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>1% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>3% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>5% Co</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td>10% Co</td><td>Rutile</td><td>Nanoparticle + nanorod</td><td>CoTiO3 (nanoflakes)</td></tr><tr><td>1% Co-doped</td><td></td><td></td><td></td></tr><tr><td>1,098 K/8 h</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>1,173 K/8 h</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>2 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>8 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>16 h/1,098 K</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>5% Co-doped</td><td></td><td></td><td></td></tr><tr><td>1,098 K/8 h</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td>1,173 K</td><td>R</td><td>Nano</td><td>-</td></tr></table>
<table><tr><td></td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>/8 h</td><td>utile</td><td>particle</td><td></td></tr><tr><td>2 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td>8 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td>16 h/1,098 K</td><td>Rutile</td><td>Nanoparticle</td><td>Co2P4O12</td></tr></table>
ffc86d2823847f057b5e4f94142ca6976449e8f366a40edbcec5bb02f5fc13f5.png
simple
<table><tr><td></td><td>Men (<i>n</i> = 123)</td><td>Women (<i>n</i> = 169)</td><td>Total (<i>n</i> = 292)</td></tr><tr><td>Non-smokers, <i>n</i> (%)</td><td>47 (38.2)</td><td>74 (43.8)</td><td>121 (41.4)</td></tr><tr><td>Ever-smokers, <i>n</i> (%)</td><td>76 (61.8)</td><td>95 (56.2)</td><td>171 (58.6)</td></tr><tr><td>1 positive SPT reaction, <i>n</i> (%)</td><td>55 (50.0)</td><td>63 (44.7)</td><td>118 (47.0)</td></tr><tr><td>&#8805;6 positive SPT reactions, <i>n</i> (%)</td><td>10 (9.1)</td><td>5 (3.5)</td><td>15 (6.0)</td></tr><tr><td>Allergic rhinoconjunctivitis (ARC), <i>n</i> (%)</td><td>40 (32.5)</td><td>71 (42.0)</td><td>111 (38.0)</td></tr><tr><td>Family history of asthma, <i>n</i> (%)</td><td>17 (13.8)</td><td>36 (21.3)</td><td>53 (18.2)</td></tr><tr><td>Physician-diagnosed asthma, <i>n</i> (%)</td><td>7 (5.7)</td><td>6 (3.6)</td><td>13 (4.5)</td></tr><tr><td>Asthma medication ever, <i>n</i> (%)</td><td>21 (17.1)</td><td>31 (18.3)</td><td>52 (17.8)</td></tr><tr><td>Asthma medication past 12 months, <i>n</i> (%)</td><td>9 (7.3)</td><td>13 (7.7)</td><td>22 (7.5)</td></tr></table>
<table><tr><td></td><td>Men (n = 123)</td><td>Women (n = 169)</td><td>Total (n = 292)</td></tr><tr><td>Non-smokers, n (%)</td><td>47 (38.2)</td><td>74 (43.8)</td><td>121 (41.4)</td></tr><tr><td>Ever-smokers, n (%)</td><td>76 (61.8)</td><td>95 (56.2)</td><td>171 (58.6)</td></tr><tr><td>1 positive SPT reaction, n (%)</td><td>55 (50.0)</td><td>63 (44.7)</td><td>118 (47.0)</td></tr><tr><td>≥6 positive SPT reactions, n (%)</td><td>10 (9.1)</td><td>5 (3.5)</td><td>15 (6.0)</td></tr><tr><td>Allerg</td><td>40 (3</td><td>71 </td><td>111 (38.0</td></tr></table>
<table><tr><td>ic rhinoconjunctivitis (ARC), n (%)</td><td>2.5)</td><td>(42.0)</td><td>)</td></tr><tr><td>Family history of asthma, n (%)</td><td>17 (13.8)</td><td>36 (21.3)</td><td>53 (18.2)</td></tr><tr><td>Physician-diagnosed asthma, n (%)</td><td>7 (5.7)</td><td>6 (3.6)</td><td>13 (4.5)</td></tr><tr><td>Asthma medication ever, n (%)</td><td>21 (17.1)</td><td>31 (18.3)</td><td>52 (17.8)</td></tr><tr><td>Asthma medication past 12 months, n (%)</td><td>9 (7.3)</td><td>13 (7.7)</td><td>22 (7.5)</td></tr></table>
6f383440da897e7c34cd1524500ff2b8c5830511982d07f4397eec98075cb1c6.png
simple
<table><tr><td>Question number</td><td>Question</td></tr><tr><td>1.</td><td>Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).</td></tr><tr><td>2.</td><td>Please tell me about how your shoulder tear affected/affects you? (follow up questions to explore impact upon activities of daily living, work, leisure, relationships, emotional impact, and to explore symptoms).</td></tr><tr><td>3.</td><td>Are you right or left handed? (follow up to explore dominance, unilateral or bilateral shoulder problems, &#8220;how is your other shoulder?&#8221;).</td></tr><tr><td>4.</td><td>Please tell me anything else you&#8217;d like to tell me about your shoulder and how the tear had affected you?</td></tr></table>
<table><tr><td>Question number</td></tr><tr><td>1.</td></tr><tr><td>2.</td></tr><tr><td>3.</td></tr><tr><td>4.</td></tr></table>
<table><tr><td>Question</td></tr><tr><td>Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).</td></tr><tr><td>Please tell me about how your shoulder tear affected/affects you? (follow up questions to explore impact upon activities of daily living, work, leisure, relationships, emotional impact, and to explore symptoms).</td></tr><tr><td>Are you right or left handed? (follow up to explore dominance, unilateral or bilateral shoulder problems, “how is your other shoulder?”).</td></tr><tr><td>Please tell me anything else you’d like to tell me about your shoulder and how the tear had affected you?</td></tr></table>
20d0ef8b8fb19928f950c22ae20f7aeb93bd7f4b5c4cb36025ae204a36f66c01.png
simple
<table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1&#8211;2)</td><td>Grade 3 (3&#8211;6)</td><td>Grade 4 (&gt; 6)</td><td>Na</td></tr><tr><td>Head lifting (n)</td><td>153 (88.4%)</td><td>5 (2.9%)</td><td>4 (2.3%)</td><td>6 (3.5%)</td><td>5 (2.9%)</td></tr><tr><td>Paddling (one limb) (n)</td><td>159 (91.9%)</td><td>8 (4.6%)</td><td>1 (0.6%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Paddling (several limbs) (n)</td><td>152 (87.9%)</td><td>5 (2.9%)</td><td>8 (4.6%)</td><td>3 (1.7%)</td><td>5 (2.9%)</td></tr><tr><td>Kicking (one limb) (n)</td><td>161 (93.1%)</td><td>5 (2.9%)</td><td>1 (0.6%)</td><td>1 (0.6%)</td><td>5 (2.9%)</td></tr><tr><td>Kicking (several limbs) (n)</td><td>162 (93.6%)</td><td>4 (2.3%)</td><td>2(1.2%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Pull up (one limb) (n)</td><td>136 (78.6%)</td><td>23 (13.3%)</td><td>9 (5.2%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Pull up (several limbs) (n)</td><td>154 (89.0%)</td><td>13 (7.5%)</td><td>1 (0.6%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Focused eye movement (n)</td><td>114 (65.9%)</td><td>11 (6.4%)</td><td>6 (3.5%)</td><td>1 (0.6%)</td><td>41 (23.7%)</td></tr><tr><td>Spontaneous blinking (n)</td><td>49 (28.3%)</td><td>32 (18.5%)</td><td>24 (13.9%)</td><td>27 (15.6%)</td><td>41 (23.7%)</td></tr><tr><td>Ear movement (n)</td><td>131 (75.7%)</td><td>8 (4.6%)</td><td>1 (0.6%)</td><td>0</td><td>33 (19.1%)</td></tr><tr><td>Tail movement (n)</td><td>87 (50.3%)</td><td>34 (19.7%)</td><td>14 (8.1%)</td><td>10 (5.8%)</td><td>28 (16.2%)</td></tr><tr><td>Nose Movement (n)</td><td>132 (76.3%)</td><td>3 (1.7%)</td><td>0</td><td>0</td><td>38 (22.0%)</td></tr><tr><td>Mouth Movement (n)</td><td>124 (71.7%)</td><td>8 (4.6%)</td><td>3 (1.7%)</td><td>1 (0.6%)</td><td>37 (21.4%)</td></tr><tr><td>Groaning (stimulus-associated) (n)</td><td>96 (55.5%)</td><td>28 (16.2%)</td><td>24 (13.9%)</td><td>25 (14.5%)</td><td>0</td></tr><tr><td>Vocalisation (n)</td><td>108 (62.4%)</td><td>17 (9.8%)</td><td>21 (12.1%)</td><td>27 (15.6%)</td><td>0</td></tr></table>
<table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1–2)</td><td>Grade 3 (3–6)</td><td>Grade 4 (> 6)</td><td>Na</td></tr><tr><td>Head lifting (n)</td><td>153 (88.4%)</td><td>5 (2.9%)</td><td>4 (2.3%)</td><td>6 (3.5%)</td><td>5 (2.9%)</td></tr><tr><td>Paddling (one limb) (n)</td><td>159 (91.9%)</td><td>8 (4.6%)</td><td>1 (0.6%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Paddling (several limbs) (n)</td><td>152 (87.9%)</td><td>5 (2.9%)</td><td>8 (4.6%)</td><td>3 (1.7%)</td><td>5 (2.9%)</td></tr><tr><td>Kicking (one limb) (n)</td><td>161 (93.1%)</td><td>5 (2.9%)</td><td>1 (0.6%)</td><td>1 (0.6%)</td><td>5 (2.9%)</td></tr><tr><td>Kicking (several limbs) (n)</td><td>162 (93.6%)</td><td>4 (2.3%)</td><td>2(1.2%)</td><td>0</td><td>5 (2.9%)</td></tr></table>
<table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1–2)</td><td>Grade 3 (3–6)</td><td>Grade 4 (> 6)</td><td>Na</td></tr><tr><td>Pull up (one limb) (n)</td><td>136 (78.6%)</td><td>23 (13.3%)</td><td>9 (5.2%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Pull up (several limbs) (n)</td><td>154 (89.0%)</td><td>13 (7.5%)</td><td>1 (0.6%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Focused eye movement (n)</td><td>114 (65.9%)</td><td>11 (6.4%)</td><td>6 (3.5%)</td><td>1 (0.6%)</td><td>41 (23.7%)</td></tr><tr><td>Spontaneous blinking (n)</td><td>49 (28.3%)</td><td>32 (18.5%)</td><td>24 (13.9%)</td><td>27 (15.6%)</td><td>41 (23.7%)</td></tr><tr><td>Ear movement (n)</td><td>131 (75.7%)</td><td>8 (4.6%)</td><td>1 (0.6%)</td><td>0</td><td>33 (19.1%)</td></tr><tr><td>Tail movement (n)</td><td>87 (50.3%)</td><td>34 (19.7%)</td><td>14 (8.1%)</td><td>10 (5.8%)</td><td>28 (16.2%)</td></tr><tr><td>Nose Movement (n)</td><td>132 (76.3%)</td><td>3 (1.7%)</td><td>0</td><td>0</td><td>38 (22.0%)</td></tr><tr><td>Mouth Movement (n)</td><td>124 (71.7%)</td><td>8 (4.6%)</td><td>3 (1.7%)</td><td>1 (0.6%)</td><td>37 (21.4%)</td></tr><tr><td>Groaning (stimulus-associated) (n)</td><td>96 (55.5%)</td><td>28 (16.2%)</td><td>24 (13.9%)</td><td>25 (14.5%)</td><td>0</td></tr><tr><td>Vocalisation (n)</td><td>108 (62.4%)</td><td>17 (9.8%)</td><td>21 (12.1%)</td><td>27 (15.6%)</td><td>0</td></tr></table>
e06f0286dfc72e1572a10b1bde12497d365ca297d9ab5dc766f0d5af9d9e40d2.png
simple
<table><tr><td>Generic name</td><td>Trade name</td><td>Number of cases of monotherapy</td></tr><tr><td>Losartan</td><td>Nu-lotan&#174;</td><td>214</td></tr><tr><td>Valsartan</td><td>Diovan&#174;</td><td>266</td></tr><tr><td>Telmisartan</td><td>Micardis&#174;</td><td>185</td></tr><tr><td>Candesartan</td><td>Blopress&#174;</td><td>458</td></tr><tr><td>Olmesartan</td><td>Olmetec&#174;</td><td>192</td></tr></table>
<table><tr><td>Generic name</td><td>Trade name</td><td>Number of cases of monotherapy</td></tr><tr><td>Losartan</td><td>Nu-lotan®</td><td>214</td></tr><tr><td>Valsartan</td><td>Diovan®</td><td>266</td></tr></table>
<table><tr><td>Telmisartan</td><td>Micardis®</td><td>185</td></tr><tr><td>Candesartan</td><td>Blopress®</td><td>458</td></tr><tr><td>Olmesartan</td><td>Olmetec®</td><td>192</td></tr></table>
e2e32c476d940941003dc1b874aac51ba628fa877458796425abdb2c8961895a.png
simple
<table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>100-OD (% sat.)</td><td>&#8804;10</td><td>&#8804;20</td><td>&#8804;30</td><td>&#8804;50</td><td>&gt;50</td></tr><tr><td>BOD<sub>5</sub> (O<sub>2</sub> mg/L)</td><td>&lt;2.5</td><td>&#8804;4</td><td>&#8804;8</td><td>&#8804;15</td><td>&gt;15</td></tr><tr><td>COD (O<sub>2</sub> mg/L)</td><td>&lt;5</td><td>&#8804;10</td><td>&#8804;15</td><td>&#8804;25</td><td>&gt;25</td></tr><tr><td>NH<sub>4</sub> (N mg/L)</td><td>&lt;0.03</td><td>&#8804;0.10</td><td>&#8804;0.50</td><td>&#8804;1.50</td><td>&gt;1.50</td></tr><tr><td>NO<sub>3</sub> (N mg/L)</td><td>&lt;0.3</td><td>&#8804;1.5</td><td>&#8804;5.0</td><td>&#8804;10.0</td><td>&gt;10.0</td></tr><tr><td>Total phosphorous (P mg/L)</td><td>&lt;0.07</td><td>&#8804;0.15</td><td>&#8804;0.30</td><td>&#8804;0.60</td><td>&gt;0.60</td></tr><tr><td><i>Escherichia coli</i> (UFC/100/mL)</td><td>&lt;100</td><td>&#8804;1.000</td><td>&#8804;5.000</td><td>&#8804;20.000</td><td>&gt;20.000</td></tr><tr><td>Score to be attributed for each analysed parameter (75&#176; percentile of the monitoring period)</td><td>80</td><td>40</td><td>20</td><td>10</td><td>5</td></tr><tr><td>Pollution level expressed by the LIM</td><td>480&#8211;560</td><td>240&#8211;475</td><td>120&#8211;235</td><td>60&#8211;115</td><td>&lt;60</td></tr></table>
<table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>100-OD (% sat.)</td><td>≤10</td><td>≤20</td><td>≤30</td><td>≤50</td><td>>50</td></tr><tr><td>BOD5 (O2 mg/L)</td><td><2.5</td><td>≤4</td><td>≤8</td><td>≤15</td><td>>15</td></tr><tr><td>COD (O2 mg/L)</td><td><5</td><td>≤10</td><td>≤15</td><td>≤25</td><td>>25</td></tr><tr><td>NH4 (N mg/L)</td><td><0.03</td><td>≤0.10</td><td>≤0.50</td><td>≤1.50</td><td>>1.50</td></tr><tr><td>NO3 (N mg/L)</td><td><0.3</td><td>≤1.5</td><td>≤5.0</td><td>≤10.0</td><td>>10.0</td></tr><tr><td>Total phosphorous (P mg/L)</td><td><0.07</td><td>≤0.15</td><td>≤0.30</td><td>≤0.60</td><td>>0.60</td></tr><tr><td></td><td><10</td><td>≤1</td><td>≤5.000</td><td>≤20.000</td><td>>2</td></tr></table>
<table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>Escherichia coli (UFC/100/mL)</td><td>0</td><td>.000</td><td></td><td></td><td>0.000</td></tr><tr><td>Score to be attributed for each analysed parameter (75° percentile of the monitoring period)</td><td>80</td><td>40</td><td>20</td><td>10</td><td>5</td></tr><tr><td>Pollution level expressed by the LIM</td><td>480–560</td><td>240–475</td><td>120–235</td><td>60–115</td><td><60</td></tr></table>
6a0794db078e4abb0e1f784a6a84828b3c5f0c663a4a459535891903ee78d177.png
complex
<table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Loosening/lysis</td><td>17</td><td>46</td><td>27</td><td>52</td><td>63</td><td>46</td><td>34</td><td>42</td></tr><tr><td>Infection</td><td>2</td><td>5.4</td><td>5</td><td>9.6</td><td>19</td><td>14</td><td>25</td><td>31</td></tr><tr><td>Pain</td><td>6</td><td>16.2</td><td>6</td><td>11.5</td><td>18</td><td>13</td><td>8</td><td>9.9</td></tr><tr><td>Patello femoral pain</td><td>1</td><td>2.7</td><td>1</td><td>1.9</td><td>9</td><td>6.5</td><td>3</td><td>3.7</td></tr><tr><td>Progression of disease</td><td>2</td><td>5.4</td><td>7</td><td>14</td><td>3</td><td>2.2</td><td></td><td></td></tr><tr><td>Other</td><td>9</td><td>24.3</td><td>6</td><td>12</td><td>26</td><td>19</td><td>11</td><td>13</td></tr><tr><td>Total</td><td>37</td><td>100</td><td>52</td><td>100</td><td>138</td><td>100</td><td>81</td><td>100</td></tr></table>
<table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Loosening/lysis</td><td>17</td><td>46</td><td>27</td><td>52</td><td>63</td><td>46</td><td>34</td><td>42</td></tr><tr><td>Infection</td><td>2</td><td>5.4</td><td>5</td><td>9.6</td><td>19</td><td>14</td><td>25</td><td>31</td></tr></table>
<table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Pain</td><td>6</td><td>16.2</td><td>6</td><td>11.5</td><td>18</td><td>13</td><td>8</td><td>9.9</td></tr><tr><td>Patello femoral pain</td><td>1</td><td>2.7</td><td>1</td><td>1.9</td><td>9</td><td>6.5</td><td>3</td><td>3.7</td></tr><tr><td>Progression of disease</td><td>2</td><td>5.4</td><td>7</td><td>14</td><td>3</td><td>2.2</td><td></td><td></td></tr><tr><td>Other</td><td>9</td><td>24.3</td><td>6</td><td>12</td><td>26</td><td>19</td><td>11</td><td>13</td></tr><tr><td>Total</td><td>37</td><td>100</td><td>52</td><td>100</td><td>138</td><td>100</td><td>81</td><td>100</td></tr></table>
10731fdc0c192a221a4a2cddfd60e3a57f1d5df481b23fc1b7d8781f3f5b8a8b.png
complex
<table><tr><td>Diagnosis in MRI</td><td>Specific abnormalities in MRI</td><td><i>N</i></td><td>Total number (%)</td></tr><tr><td>Abnormal MRI</td><td> </td><td> </td><td>13 (52%)</td></tr><tr><td rowspan="2">Hepatic dysmorphia</td><td>Included lobulation of liver surface</td><td>3</td><td rowspan="2">3 (12%)</td></tr><tr><td>Included first-segment hypertrophy</td><td>0</td></tr><tr><td rowspan="3">Portal hypertension</td><td>Included splenomegaly</td><td>5</td><td rowspan="3">5 (20%)</td></tr><tr><td>Included portal vein dilatation</td><td>2</td></tr><tr><td>Included splenic vein dilatation</td><td>1</td></tr><tr><td rowspan="2">Isolated biliary abnormalities</td><td>Intrahepatic</td><td>1</td><td rowspan="2">1 (4%)</td></tr><tr><td>Extrahepatic</td><td>0</td></tr><tr><td>Hepatic dysmorphia and portal hypertension</td><td> </td><td>0</td><td>0 (0%)</td></tr><tr><td>Hepatic dysmorphia and biliary abnormalities</td><td>Included lobulation of liver surface and intrahepatic abnormalities</td><td>1</td><td>1 (4%)</td></tr><tr><td>Portal hypertension and biliary abnormalities</td><td>Included portal vein hypertrophy and intrahepatic abnormalities</td><td>1</td><td>1 (4%)</td></tr><tr><td>Hepatic dysmorphia, portal hypertension, and biliary abnormalities</td><td>Included splenomegaly, lobulation of liver surface, first-segment hypertrophy, and intrahepatic and extrahepatic abnormalities</td><td>2</td><td>2 (8%)</td></tr><tr><td>Normal MRI</td><td> </td><td> </td><td>12 (48%)</td></tr><tr><td>Total </td><td> </td><td> </td><td>25 (100%)</td></tr></table>
<table><tr><td>Diagnosis in MRI</td><td>Specific abnormalities in MRI</td><td>N</td><td>Total number (%)</td></tr><tr><td>Abnormal MRI</td><td></td><td></td><td>13 (52%)</td></tr><tr><td rowspan="2">Hepatic dysmorphia</td><td>Included lobulation of liver surface</td><td>3</td><td rowspan="2">3 (12%)</td></tr><tr><td>Included first-segment hypertrophy</td><td>0</td></tr><tr><td rowspan="3">Portal hypertension</td><td>Included splenomegaly</td><td>5</td><td rowspan="3">5 (20%)</td></tr><tr><td>Included portal vein dilatation</td><td>2</td></tr><tr><td>Included splenic vein dilatation</td><td>1</td></tr><tr><td rowspan="2">Isolated biliary abnormalities</td><td>Intrahepatic</td><td>1</td><td rowspan="2">1 (4%)</td></tr><tr><td>Extrahepatic</td><td>0</td></tr><tr><td>Hepatic dysmorphia and portal hypertension</td><td></td><td>0</td><td>0 (0%)</td></tr><tr><td>Hepatic dysmorphia and biliary abnormalities</td><td>Included lobulation of liver surface and intrahepatic abnormalities</td><td>1</td><td>1 (4%)</td></tr><tr><td>Portal hypertension and biliary abnormalities</td><td>Included portal vein hypertrophy and intrahepatic abnormalities</td><td>1</td><td>1 (4%)</td></tr><tr><td>Hepatic dysmorphia, portal hypertension, and biliary abnormalities</td><td>Included splenomegaly, lobulation of liver surface, first-segment hypertrophy, and intrahepatic and extrahepatic abnormalities</td><td>2</td><td>2 (8%)</td></tr><tr><td>Normal MRI</td><td></td><td></td><td>12 (48%)</td></tr></table>
<table><tr><td>Diagnosis in MRI</td><td>Total number (%)</td></tr><tr><td>Total</td><td>25 (100%)</td></tr></table>
d6262c934d811551f3a5e04ce8d29c5e590e7b6b90f56b1b703c225426f06e50.png
simple
<table><tr><td>Variable</td><td>OR [95%CI]</td><td>P value</td></tr><tr><td>Steroids before ICU stay</td><td>0.77 [0.17-3.49]</td><td>0.74</td></tr><tr><td>Steroids during ICU stay</td><td> </td><td> </td></tr><tr><td>No Steroid</td><td>5.64 [0.70-45.5]</td><td> </td></tr><tr><td>Low Dose Steroid</td><td>1</td><td>0.02</td></tr><tr><td>High Dose Steroids</td><td>9.33 [1.97-44.3]</td><td> </td></tr><tr><td>SAPS II per point</td><td>1.04 [1.01-1.08]</td><td>0.01</td></tr><tr><td>Underlying disease</td><td> </td><td> </td></tr><tr><td>Hematological disease</td><td>1</td><td> </td></tr><tr><td>Other</td><td>4.06 [1.19-13.09]</td><td>0.03</td></tr><tr><td>Shock</td><td>20.31 [6.45-63.9]</td><td>&lt;0.001</td></tr></table>
<table><tr><td>Variable</td><td>OR [95%CI]</td><td>P value</td></tr><tr><td>Steroids before ICU stay</td><td>0.77 [0.17-3.49]</td><td>0.74</td></tr><tr><td>Steroids during ICU stay</td><td></td><td></td></tr><tr><td>No Steroid</td><td>5.64 [0.70-45.5]</td><td></td></tr><tr><td>Low Dose Steroi</td><td>1</td><td></td></tr></table>
<table><tr><td>d</td><td></td><td>0.02</td></tr><tr><td>High Dose Steroids</td><td>9.33 [1.97-44.3]</td><td></td></tr><tr><td>SAPS II per point</td><td>1.04 [1.01-1.08]</td><td>0.01</td></tr><tr><td>Underlying disease</td><td></td><td></td></tr><tr><td>Hematological disease</td><td>1</td><td></td></tr><tr><td>Other</td><td>4.06 [1.19-13.09]</td><td>0.03</td></tr><tr><td>Shock</td><td>20.31 [6.45-63.9]</td><td><0.001</td></tr></table>
0f9d96f0b72e8d74928ed223907880e61d0b0d4b295cd37a42eb78de678c8b3d.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Male</td><td colspan="3">Female</td></tr><tr><td>C</td><td>NC</td><td><i>p</i>-value</td><td>C</td><td>NC</td><td><i>p</i>-value</td></tr><tr><td>Dietary component</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Energy (kJ)</td><td>9665</td><td>9863</td><td>0.1573</td><td>7238</td><td>7408</td><td>0.0684</td></tr><tr><td>Nutrients</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Carbohydrates (%E)</td><td>42.8</td><td>43.4</td><td>0.1154</td><td>42.3</td><td>43.8</td><td>&lt;0.0001 *</td></tr><tr><td> Total Sugars (%E)</td><td>18.1</td><td>18.7</td><td>0.0789</td><td>19.2</td><td>19.9</td><td>0.0209</td></tr><tr><td> Free Sugar (%E)</td><td>9.2</td><td>10.7</td><td>&lt;0.0001 *</td><td>9.2</td><td>10.3</td><td>&lt;0.0001 *</td></tr><tr><td> Total Fat (%E)</td><td>30.5</td><td>30.3</td><td>0.5978</td><td>31.1</td><td>31.3</td><td>0.4329</td></tr><tr><td> Saturated Fat (%E)</td><td>11.9</td><td>12.0</td><td>0.4937</td><td>11.9</td><td>12.2</td><td>0.1099</td></tr><tr><td> MUFA (%E)</td><td>11.8</td><td>11.6</td><td>0.2112</td><td>11.9</td><td>11.9</td><td>0.8910</td></tr><tr><td> PUFA (%E)</td><td>4.7</td><td>4.6</td><td>0.1968</td><td>5.0</td><td>5.0</td><td>0.5831</td></tr><tr><td> Protein (%E)</td><td>19.5</td><td>17.9</td><td>&lt;0.0001 *</td><td>19.9</td><td>18.1</td><td>&lt;0.0001 *</td></tr><tr><td> Sodium (mg)</td><td>2838</td><td>2677</td><td>0.0005 *</td><td>2112</td><td>2062</td><td>0.0979</td></tr><tr><td> Fibre (%E)</td><td>2.2</td><td>2.1</td><td>0.2967</td><td>2.3</td><td>2.4</td><td>0.0613</td></tr><tr><td>Food Groups</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Discretionary Foods (%E)</td><td>33.7</td><td>34.4</td><td>0.307</td><td>30.4</td><td>30.6</td><td>0.8011</td></tr><tr><td> Grains and Cereals (serves)</td><td>5.0</td><td>5.2</td><td>0.0912</td><td>3.7</td><td>3.9</td><td>0.0011</td></tr><tr><td> Meat and Alternatives (serves)</td><td>2.2</td><td>2.1</td><td>0.3305</td><td>1.7</td><td>1.6</td><td>0.0139</td></tr><tr><td> Dairy and alternatives (serves)</td><td>1.7</td><td>1.4</td><td>&lt;0.0001 *</td><td>1.5</td><td>1.3</td><td>&lt;0.0001 *</td></tr><tr><td> Fruit (serves)</td><td>1.7</td><td>1.5</td><td>0.0496</td><td>1.4</td><td>1.5</td><td>0.0474</td></tr><tr><td> Vegetables (serves)</td><td>2.9</td><td>3.2</td><td>0.0013</td><td>2.8</td><td>3.0</td><td>0.0034</td></tr></table>
<table><tr><td rowspan="2"></td><td>Male</td></tr><tr><td>C</td></tr><tr><td>Dietary component</td><td></td></tr><tr><td>Energy (kJ)</td><td>9665</td></tr><tr><td>Nutrients</td><td></td></tr><tr><td>Carbohydrates (%E)</td><td>42.8</td></tr><tr><td>Total Sugars (%E)</td><td>18.1</td></tr><tr><td>Free Sugar (%E)</td><td>9.2</td></tr><tr><td>Total Fat (%E)</td><td>30.5</td></tr><tr><td>Saturated Fat (%E)</td><td>11.9</td></tr><tr><td>MUFA (%E)</td><td>11.8</td></tr><tr><td>PUFA (%E)</td><td>4.7</td></tr><tr><td>Protein (%E)</td><td>19.5</td></tr><tr><td>Sodium (mg)</td><td>2838</td></tr><tr><td>Fibre (%E)</td><td>2.2</td></tr><tr><td>Food Groups</td><td></td></tr><tr><td>Discretionary Foods (%E)</td><td>33.7</td></tr><tr><td>Grains and Cereals (serves)</td><td>5.0</td></tr><tr><td>Meat and Alternatives (serves)</td><td>2.2</td></tr><tr><td>Dairy and alternatives (serves)</td><td>1.7</td></tr><tr><td>Fruit (serves)</td><td>1.7</td></tr><tr><td>Vegetables (serves)</td><td>2.9</td></tr></table>
<table><tr><td colspan="2">Male</td><td colspan="3">Female</td></tr><tr><td>NC</td><td>p-value</td><td>C</td><td>NC</td><td>p-value</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>9863</td><td>0.1573</td><td>7238</td><td>7408</td><td>0.0684</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>43.4</td><td>0.1154</td><td>42.3</td><td>43.8</td><td><0.0001 *</td></tr><tr><td>18.7</td><td>0.0789</td><td>19.2</td><td>19.9</td><td>0.0209</td></tr><tr><td>10.7</td><td><0.0001 *</td><td>9.2</td><td>10.3</td><td><0.0001 *</td></tr><tr><td>30.3</td><td>0.5978</td><td>31.1</td><td>31.3</td><td>0.4329</td></tr><tr><td>12.0</td><td>0.4937</td><td>11.9</td><td>12.2</td><td>0.1099</td></tr><tr><td>11.6</td><td>0.2112</td><td>11.9</td><td>11.9</td><td>0.8910</td></tr><tr><td>4.6</td><td>0.1968</td><td>5.0</td><td>5.0</td><td>0.5831</td></tr><tr><td>17.9</td><td><0.0001 *</td><td>19.9</td><td>18.1</td><td><0.0001 *</td></tr><tr><td>2677</td><td>0.0005 *</td><td>2112</td><td>2062</td><td>0.0979</td></tr><tr><td>2.1</td><td>0.2967</td><td>2.3</td><td>2.4</td><td>0.0613</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>34.4</td><td>0.307</td><td>30.4</td><td>30.6</td><td>0.8011</td></tr><tr><td>5.2</td><td>0.0912</td><td>3.7</td><td>3.9</td><td>0.0011</td></tr><tr><td>2.1</td><td>0.3305</td><td>1.7</td><td>1.6</td><td>0.0139</td></tr><tr><td>1.4</td><td><0.0001 *</td><td>1.5</td><td>1.3</td><td><0.0001 *</td></tr><tr><td>1.5</td><td>0.0496</td><td>1.4</td><td>1.5</td><td>0.0474</td></tr><tr><td>3.2</td><td>0.0013</td><td>2.8</td><td>3.0</td><td>0.0034</td></tr></table>
c2c7c821612ce295ebf8553c1f2f9f04fbd1eedbb8499e03049ce0030013e504.png
simple
<table><tr><td>Variablea</td><td>HR (95% CI)</td><td><i>P</i></td></tr><tr><td>Bowel obstruction/perforation (positive vs negative)</td><td>4.118 (2.270-7.471)</td><td>&lt;.001</td></tr><tr><td>Lymphovascular invasion (positive vs negative)</td><td>1.766 (1.156-2.697)</td><td>.009</td></tr><tr><td>Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence)</td><td>1.644 (1.035-2.610)</td><td>.035</td></tr></table>
<table><tr><td>Variablea</td><td>HR (95% CI)</td><td>P</td></tr><tr><td>Bowel obstruction/perforation (positive vs negative)</td><td>4.118 (2.270-7.471)</td><td><.001</td></tr></table>
<table><tr><td>Variablea</td><td>HR (95% CI)</td><td>P</td></tr><tr><td>Lymphovascular invasion (positive vs negative)</td><td>1.766 (1.156-2.697)</td><td>.009</td></tr><tr><td>Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence)</td><td>1.644 (1.035-2.610)</td><td>.035</td></tr></table>
9e98077623fc16c7449c488bcf030ef762905d066651c779620c12c47f89bd47.png
simple
<table><tr><td>Subject</td><td>R (mean &#177; std. deviation)</td></tr><tr><td>1</td><td>0.8084 &#177; 0.0140</td></tr><tr><td>2</td><td>0.7605 &#177; 0.1104</td></tr><tr><td>3</td><td>0.7915 &#177; 0.0147</td></tr><tr><td>4</td><td>0.8045 &#177; 0.0173</td></tr><tr><td>5</td><td>0.7970 &#177; 0.0204</td></tr></table>
<table><tr><td>Subject</td><td>R (mean ± std. deviation)</td></tr><tr><td>1</td><td>0.8084 ± 0.0140</td></tr></table>
<table><tr><td>Subject</td><td>R (mean ± std. deviation)</td></tr><tr><td>2</td><td>0.7605 ± 0.1104</td></tr><tr><td>3</td><td>0.7915 ± 0.0147</td></tr><tr><td>4</td><td>0.8045 ± 0.0173</td></tr><tr><td>5</td><td>0.7970 ± 0.0204</td></tr></table>
318ab7b48e1d03e83ed69b86c9d5420be14cfb5142ac491330000d1f6019738c.png
complex
<table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td rowspan="2">Healthy: Mean Coronary Wall Thickness</td><td><i>R</i> = -0.17</td><td><i>R</i> = 0.02</td><td><i>R</i> = -0.02</td></tr><tr><td><i>P</i> = 0.46</td><td><i>P</i> = 0.93</td><td><i>P</i> = 0.92</td></tr><tr><td rowspan="2">Healthy: Eccentricity Index</td><td><i>R</i> = 0.18</td><td><i>R</i> = 0.08</td><td><i>R</i> = 0.14</td></tr><tr><td><i>P</i> = 0.46</td><td><i>P</i> = 0.74</td><td><i>P</i> = 0.56</td></tr><tr><td rowspan="2">CAD: Mean Coronary Wall Thickness</td><td><i>R</i> = -<i>0.54</i></td><td><i>R</i> = -0.11</td><td>R = -0.34</td></tr><tr><td><i>P</i> = <i>0.001</i></td><td><i>P</i> = 0.51</td><td>P = 0.05</td></tr><tr><td rowspan="2">CAD: Eccentricity Index</td><td><i>R</i> = -<i>0.60</i></td><td><i>R</i> = -0.06</td><td><i>R</i> = -0.27</td></tr><tr><td><i>P</i> = <i>0.0002</i></td><td><i>P</i> = 0.75</td><td><i>P</i> = 0.13</td></tr></table>
<table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td rowspan="2">Healthy: Mean Coronary Wall Thickness</td><td>R = -0.17</td><td>R = 0.02</td><td>R = -0.02</td></tr><tr><td>P = 0.46</td><td>P = 0.93</td><td>P = 0.92</td></tr><tr><td>Healthy: Eccentricity Index</td><td>R = 0.18</td><td>R = 0.08</td><td>R = 0.14</td></tr></table>
<table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td>Healthy: Eccentricity Index</td><td>P = 0.46</td><td>P = 0.74</td><td>P = 0.56</td></tr><tr><td rowspan="2">CAD: Mean Coronary Wall Thickness</td><td>R = -0.54</td><td>R = -0.11</td><td>R = -0.34</td></tr><tr><td>P = 0.001</td><td>P = 0.51</td><td>P = 0.05</td></tr><tr><td rowspan="2">CAD: Eccentricity Index</td><td>R = -0.60</td><td>R = -0.06</td><td>R = -0.27</td></tr><tr><td>P = 0.0002</td><td>P = 0.75</td><td>P = 0.13</td></tr></table>
6a2464423d34de68930744a48e292631e1dd45543601c31834fa860cf5856b02.png
complex
<table><tr><td rowspan="3">Survey Data</td><td colspan="2">Model 1&#8211;30 min/day</td><td colspan="2">Model 2&#8211;60 min/day</td><td colspan="4">Model 3 &#8211; KKD</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2"><i>Active</i> vs <i>Inactive</i></td><td colspan="2"><i>Moderately Active</i> vs <i>Inactive</i></td></tr><tr><td>Fixed effect (95% CI)</td><td><i>P</i> value</td><td>Fixed effect (95% CI)</td><td><i>P</i> value</td><td>Fixed effect (95% CI)</td><td><i>P</i> value</td><td>Fixed effect (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="9">Study Condition</td></tr><tr><td> Comparison (PEI)</td><td>Referent</td><td>&lt;.0001</td><td>Referent</td><td>&lt;.0001</td><td>Referent</td><td>0.23</td><td>Referent</td><td>0.32</td></tr><tr><td> Intervention (Manitoba)</td><td>2.24 (1.88, 2.66)</td><td></td><td>1.32 (1.16, 1.50)</td><td></td><td>1.16 (0.91,1.48)</td><td></td><td>1.13 (0.89, 1.45)</td><td></td></tr><tr><td colspan="9">Time</td></tr><tr><td> Baseline</td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td></tr><tr><td> Follow-up</td><td>0.79 (0.65, 0.95)</td><td>0.01</td><td>0.95 (0.82, 1.10)</td><td>0.49</td><td>1.13 (0.84, 1.51)</td><td>0.41</td><td>1.15 (0.86, 1.52)</td><td>0.35</td></tr><tr><td>Condition*Time Interaction</td><td>1.13 (0.92, 1.39)</td><td>0.24</td><td>0.92 (0.78, 1.07)</td><td>0.26</td><td>0.63 (0.47, 0.85)</td><td>0.0021</td><td>0.82 (0.61, 1.11)</td><td>0.20</td></tr><tr><td colspan="9">Grade</td></tr><tr><td> 9</td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td></tr><tr><td> 10</td><td>0.91 (0.82, 1.00)</td><td>0.05</td><td>0.91 (0.86, 0.97)</td><td>0.0016</td><td>0.84 (0.75, 0.93)</td><td>0.0008</td><td>0.92 (0.82, 1.02)</td><td>0.12</td></tr><tr><td> 11</td><td>0.75 (0.68, 0.82)</td><td>&lt;.0001</td><td>0.73 (0.69, 0.77)</td><td>&lt;.0001</td><td>0.58 (0.52, 0.64)</td><td>&lt;.0001</td><td>0.81 (0.73, 0.90)</td><td>&lt;.0001</td></tr><tr><td> 12</td><td>0.66 (0.60, 0.73)</td><td>&lt;.0001</td><td>0.68 (0.64, 0.72)</td><td>&lt;.0001</td><td>0.52 (0.47, 0.57)</td><td>&lt;.0001</td><td>0.80 (0.72, 0.89)</td><td>&lt;.0001</td></tr><tr><td colspan="9">Sex</td></tr><tr><td> Female</td><td>Referent</td><td>&lt;.0001</td><td>Referent</td><td>&lt; .0001</td><td>Referent</td><td>&lt; .0001</td><td>Referent</td><td>&lt;.0001</td></tr><tr><td> Male</td><td colspan="2">1.87 (1.74, 2.00)</td><td>1.88 (1.80, 1.95)</td><td></td><td>2.26 (2.10, 2.43)</td><td></td><td>1.29 (1.20, 1.39)</td><td></td></tr><tr><td colspan="9">BMI status</td></tr><tr><td> Healthy weight</td><td>Referent</td><td>0.0007</td><td>Referent</td><td>0.0006</td><td>Referent</td><td>&lt; .0001</td><td>Referent</td><td>0.20</td></tr><tr><td> Overweight or obese</td><td>0.88 (0.81, 0.95)</td><td></td><td>0.92 (0.88, 0.97)</td><td></td><td>0.85 (0.78, 0.92)</td><td></td><td>0.95 (0.87, 1.03)</td><td></td></tr></table>
<table><tr><td rowspan="3">Survey Data</td><td colspan="2">Model 1–30 min/day</td><td colspan="2">Model 2–60 min/day</td><td colspan="4">Model 3 – KKD</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Active vs Inactive</td><td colspan="2">Moderately Active vs Inactive</td></tr><tr><td>Fixed effect (95% CI)</td><td>P value</td><td>Fixed effect (95% CI)</td><td>P value</td><td>Fixed effect (95% CI)</td><td>P value</td><td>Fixed effect (95% CI)</td><td>P value</td></tr><tr><td colspan="9">Study Condition</td></tr><tr><td>Comparison (PEI)</td><td>Referent</td><td><.0001</td><td>Referent</td><td><.0001</td><td>Referent</td><td>0.23</td><td>Referent</td><td>0.32</td></tr><tr><td>Intervention (Manitoba)</td><td>2.24 (1.88, 2.66)</td><td></td><td>1.32 (1.16, 1.50)</td><td></td><td>1.16 (0.91,1.48)</td><td></td><td>1.13 (0.89, 1.45)</td><td></td></tr><tr><td colspan="9">Time</td></tr><tr><td>Baseline</td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td></tr><tr><td>Follow-up</td><td>0.79 (0.65, 0.95)</td><td>0.01</td><td>0.95 (0.82, 1.10)</td><td>0.49</td><td>1.13 (0.84, 1.51)</td><td>0.41</td><td>1.15 (0.86, 1.52)</td><td>0.35</td></tr><tr><td>Condition*Time Interaction</td><td>1.13 (0.92, 1.39)</td><td>0.24</td><td>0.92 (0.78, 1.07)</td><td>0.26</td><td>0.63 (0.47, 0.85)</td><td>0.0021</td><td>0.82 (0.61, 1.11)</td><td>0.20</td></tr><tr><td colspan="9">Grade</td></tr><tr><td>9</td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td><td>Referent</td><td></td></tr><tr><td>10</td><td>0.91 (0.82, 1.00)</td><td>0.05</td><td>0.91 (0.86, 0.97)</td><td>0.0016</td><td>0.84 (0.75, 0.93)</td><td>0.0008</td><td>0.92 (0.82, 1.02)</td><td>0.12</td></tr><tr><td>11</td><td>0.75 (0.68, 0.82)</td><td><.0001</td><td>0.73 (0.69, 0.77)</td><td><.0001</td><td>0.58 (0.52, 0.64)</td><td><.0001</td><td>0.81 (0.73, 0.90)</td><td><.0001</td></tr><tr><td>12</td><td>0.66 (0.60, 0.73)</td><td><.0001</td><td>0.68 (0.64, 0.72)</td><td><.0001</td><td>0.52 (0.47, 0.57)</td><td><.0001</td><td>0.80 (0.72, 0.89)</td><td><.0001</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>Female</td><td>Referent</td><td><.0001</td><td>Referent</td><td>< .0001</td><td>Referent</td><td>< .0001</td><td>Referent</td><td><.0001</td></tr></table>
<table><tr><td>Male</td><td colspan="2">1.87 (1.74, 2.00)</td><td>1.88 (1.80, 1.95)</td><td></td><td>2.26 (2.10, 2.43)</td><td></td><td>1.29 (1.20, 1.39)</td><td></td></tr><tr><td colspan="9">BMI status</td></tr><tr><td>Healthy weight</td><td>Referent</td><td>0.0007</td><td>Referent</td><td>0.0006</td><td>Referent</td><td>< .0001</td><td>Referent</td><td>0.20</td></tr><tr><td>Overweight or obese</td><td>0.88 (0.81, 0.95)</td><td></td><td>0.92 (0.88, 0.97)</td><td></td><td>0.85 (0.78, 0.92)</td><td></td><td>0.95 (0.87, 1.03)</td><td></td></tr></table>
a56b85e332f7f96fcd9850a8fe0dfb90a9f8748e61a88def87f5f22752e85c14.png
simple
<table><tr><td> </td><td>GOLD II</td><td>GOLD III</td><td>GOLD IV</td><td>Total</td></tr><tr><td> </td><td>(n = 12)</td><td>(n = 21)</td><td>(n = 10)</td><td>(n = 43)</td></tr><tr><td>Short acting bronchodilator</td><td>75.0%</td><td>80.9%</td><td>80.0%</td><td>79.1%</td></tr><tr><td>Combined LABA with steroid</td><td>58.3%</td><td>61.9%</td><td>70.0%</td><td>62.8%</td></tr><tr><td>Antibiotics</td><td>58.3%</td><td>61.9%</td><td>60.0%</td><td>60.5%</td></tr><tr><td>Expectorants</td><td>50%</td><td>52.4%</td><td>70.0%</td><td>55.8%</td></tr><tr><td>Combined &#8805;2 bronchodilators</td><td>50.%</td><td>76.2%</td><td>70.0%</td><td>67.4%</td></tr><tr><td>Long acting bronchodilator</td><td>16.7%</td><td>9.5%</td><td>20.0%</td><td>14.0%</td></tr><tr><td>Anti-tussive</td><td>8.3%</td><td>47.6%</td><td>10.0%</td><td>27.9%</td></tr><tr><td>Chinese traditional medicine</td><td>8.3%</td><td>19.1%</td><td>20.0%</td><td>16.3%</td></tr><tr><td>Oral corticosteroids</td><td>0.0%</td><td>14.3%</td><td>0.0%</td><td>7.0%</td></tr><tr><td>ICS</td><td>0.0%</td><td>0%</td><td>10.0%</td><td>2.3%</td></tr></table>
<table><tr><td></td><td>GOLD II</td><td>GOLD III</td><td>GOLD IV</td><td>Total</td></tr><tr><td></td><td>(n = 12)</td><td>(n = 21)</td><td>(n = 10)</td><td>(n = 43)</td></tr></table>
<table><tr><td>Short acting bronchodilator</td><td>75.0%</td><td>80.9%</td><td>80.0%</td><td>79.1%</td></tr><tr><td>Combined LABA with steroid</td><td>58.3%</td><td>61.9%</td><td>70.0%</td><td>62.8%</td></tr><tr><td>Antibiotics</td><td>58.3%</td><td>61.9%</td><td>60.0%</td><td>60.5%</td></tr><tr><td>Expectorants</td><td>50%</td><td>52.4%</td><td>70.0%</td><td>55.8%</td></tr><tr><td>Combined ≥2 bronchodilators</td><td>50.%</td><td>76.2%</td><td>70.0%</td><td>67.4%</td></tr><tr><td>Long acting bronchodilator</td><td>16.7%</td><td>9.5%</td><td>20.0%</td><td>14.0%</td></tr><tr><td>Anti-tussive</td><td>8.3%</td><td>47.6%</td><td>10.0%</td><td>27.9%</td></tr><tr><td>Chinese traditional medicine</td><td>8.3%</td><td>19.1%</td><td>20.0%</td><td>16.3%</td></tr><tr><td>Oral corticosteroids</td><td>0.0%</td><td>14.3%</td><td>0.0%</td><td>7.0%</td></tr><tr><td>ICS</td><td>0.0%</td><td>0%</td><td>10.0%</td><td>2.3%</td></tr></table>
dc2990f6786ed9b47af01a5071897fbd3e55a5db4554e90b007e2408500608f4.png
complex
<table><tr><td>Adipokine</td><td colspan="2">Study time point</td><td>Media alone</td><td>Stimulated</td><td><i>P</i> values</td></tr><tr><td rowspan="4">Adipsin</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.83 (2.12)</td><td>4.74 (3.89)</td><td>0.743 (ns)</td></tr><tr><td>Range</td><td>0&#8211;23.14</td><td>0&#8211;57.72</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>103.40 (48.23)</td><td>92.73 (48.59)</td><td>0.132 (ns)</td></tr><tr><td>Range</td><td>0&#8211;661.30</td><td>0&#8211;651.00</td><td></td></tr><tr><td rowspan="4">MCP-1</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>16.19 (5.12)</td><td>33.22 (13.63)</td><td>0.093 (ns)</td></tr><tr><td>Range</td><td>0&#8211;57.54</td><td>0&#8211;199.90</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>199.80 (183.30)</td><td>179.20 (166.00)</td><td>0.264 (ns)</td></tr><tr><td>Range</td><td>0&#8211;2,398</td><td>0&#8211;2,170</td><td></td></tr><tr><td rowspan="4">IL-1&#946;</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>0.59 (0.54)</td><td>16.37 (5.25)</td><td>0.009</td></tr><tr><td>Range</td><td>0&#8211;8.17</td><td>0&#8211;52.37</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>41.26 (30.94)</td><td>16.57 (11.54)</td><td>0.447 (ns)</td></tr><tr><td>Range</td><td>0&#8211;401.60</td><td>0&#8211;152.20</td><td></td></tr><tr><td rowspan="4">IP-10</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>0.73 (0.33)</td><td>1.30 (0.61)</td><td>0.225 (ns)</td></tr><tr><td>Range</td><td>0&#8211;4.28</td><td>0&#8211;7.67</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>30.97 (28.74)</td><td>9.89 (7.62)</td><td>0.338 (ns)</td></tr><tr><td>Range</td><td>0&#8211;375.70</td><td>0&#8211;101.00</td><td></td></tr><tr><td rowspan="4">CXCL8</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>175.80 (104.20)</td><td>523.40 (191.30)</td><td>0.018</td></tr><tr><td>Range</td><td>0&#8211;1,610</td><td>7.07&#8211;2,422</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>810.60 (395.90)</td><td>961.10 (480.10)</td><td>0.226 (ns)</td></tr><tr><td>Range</td><td>0&#8211;4,738</td><td>17.27&#8211;6,130</td><td></td></tr><tr><td rowspan="4">IL-6</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.69 (3.56)</td><td>23.89 (12.82)</td><td>0.056 (ns)</td></tr><tr><td>Range</td><td>0&#8211;53.43</td><td>0&#8211;187.40</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>218.60 (208.80)</td><td>15.71 (6.24)</td><td>0.342 (ns)</td></tr><tr><td>Range</td><td>0&#8211;2,723</td><td>0&#8211;64.81</td><td></td></tr><tr><td rowspan="4">Resistin</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>89.80 (53.89)</td><td>101.70 (60.39)</td><td>0.204 (ns)</td></tr><tr><td>Range</td><td>0&#8211;747.20</td><td>0&#8211;790.70</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>304.60 (110.40)</td><td>251.10 (101.80)</td><td>0.049</td></tr><tr><td>Range</td><td>14.03&#8211;1,320</td><td>12.98&#8211;1,262</td><td></td></tr><tr><td rowspan="4">TNF-&#945;</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>1.28 (1.02)</td><td>71.44 (26.68)</td><td>0.021</td></tr><tr><td>Range</td><td>0&#8211;15.42</td><td>0&#8211;350.90</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>394.20 (393.10)</td><td>18.35 (6.57)</td><td>0.360 (ns)</td></tr><tr><td>Range</td><td>0&#8211;5,111</td><td>0&#8211;64.89</td><td></td></tr></table>
<table><tr><td>Adipokine</td></tr><tr><td rowspan="4">Adipsin</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">MCP-1</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">IL-1β</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">IP-10</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">CXCL8</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">IL-6</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">Resistin</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">TNF-α</td></tr><tr></tr><tr></tr><tr></tr></table>
<table><tr><td colspan="2">Study time point</td><td>Media alone</td><td>Stimulated</td><td>P values</td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.83 (2.12)</td><td>4.74 (3.89)</td><td>0.743 (ns)</td></tr><tr><td>Range</td><td>0–23.14</td><td>0–57.72</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>103.40 (48.23)</td><td>92.73 (48.59)</td><td>0.132 (ns)</td></tr><tr><td>Range</td><td>0–661.30</td><td>0–651.00</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>16.19 (5.12)</td><td>33.22 (13.63)</td><td>0.093 (ns)</td></tr><tr><td>Range</td><td>0–57.54</td><td>0–199.90</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>199.80 (183.30)</td><td>179.20 (166.00)</td><td>0.264 (ns)</td></tr><tr><td>Range</td><td>0–2,398</td><td>0–2,170</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>0.59 (0.54)</td><td>16.37 (5.25)</td><td>0.009</td></tr><tr><td>Range</td><td>0–8.17</td><td>0–52.37</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>41.26 (30.94)</td><td>16.57 (11.54)</td><td>0.447 (ns)</td></tr><tr><td>Range</td><td>0–401.60</td><td>0–152.20</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>0.73 (0.33)</td><td>1.30 (0.61)</td><td>0.225 (ns)</td></tr><tr><td>Range</td><td>0–4.28</td><td>0–7.67</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>30.97 (28.74)</td><td>9.89 (7.62)</td><td>0.338 (ns)</td></tr><tr><td>Range</td><td>0–375.70</td><td>0–101.00</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>175.80 (104.20)</td><td>523.40 (191.30)</td><td>0.018</td></tr><tr><td>Range</td><td>0–1,610</td><td>7.07–2,422</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>810.60 (395.90)</td><td>961.10 (480.10)</td><td>0.226 (ns)</td></tr><tr><td>Range</td><td>0–4,738</td><td>17.27–6,130</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.69 (3.56)</td><td>23.89 (12.82)</td><td>0.056 (ns)</td></tr><tr><td>Range</td><td>0–53.43</td><td>0–187.40</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>218.60 (208.80)</td><td>15.71 (6.24)</td><td>0.342 (ns)</td></tr><tr><td>Range</td><td>0–2,723</td><td>0–64.81</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>89.80 (53.89)</td><td>101.70 (60.39)</td><td>0.204 (ns)</td></tr><tr><td>Range</td><td>0–747.20</td><td>0–790.70</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>304.60 (110.40)</td><td>251.10 (101.80)</td><td>0.049</td></tr><tr><td>Range</td><td>14.03–1,320</td><td>12.98–1,262</td><td></td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>1.28 (1.02)</td><td>71.44 (26.68)</td><td>0.021</td></tr><tr><td>Range</td><td>0–15.42</td><td>0–350.90</td><td></td></tr><tr><td rowspan="2">Post-int</td><td>Mean (SEM)</td><td>394.20 (393.10)</td><td>18.35 (6.57)</td><td>0.360 (ns)</td></tr><tr><td>Range</td><td>0–5,111</td><td>0–64.89</td><td></td></tr></table>
441eb1c54a2f03d7a83523765491f3808cb5d892dbaceed1350067e33fb87282.png
complex
<table><tr><td>Grade</td><td colspan="3">Normal group</td><td colspan="8">Osteoarthritis group</td></tr><tr><td></td><td>12 F</td><td>39 F</td><td>43 M</td><td>42 M</td><td>49 F</td><td>54 F</td><td>55 M</td><td>58 F</td><td>65 F</td><td>66 F</td><td>70 F</td></tr><tr><td>Transverse section</td><td>0</td><td>0</td><td>0</td><td>2</td><td>2</td><td>3</td><td>3</td><td>1</td><td>3</td><td>4</td><td>4</td></tr><tr><td>Longitudinal section</td><td>0</td><td>0</td><td>0</td><td>3</td><td>1</td><td>3</td><td>3</td><td>1</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Average<sup>a</sup></td><td>0</td><td>0</td><td>0</td><td>2.5</td><td>1.5</td><td>3</td><td>3</td><td>1</td><td>3.5</td><td>4</td><td>4</td></tr></table>
<table><tr><td>Grade</td><td colspan="3">Normal group</td><td colspan="8">Osteoarthritis group</td></tr><tr><td></td><td>12 F</td><td>39 F</td><td>43 M</td><td>42 M</td><td>49 F</td><td>54 F</td><td>55 M</td><td>58 F</td><td>65 F</td><td>66 F</td><td>70 F</td></tr><tr><td>Transverse se</td><td>0</td><td></td><td>0</td><td>2</td><td>2</td><td></td><td>3</td><td>1</td><td>3</td><td></td><td>4</td></tr></table>
<table><tr><td>ction</td><td></td><td>0</td><td></td><td></td><td></td><td>3</td><td></td><td></td><td></td><td>4</td><td></td></tr><tr><td>Longitudinal section</td><td>0</td><td>0</td><td>0</td><td>3</td><td>1</td><td>3</td><td>3</td><td>1</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Averagea</td><td>0</td><td>0</td><td>0</td><td>2.5</td><td>1.5</td><td>3</td><td>3</td><td>1</td><td>3.5</td><td>4</td><td>4</td></tr></table>
fe4947d31561efd4455d129c81aa3fa9eae1087c0acf9a6ad6019c903c49a11f.png
simple
<table><tr><td>Variable</td><td>Comparison used in rate ratio</td><td>Rate ratio (other death/HIV/TB death)</td><td>95% Confidence interval (<i>p</i> value)</td></tr><tr><td>Sex</td><td>Male/female</td><td>1.12</td><td>0.99&#8211;1.27 (0.077)</td></tr><tr><td>Country of origin</td><td>South Africa/Mozambique</td><td>0.85</td><td>0.75&#8211;0.98 (0.023)</td></tr><tr><td>Residence status</td><td>Temporary/permanent</td><td>1.05</td><td>0.91&#8211;1.21 (0.493)</td></tr><tr><td>Distance from Bhubezi(km)</td><td>Greater than 5 km/5 km or less</td><td>1.02</td><td>0.86&#8211;1.20 (0.842)</td></tr><tr><td>SEP quintiles</td><td>Quintiles 2&#8211;5/quintile 1</td><td>0.95</td><td>0.81&#8211;1.11 (0.503)</td></tr><tr><td>Mean level of household education</td><td>Greater than 7 years/7 years or less</td><td>0.93</td><td>0.82&#8211;1.06 (0.294)</td></tr></table>
<table><tr><td>Variable</td><td>Comparison used in rate ratio</td><td>Rate ratio (other death/HIV/TB death)</td><td>95% Confidence interval (p value)</td></tr></table>
<table><tr><td>Sex</td><td>Male/female</td><td>1.12</td><td>0.99–1.27 (0.077)</td></tr><tr><td>Country of origin</td><td>South Africa/Mozambique</td><td>0.85</td><td>0.75–0.98 (0.023)</td></tr><tr><td>Residence status</td><td>Temporary/permanent</td><td>1.05</td><td>0.91–1.21 (0.493)</td></tr><tr><td>Distance from Bhubezi(km)</td><td>Greater than 5 km/5 km or less</td><td>1.02</td><td>0.86–1.20 (0.842)</td></tr><tr><td>SEP quintiles</td><td>Quintiles 2–5/quintile 1</td><td>0.95</td><td>0.81–1.11 (0.503)</td></tr><tr><td>Mean level of household education</td><td>Greater than 7 years/7 years or less</td><td>0.93</td><td>0.82–1.06 (0.294)</td></tr></table>
afb3f9e5bd4f871f1d3b263a3e2e79aa62313b08f41ba94b092294f589822ae3.png
complex
<table><tr><td colspan="2">ABRA system delayed closure system</td></tr><tr><td>Pros</td><td>Cons</td></tr><tr><td>ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequential dressings, preventing fascial retraction</td><td>ABRA abdominal wall closure requires two to three interventions in operation room under general anesthesia</td></tr><tr><td>No skin grafts required when using ABRA</td><td>ABRA system need a normal skin of 5&#8211;6 cm around the abdominal wound (in order to place the elastomers)</td></tr><tr><td>Reduction in the numbers of days to any closure</td><td>The possibility to need to be used in conjunction with another dressing system</td></tr><tr><td>The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system</td><td>There is no active removal of the fluids. So if the peritonitis is still active a dressing system with 24&#8211;48 h re-interventions could be the best option</td></tr></table>
<table><tr><td colspan="2">ABRA system delayed closure system</td></tr><tr><td>Pros</td><td>Cons</td></tr><tr><td>ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequential dressings, preventing fascial retraction</td><td>ABRA abdominal wall closure requires two to three interventions in operation room under general anesthesia</td></tr><tr><td>No skin grafts required when using ABRA</td><td>ABRA system need a normal skin of 5–6 cm around the abdominal wound (in order to place the elastomers)</td></tr><tr><td>Reduction in the numbers of days to any cl</td><td>T</td></tr></table>
<table><tr><td>osure</td><td>he possibility to need to be used in conjunction with another dressing system</td></tr><tr><td>The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system</td><td>There is no active removal of the fluids. So if the peritonitis is still active a dressing system with 24–48 h re-interventions could be the best option</td></tr></table>
f4064b9fdbc7cce1191133eebba77c9db43fd93e5ef4f88585979e6da361816d.png
simple
<table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>Greek</td><td>34/2467 (1.4%)</td><td>3/174 (1.7%)</td></tr><tr><td>Albanian</td><td>20/227 (8.8%)</td><td>6/61 (9.8%)</td></tr><tr><td>Others*</td><td>11/135 (8.1%)</td><td>2/27 (7.4%)</td></tr><tr><td>Total</td><td>65/2829 (2.3%)**</td><td>11/262 (4.2%)**</td></tr></table>
<table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>Greek</td><td>34/2467 (1.4%)</td><td>3/174 (1.7%)</td></tr><tr><td>A</td><td>2</td><td>6/61 (9.8%</td></tr></table>
<table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>lbanian</td><td>0/227 (8.8%)</td><td>)</td></tr><tr><td>Others*</td><td>11/135 (8.1%)</td><td>2/27 (7.4%)</td></tr><tr><td>Total</td><td>65/2829 (2.3%)**</td><td>11/262 (4.2%)**</td></tr></table>
b0817948de46d0b3c6551eaebc4dd0fa5b3fb6c4b03315a7a191845effd24884.png
simple
<table><tr><td>Study characteristics</td><td>Nepal trial*</td><td>Bangladesh trial</td><td>Pakistan trial</td></tr><tr><td>Type of study</td><td>Cluster RCT</td><td>Cluster RCT</td><td>2 &#215; 2 factorial design cluster RCT</td></tr><tr><td>No. clusters (average size)</td><td>413 (700)</td><td>133 (4100)</td><td>187 (1000)</td></tr><tr><td>Sample size total</td><td>15,123</td><td>29,760</td><td>9,741</td></tr><tr><td>Average sample size per group</td><td>~ 5,050</td><td>~ 9,900</td><td>~ 4,850</td></tr><tr><td>Duration of trial</td><td>Nov 2002 to Mar 2005</td><td>Jun 2007 to Sep 2009</td><td>Jan 2008 to Jun 2009</td></tr><tr><td>Overall NMR</td><td>32/1000</td><td>36/1000</td><td>30/1000</td></tr><tr><td>% of home births</td><td>92 %</td><td>93 %</td><td>80 %</td></tr><tr><td>Inclusion criteria</td><td>All live births in the study area</td><td>All live births in the study area</td><td>All live births in the study area were included except those who were born in hospitals.</td></tr><tr><td>Exclusion criteria</td><td>Not met within 10 days after birth</td><td>Didn&#8217;t receive intervention within 7 days after birth</td><td>Not met within 3 days after birth. Babies with congenital anomalies</td></tr><tr><td>Comparison group</td><td>Dry cord care</td><td>Dry cord care</td><td>Dry cord care</td></tr><tr><td>Intervention groups</td><td>1.Multiple CHX2.Soap/H<sub>2</sub>O</td><td>1.Multiple CHX2.Single CHX</td><td>1.Multiple CHX2.Handwashing (HW)3.CHX + HW</td></tr><tr><td>CHX concentration</td><td>4.0 %</td><td>4.0 %</td><td>4.0 %</td></tr><tr><td>Participants recruiters</td><td>Local female worker</td><td>CHWs</td><td>CHWs</td></tr><tr><td>Intervention providers</td><td>Local project staff</td><td>Village health worker</td><td>TBA to caretaker</td></tr><tr><td>Outcome assessors</td><td>(Nonmedical) field workers</td><td>CHWs</td><td>CHWs</td></tr><tr><td>Basic interventions to all babies/mothers</td><td>CDK, FE/FA, TT, promotion of ANC/ENC</td><td>CDK. FE/FA, promotion of TT, ANC, birth preparedness, ENC</td><td>Basic component of ENC as promoted by Ministry of Health</td></tr><tr><td>Primary outcomes</td><td>Omphalitis, neonatal mortality</td><td>Omphalitis, neonatal mortality</td><td>Omphalitis, neonatal mortality</td></tr><tr><td>Follow up days</td><td>1, 2, 3, 4, 6, 8, 10, 12, 14, 21, 28</td><td>1,3,6,9,15,28</td><td>1,3,5,7,14,28</td></tr></table>
<table><tr><td>Study characteristics</td></tr><tr><td>Type of study</td></tr><tr><td>No. clusters (average size)</td></tr><tr><td>Sample size total</td></tr><tr><td>Average sample size per group</td></tr><tr><td>Duration of trial</td></tr><tr><td>Overall NMR</td></tr><tr><td>% of home births</td></tr><tr><td>Inclusion criteria</td></tr><tr><td>Exclusion criteria</td></tr><tr><td>Comparison group</td></tr><tr><td>Intervention groups</td></tr><tr><td>CHX concentration</td></tr><tr><td>Participants recruiters</td></tr><tr><td>Intervention providers</td></tr><tr><td>Outcome assessors</td></tr><tr><td>Basic interventions to all babies/mothers</td></tr><tr><td>Primary outcomes</td></tr><tr><td>Follow up days</td></tr></table>
<table><tr><td>Nepal trial*</td><td>Bangladesh trial</td><td>Pakistan trial</td></tr><tr><td>Cluster RCT</td><td>Cluster RCT</td><td>2 × 2 factorial design cluster RCT</td></tr><tr><td>413 (700)</td><td>133 (4100)</td><td>187 (1000)</td></tr><tr><td>15,123</td><td>29,760</td><td>9,741</td></tr><tr><td>~ 5,050</td><td>~ 9,900</td><td>~ 4,850</td></tr><tr><td>Nov 2002 to Mar 2005</td><td>Jun 2007 to Sep 2009</td><td>Jan 2008 to Jun 2009</td></tr><tr><td>32/1000</td><td>36/1000</td><td>30/1000</td></tr><tr><td>92 %</td><td>93 %</td><td>80 %</td></tr><tr><td>All live births in the study area</td><td>All live births in the study area</td><td>All live births in the study area were included except those who were born in hospitals.</td></tr><tr><td>Not met within 10 days after birth</td><td>Didn’t receive intervention within 7 days after birth</td><td>Not met within 3 days after birth. Babies with congenital anomalies</td></tr><tr><td>Dry cord care</td><td>Dry cord care</td><td>Dry cord care</td></tr><tr><td>1.Multiple CHX2.Soap/H2O</td><td>1.Multiple CHX2.Single CHX</td><td>1.Multiple CHX2.Handwashing (HW)3.CHX + HW</td></tr><tr><td>4.0 %</td><td>4.0 %</td><td>4.0 %</td></tr><tr><td>Local female worker</td><td>CHWs</td><td>CHWs</td></tr><tr><td>Local project staff</td><td>Village health worker</td><td>TBA to caretaker</td></tr><tr><td>(Nonmedical) field workers</td><td>CHWs</td><td>CHWs</td></tr><tr><td>CDK, FE/FA, TT, promotion of ANC/ENC</td><td>CDK. FE/FA, promotion of TT, ANC, birth preparedness, ENC</td><td>Basic component of ENC as promoted by Ministry of Health</td></tr><tr><td>Omphalitis, neonatal mortality</td><td>Omphalitis, neonatal mortality</td><td>Omphalitis, neonatal mortality</td></tr><tr><td>1, 2, 3, 4, 6, 8, 10, 12, 14, 21, 28</td><td>1,3,6,9,15,28</td><td>1,3,5,7,14,28</td></tr></table>
145b658c4b48cbc5eb6ee5a81f6b081a4f8504427ce2ea7d2e7479b3869c280a.png
complex
<table><tr><td></td><td colspan="2">WHO guideline<sup>a</sup></td><td colspan="2">Swiss TPH guideline<sup>a</sup></td></tr><tr><td></td><td><i>Trichuris trichiura</i></td><td><i>Ascaris lumbricoides</i></td><td><i>Trichuris trichiura</i></td><td><i>Ascaris lumbricoides</i></td></tr><tr><td>Total number of Kato-Katz thick smears (positive/negative)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td></tr><tr><td>1. No. of Kato-Katz thick smears with difference in FECs (%)</td><td>345 (23.9%)</td><td>148 (10.2%)</td><td>97 (6.7%)</td><td>108 (7.5%)</td></tr><tr><td>2. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%)</td><td>51 (3.5%)</td><td>32 (2.2%)</td><td>51 (3.5%)</td><td>32 (2.2%)</td></tr><tr><td>3. No. of Kato-Katz thick smears with difference in FECs (%) among samples with egg counts</td><td>345 (29.0%)</td><td>148 (49.8%)</td><td>97 (8.2%)</td><td>108 (36.4%)</td></tr><tr><td>4. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%) among samples with egg counts</td><td>51 (4.3%)</td><td>32 (10.8%)</td><td>51 (4.3%)</td><td>32 (10.8%)</td></tr><tr><td>1. and/or 2. (%)</td><td>381 (26.4%)</td><td>164 (11.4%)</td><td>145 (10.0%)</td><td>130 (9.0%)</td></tr><tr><td>No. of Kato-Katz thick smears with discrepancies according to respective guideline<sup>b</sup> (%)</td><td>345 (23.9%)</td><td>164 (11.4%)</td><td>145 (10.0%)</td><td>130 (9.0%)</td></tr><tr><td>3. and/or 4. and proportion as percentage (%) among Kato-Katz thick smears with positive egg counts</td><td>381 (32.0%)</td><td>164 (55.2%)</td><td>145 (12.2%)</td><td>130 (43.8%)</td></tr><tr><td>No. of Kato-Katz thick smears with discrepancies according to respective guideline<sup>b</sup> (%) among Kato-Katz thick smears with positive egg counts</td><td>345 (29.0%)</td><td>148 (49.8%)</td><td>145 (12.2%)</td><td>130 (43.8%)</td></tr></table>
<table><tr><td></td><td colspan="2">WHO guidelinea</td><td colspan="2">Swiss TPH guidelinea</td></tr><tr><td></td><td>Trichuris trichiura</td><td>Ascaris lumbricoides</td><td>Trichuris trichiura</td><td>Ascaris lumbricoides</td></tr></table>
<table><tr><td>Total number of Kato-Katz thick smears (positive/negative)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td></tr><tr><td>1. No. of Kato-Katz thick smears with difference in FECs (%)</td><td>345 (23.9%)</td><td>148 (10.2%)</td><td>97 (6.7%)</td><td>108 (7.5%)</td></tr><tr><td>2. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%)</td><td>51 (3.5%)</td><td>32 (2.2%)</td><td>51 (3.5%)</td><td>32 (2.2%)</td></tr><tr><td>3. No. of Kato-Katz thick smears with difference in FECs (%) among samples with egg counts</td><td>345 (29.0%)</td><td>148 (49.8%)</td><td>97 (8.2%)</td><td>108 (36.4%)</td></tr><tr><td>4. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%) among samples with egg counts</td><td>51 (4.3%)</td><td>32 (10.8%)</td><td>51 (4.3%)</td><td>32 (10.8%)</td></tr><tr><td>1. and/or 2. (%)</td><td>381 (26.4%)</td><td>164 (11.4%)</td><td>145 (10.0%)</td><td>130 (9.0%)</td></tr><tr><td>No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%)</td><td>345 (23.9%)</td><td>164 (11.4%)</td><td>145 (10.0%)</td><td>130 (9.0%)</td></tr><tr><td>3. and/or 4. and proportion as percentage (%) among Kato-Katz thick smears with positive egg counts</td><td>381 (32.0%)</td><td>164 (55.2%)</td><td>145 (12.2%)</td><td>130 (43.8%)</td></tr><tr><td>No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%) among Kato-Katz thick smears with positive egg counts</td><td>345 (29.0%)</td><td>148 (49.8%)</td><td>145 (12.2%)</td><td>130 (43.8%)</td></tr></table>
6abf16cd0b41fb3a390497ed183cfe53079fb71f04fb53f6ea5fc44157f086bf.png
complex
<table><tr><td rowspan="2">Biologics</td><td colspan="3">Pooled incremental efficacy</td><td colspan="3">6-month incremental cost-effectiveness ratio</td></tr><tr><td>Base case</td><td>Best case </td><td>Worst case</td><td>Base case</td><td>Best case</td><td>Worst case </td></tr><tr><td>Etanercept</td><td>58%</td><td>71%</td><td>45%</td><td>$30,954</td><td>$25,287</td><td>$39,897</td></tr><tr><td>Adalimumab</td><td>56%</td><td>59%</td><td>52%</td><td>$23,980</td><td>$22,760</td><td>$25,824</td></tr><tr><td>Infliximab</td><td>69%</td><td>76%</td><td>63%</td><td>$28,587</td><td>$25,954</td><td>$31,310</td></tr><tr><td>Ustekinumab 45 mg</td><td>58%</td><td>64%</td><td>51%</td><td>$28,943</td><td>$26,229</td><td>$32,915</td></tr><tr><td>Ustekinumab 90 mg</td><td>62%</td><td>66%</td><td>58%</td><td>$54,151</td><td>$50,869</td><td>$57,886</td></tr></table>
<table><tr><td rowspan="2">Biologics</td><td colspan="3">Pooled incremental efficacy</td></tr><tr><td>Base case</td><td>Best case</td><td>Worst case</td></tr><tr><td>Etanercept</td><td>58%</td><td>71%</td><td>45%</td></tr><tr><td>Adalimumab</td><td>56%</td><td>59%</td><td>52%</td></tr><tr><td>Infliximab</td><td>69%</td><td>76%</td><td>63%</td></tr><tr><td>Ustekinumab 45 mg</td><td>58%</td><td>64%</td><td>51%</td></tr><tr><td>Ustekinumab 90 mg</td><td>62%</td><td>66%</td><td>58%</td></tr></table>
<table><tr><td colspan="3">6-month incremental cost-effectiveness ratio</td></tr><tr><td>Base case</td><td>Best case</td><td>Worst case</td></tr><tr><td>$30,954</td><td>$25,287</td><td>$39,897</td></tr><tr><td>$23,980</td><td>$22,760</td><td>$25,824</td></tr><tr><td>$28,587</td><td>$25,954</td><td>$31,310</td></tr><tr><td>$28,943</td><td>$26,229</td><td>$32,915</td></tr><tr><td>$54,151</td><td>$50,869</td><td>$57,886</td></tr></table>
5f6efd8a98a9d3a8efa8db04b6c10aa609213228e12e9d16fcfef1390f330e92.png
complex
<table><tr><td colspan="2">Architecture</td><td>DeepLab without CRF (Chen et al., 2014)</td><td>FCN (Long et al., 2015)</td><td>U-Net (Ronneberger et al., 2015)</td><td>DeconvNet (Noh et al., 2015)</td></tr><tr><td colspan="2">Side length of receptive field</td><td>44</td><td>52</td><td>46</td><td>44</td></tr><tr><td rowspan="3">Dice</td><td>train</td><td>0.60</td><td>0.66</td><td>0.71</td><td>0.71</td></tr><tr><td>val</td><td>0.55</td><td>0.60</td><td>0.64</td><td>0.62</td></tr><tr><td>test</td><td>0.48</td><td>0.50</td><td>0.52</td><td>0.55</td></tr><tr><td rowspan="3">m#FP</td><td>train</td><td>10.35</td><td>11.73</td><td>7.86</td><td>8.32</td></tr><tr><td>val</td><td>11.51</td><td>13.30</td><td>8.95</td><td>10.08</td></tr><tr><td>test</td><td>12.81</td><td>16.44</td><td>12.85</td><td>11.78</td></tr><tr><td rowspan="3">m#FN</td><td>train</td><td>4.80</td><td>2.96</td><td>2.35</td><td>2.19</td></tr><tr><td>val</td><td>4.91</td><td>4.00</td><td>3.92</td><td>4.03</td></tr><tr><td>test</td><td>5.22</td><td>3.88</td><td>3.99</td><td>3.99</td></tr><tr><td rowspan="3">mSFP</td><td>train</td><td>7.23</td><td>8.40</td><td>9.56</td><td>8.60</td></tr><tr><td>val</td><td>7.29</td><td>8.66</td><td>9.10</td><td>8.69</td></tr><tr><td>test</td><td>8.25</td><td>9.92</td><td>11.50</td><td>10.14</td></tr><tr><td rowspan="3">mSFN</td><td>train</td><td>3.34</td><td>2.03</td><td>2.17</td><td>1.80</td></tr><tr><td>val</td><td>6.53</td><td>5.84</td><td>6.20</td><td>5.11</td></tr><tr><td>test</td><td>4.08</td><td>3.66</td><td>4.17</td><td>3.58</td></tr><tr><td rowspan="3">DR</td><td>train</td><td>0.97</td><td>0.99</td><td>0.99</td><td>0.99</td></tr><tr><td>val</td><td>0.98</td><td>0.99</td><td>0.99</td><td>0.97</td></tr><tr><td>test</td><td>0.93</td><td>0.94</td><td>0.94</td><td>0.94</td></tr></table>
<table><tr><td colspan="2">Architecture</td><td>DeepLab without CRF (Chen et al., 2014)</td><td>FCN (Long et al., 2015)</td><td>U-Net (Ronneberger et al., 2015)</td><td>DeconvNet (Noh et al., 2015)</td></tr><tr><td colspan="2">Side length of receptive field</td><td>44</td><td>52</td><td>46</td><td>44</td></tr><tr><td rowspan="3">Dice</td><td>train</td><td>0.60</td><td>0.66</td><td>0.71</td><td>0.71</td></tr><tr><td>val</td><td>0.55</td><td>0.60</td><td>0.64</td><td>0.62</td></tr><tr><td>test</td><td>0.48</td><td>0.50</td><td>0.52</td><td>0.55</td></tr><tr><td rowspan="3">m#FP</td><td>train</td><td>10.35</td><td>11.73</td><td>7.86</td><td>8.32</td></tr><tr><td>val</td><td>11.51</td><td>13.30</td><td>8.95</td><td>10.08</td></tr><tr><td>test</td><td>12.81</td><td>16.44</td><td>12.85</td><td>11.78</td></tr><tr><td rowspan="3">m#FN</td><td>train</td><td>4.80</td><td>2.96</td><td>2.35</td><td>2.19</td></tr><tr><td>val</td><td>4.91</td><td>4.00</td><td>3.92</td><td>4.03</td></tr><tr><td>test</td><td>5.22</td><td>3.88</td><td>3.99</td><td>3.99</td></tr><tr><td rowspan="3">mSFP</td><td>train</td><td>7.23</td><td>8.40</td><td>9.56</td><td>8.60</td></tr><tr><td>val</td><td>7.29</td><td>8.66</td><td>9.10</td><td>8.69</td></tr><tr><td>test</td><td>8.25</td><td>9.92</td><td>11.50</td><td>10.14</td></tr><tr><td rowspan="2">mSFN</td><td>train</td><td>3.34</td><td>2.03</td><td>2.17</td><td>1.80</td></tr><tr><td>va</td><td>6.5</td><td>5.</td><td>6.20</td><td>5.</td></tr></table>
<table><tr><td rowspan="2"></td><td>l</td><td>3</td><td>84</td><td></td><td>11</td></tr><tr><td>test</td><td>4.08</td><td>3.66</td><td>4.17</td><td>3.58</td></tr><tr><td rowspan="3">DR</td><td>train</td><td>0.97</td><td>0.99</td><td>0.99</td><td>0.99</td></tr><tr><td>val</td><td>0.98</td><td>0.99</td><td>0.99</td><td>0.97</td></tr><tr><td>test</td><td>0.93</td><td>0.94</td><td>0.94</td><td>0.94</td></tr></table>
881dc21d1cb9252d760f00d67998f553edca3f1665832524d94c9b27eae25418.png
complex
<table><tr><td></td><td colspan="3">All suicide</td><td colspan="3">Firearm suicide</td><td colspan="3">Nonfirearm suicide</td></tr><tr><td></td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td></tr><tr><td>Crude analyses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NonTCA^:TCA ratio</td><td>0.85</td><td>(0.76, 0.95)</td><td>0.0040</td><td>0.69</td><td>(0.57, 0.84)</td><td>0.0002</td><td>1.07</td><td>(0.96, 1.18)</td><td>0.2270</td></tr><tr><td>Multivariate analyses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Household firearm ownership</td><td>1.29</td><td>(1.18, 1.40)</td><td>&lt;.0001</td><td>1.67</td><td>(1.49, 1.88)</td><td>&lt;.0001</td><td>1.04</td><td>(0.94, 1.16)</td><td>0.4441</td></tr><tr><td>NonTCA^:TCA ratio</td><td>1.02</td><td>(0.91, 1.14)</td><td>0.7462</td><td>1.05</td><td>(0.90, 1.22)</td><td>0.5392</td><td>1.02</td><td>(0.89, 1.17)</td><td>0.8198</td></tr><tr><td>% Population living in urban area</td><td>1.09</td><td>(1.01, 1.19)</td><td>0.0293</td><td>1.14</td><td>(1.02, 1.27)</td><td>0.0211</td><td>1.08</td><td>(0.98, 1.20)</td><td>0.1407</td></tr><tr><td>Median income</td><td>0.99</td><td>(0.95, 1.02)</td><td>0.4770</td><td>0.97</td><td>(0.93, 1.02)</td><td>0.2758</td><td>1.01</td><td>(0.96, 1.07)</td><td>0.6421</td></tr><tr><td>Unemployment rate</td><td>1.01</td><td>(0.98, 1.03)</td><td>0.6227</td><td>0.99</td><td>(0.96, 1.03)</td><td>0.6932</td><td>1.01</td><td>(0.98, 1.05)</td><td>0.5231</td></tr></table>
<table><tr><td></td><td colspan="3">All suicide</td><td colspan="3">Firearm suicide</td><td colspan="3">Nonfirearm suicide</td></tr><tr><td></td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td></tr></table>
<table><tr><td>Crude analyses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NonTCA^:TCA ratio</td><td>0.85</td><td>(0.76, 0.95)</td><td>0.0040</td><td>0.69</td><td>(0.57, 0.84)</td><td>0.0002</td><td>1.07</td><td>(0.96, 1.18)</td><td>0.2270</td></tr><tr><td>Multivariate analyses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Household firearm ownership</td><td>1.29</td><td>(1.18, 1.40)</td><td><.0001</td><td>1.67</td><td>(1.49, 1.88)</td><td><.0001</td><td>1.04</td><td>(0.94, 1.16)</td><td>0.4441</td></tr><tr><td>NonTCA^:TCA ratio</td><td>1.02</td><td>(0.91, 1.14)</td><td>0.7462</td><td>1.05</td><td>(0.90, 1.22)</td><td>0.5392</td><td>1.02</td><td>(0.89, 1.17)</td><td>0.8198</td></tr><tr><td>% Population living in urban area</td><td>1.09</td><td>(1.01, 1.19)</td><td>0.0293</td><td>1.14</td><td>(1.02, 1.27)</td><td>0.0211</td><td>1.08</td><td>(0.98, 1.20)</td><td>0.1407</td></tr><tr><td>Median income</td><td>0.99</td><td>(0.95, 1.02)</td><td>0.4770</td><td>0.97</td><td>(0.93, 1.02)</td><td>0.2758</td><td>1.01</td><td>(0.96, 1.07)</td><td>0.6421</td></tr><tr><td>Unemployment rate</td><td>1.01</td><td>(0.98, 1.03)</td><td>0.6227</td><td>0.99</td><td>(0.96, 1.03)</td><td>0.6932</td><td>1.01</td><td>(0.98, 1.05)</td><td>0.5231</td></tr></table>
9322965dadc8a9a52fd5a7c5faa7d0b4d3d3d49ae7ea439b99080bf82ff05e04.png
simple
<table><tr><td> </td><td>Low-income countries</td><td>Middle-income countries</td><td>High-income countries</td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Number of global countries where data is &lt; 5% gross monthly income</td><td>5</td><td>78</td><td>46</td></tr><tr><td>% of subscriptions with broadband speeds 10 mbps or higher</td><td>7</td><td>50</td><td>75</td></tr></table>
<table><tr><td></td><td>Low-income countries</td><td>Middle-income countries</td><td>High-income countries</td></tr></table>
<table><tr><td></td><td></td><td></td><td></td></tr><tr><td>Number of global countries where data is < 5% gross monthly income</td><td>5</td><td>78</td><td>46</td></tr><tr><td>% of subscriptions with broadband speeds 10 mbps or higher</td><td>7</td><td>50</td><td>75</td></tr></table>
e9d01862d3bdafff21ee423db8d43c950c69c544c86b6a98fcb0d2e3c2390fbe.png
simple
<table><tr><td>Variable</td><td>RBHS group (<i>n</i> = 36)</td><td>Control group (<i>n</i> = 38)</td><td><i>P</i>value</td></tr><tr><td>Composite outcome (any morbid event)</td><td>1 (2.8)</td><td>5 (13.1)</td><td>0.20</td></tr><tr><td>Morbid events<sup>a</sup></td><td> </td><td> </td><td> </td></tr><tr><td>Infection</td><td>0 (0%)</td><td>1 (2.8%)</td><td>0.20</td></tr><tr><td>Thrombotic</td><td>1 (2.8%)</td><td>2 (5.3%)</td><td>0.87</td></tr><tr><td>Renal</td><td>1 (2.8%)</td><td>2 (5.3%)</td><td>0.87</td></tr><tr><td>Respiratory</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr><tr><td>Stroke</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr><tr><td>Myocardial infarction</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr></table>
<table><tr><td>Variable</td><td>RBHS group (n = 36)</td><td>Control group (n = 38)</td><td>Pvalue</td></tr></table>
<table><tr><td>Composite outcome (any morbid event)</td><td>1 (2.8)</td><td>5 (13.1)</td><td>0.20</td></tr><tr><td>Morbid eventsa</td><td></td><td></td><td></td></tr><tr><td>Infection</td><td>0 (0%)</td><td>1 (2.8%)</td><td>0.20</td></tr><tr><td>Thrombotic</td><td>1 (2.8%)</td><td>2 (5.3%)</td><td>0.87</td></tr><tr><td>Renal</td><td>1 (2.8%)</td><td>2 (5.3%)</td><td>0.87</td></tr><tr><td>Respiratory</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr><tr><td>Stroke</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr><tr><td>Myocardial infarction</td><td>0 (0%)</td><td>0 (0%)</td><td>NS</td></tr></table>
654c68c317a8e166c351f5696c53739ea0216d723d9733c8cae47a5f3b2227db.png
simple
<table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td><i>n</i></td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>Italy</td><td>SEpiAs</td><td>2010</td><td>20&#8211;44</td><td>271</td><td>8.76</td><td>7.78</td><td>86.28</td><td>[49]</td></tr><tr><td>Germany</td><td>GerES-III</td><td>1998</td><td>18&#8211;6925&#8211;69</td><td>47414052</td><td>3.923.87</td><td>4.14.0</td><td>18.919.3</td><td>[90,91]</td></tr><tr><td>France</td><td>ENNS</td><td>2006&#8211;2007</td><td>18&#8211;3918&#8211;74</td><td>4441500</td><td>4.073.75</td><td>4.494.03</td><td>10.7210.68</td><td>[92]</td></tr><tr><td>France</td><td>ENNS</td><td>2006&#8211;2007</td><td>18&#8211;74</td><td>3015</td><td>3.75</td><td>nr</td><td>nr</td><td>[83]</td></tr><tr><td>USA</td><td>NHANES</td><td>2009&#8211;20102011&#8211;2012</td><td>&gt;20 years</td><td>20201724</td><td>6.75.6</td><td>5.955.15</td><td>23.217.6</td><td>[57]</td></tr></table>
<table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td>n</td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>Italy</td><td>SEpiAs</td><td>2010</td><td>20–44</td><td>271</td><td>8.76</td><td>7.78</td><td>86.28</td><td>[49]</td></tr><tr><td>Germany</td><td>GerES-III</td><td>1998</td><td>18–6925–69</td><td>47414052</td><td>3.923.87</td><td>4.14.0</td><td>18.919.3</td><td>[90,91]</td></tr><tr><td>France</td><td>ENNS</td><td>2006–2007</td><td>18–3918–74</td><td>4441500</td><td>4.073.75</td><td>4.494.03</td><td>10.7210.68</td><td>[92]</td></tr><tr><td>France</td><td>ENNS</td><td>2006–2007</td><td>18–74</td><td>3015</td><td>3.75</td><td>nr</td><td>nr</td><td>[83]</td></tr></table>
<table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td>n</td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>USA</td><td>NHANES</td><td>2009–20102011–2012</td><td>>20 years</td><td>20201724</td><td>6.75.6</td><td>5.955.15</td><td>23.217.6</td><td>[57]</td></tr></table>
ea1e6b33085e4c667c7e53f6fae6b8121c82a1ea38d0e19a1fd7dbd2191a9f28.png
simple
<table><tr><td>Data Set</td><td>Original</td><td>Global Median</td><td>Quantile</td><td>Cyclic Loess</td><td>IS.Median</td><td>Invariant Set</td></tr><tr><td>PSD</td><td>4.18% (1.96%)</td><td>2.15% (1.41%)</td><td>1.97% (1.12%)</td><td>2.12% (1.39%)</td><td>3.09% (1.51%)</td><td>1.99% (1.29%)</td></tr><tr><td>CSP</td><td>4.04% (2.82%)</td><td>3.47% (2.75%)</td><td>2.85% (2.03%)</td><td>3.26% (2.16%)</td><td>NA</td><td>3.29% (2.43%)</td></tr><tr><td><i>S. Pyogene</i></td><td>3.05% (2.78%)</td><td>3.47% (2.84%)</td><td>2.34% (2.02%)</td><td>2.85% (3.15%)</td><td>3.12% (3.32%)</td><td>2.69% (2.74%)</td></tr></table>
<table><tr><td>Data Set</td><td>Original</td><td>Global Median</td><td>Quantile</td><td>Cyclic Loess</td><td>IS.Median</td><td>Invariant Set</td></tr><tr><td>PSD</td><td>4.18% (1.96%)</td><td>2.15% (1.41%)</td><td>1.97% (1.12%)</td><td>2.12% (1.39%)</td><td>3.09% (1.51%)</td><td>1.99% (1.29%)</td></tr><tr><td>CSP</td><td>4.04% (2.82%)</td><td>3.47% (2.75%)</td><td>2.85% (2.03%)</td><td>3.26% (2.16%)</td><td>NA</td><td>3.29% (2.43%)</td></tr></table>
<table><tr><td>S. Pyogene</td><td>3.05% (2.78%)</td><td>3.47% (2.84%)</td><td>2.34% (2.02%)</td><td>2.85% (3.15%)</td><td>3.12% (3.32%)</td><td>2.69% (2.74%)</td></tr></table>
4a742c470c67b5180dab320c5f43da5d4283917c4d0c3004c8edabb5a921548a.png
simple
<table><tr><td>Clinical indicators</td><td>OR (95 % CI)</td><td><i>p</i>-value</td><td>Multivariable OR (95 % CI)</td><td><i>p</i>-value</td></tr><tr><td>LDL-C goal attainment</td><td></td><td></td><td></td><td></td></tr><tr><td> LDL-C &#8805; 100 mg/dL</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td> LDL-C 70&#8211;99 mg/dL</td><td>0.75 (0.36&#8211;1.58)</td><td>0.448</td><td>0.67 (0.35&#8211;1.30)</td><td>0.240</td></tr><tr><td> LDL-C &lt; 70 mg/dL</td><td>0.55 (0.33&#8211;0.91)</td><td>0.019</td><td>0.43 (0.27&#8211;0.69)</td><td>&lt;0.001</td></tr><tr><td>Revascularization</td><td>0.32 (0.17&#8211;0.63)</td><td>0.001</td><td>0.44 (0.24&#8211;0.81)</td><td>0.009</td></tr><tr><td>eGFR &lt; 60 mL/min/1.73 m<sup>2</sup></td><td>3.24 (2.74&#8211;3.82)</td><td>&lt;0.001</td><td>2.46 (2.21&#8211;2.75)</td><td>&lt;0.001</td></tr><tr><td>Male gender</td><td>1.25 (0.79&#8211;1.96)</td><td>0.337</td><td>1.85 (1.29&#8211;2.66)</td><td>0.001</td></tr><tr><td>Age (year)</td><td>1.03 (1.01&#8211;1.04)</td><td>&lt;0.001</td><td>1.00 (0.99&#8211;1.03)</td><td>0.258</td></tr><tr><td>Hypertension</td><td>2.39 (1.20&#8211;4.73)</td><td>0.013</td><td>1.66 (0.70&#8211;3.95)</td><td>0.249</td></tr><tr><td>ACEI/ARB</td><td>0.53 (0.35&#8211;0.81)</td><td>0.003</td><td>0.72 (0.49&#8211;1.06)</td><td>0.101</td></tr><tr><td>Diabetes mellitus</td><td>2.09 (0.67&#8211;6.50)</td><td>0.202</td><td>1.56 (0.52&#8211;4.73)</td><td>0.428</td></tr><tr><td>Follow-up time (day)<sup>a</sup></td><td>1.00 (1.00&#8211;1.00)</td><td>0.908</td><td>1.00 (1.00&#8211;1.00)</td><td>0.890</td></tr></table>
<table><tr><td>Clinical indicators</td><td>OR (95 % CI)</td><td>p-value</td><td>Multivariable OR (95 % CI)</td></tr><tr><td>LDL-C goal attainment</td><td></td><td></td><td></td></tr><tr><td>LDL-C ≥ 100 mg/dL</td><td>1.00</td><td></td><td>1.00</td></tr><tr><td>LDL-C 70–99 mg/dL</td><td>0.75 (0.36–1.58)</td><td>0.448</td><td>0.67 (0.35–1.30)</td></tr><tr><td>LDL-C < 70 mg/dL</td><td>0.55 (0.33–0.91)</td><td>0.019</td><td>0.43 (0.27–0.69)</td></tr><tr><td>Revascularization</td><td>0.32 (0.17–0.63)</td><td>0.001</td><td>0.44 (0.24–0.81)</td></tr><tr><td>eGFR < 60 mL/min/1.73 m2</td><td>3.24 (2.74–3.82)</td><td><0.001</td><td>2.46 (2.21–2.75)</td></tr><tr><td>Male gender</td><td>1.25 (0.79–1.96)</td><td>0.337</td><td>1.85 (1.29–2.66)</td></tr><tr><td>Age (year)</td><td>1.03 (1.01–1.04)</td><td><0.001</td><td>1.00 (0.99–1.03)</td></tr><tr><td>Hypertension</td><td>2.39 (1.20–4.73)</td><td>0.013</td><td>1.66 (0.70–3.95)</td></tr><tr><td>ACEI/ARB</td><td>0.53 (0.35–0.81)</td><td>0.003</td><td>0.72 (0.49–1.06)</td></tr><tr><td>Diabetes mellitus</td><td>2.09 (0.67–6.50)</td><td>0.202</td><td>1.56 (0.52–4.73)</td></tr><tr><td>Follow-up time (day)a</td><td>1.00 (1.00–1.00)</td><td>0.908</td><td>1.00 (1.00–1.00)</td></tr></table>
<table><tr><td>p-value</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>0.240</td></tr><tr><td><0.001</td></tr><tr><td>0.009</td></tr><tr><td><0.001</td></tr><tr><td>0.001</td></tr><tr><td>0.258</td></tr><tr><td>0.249</td></tr><tr><td>0.101</td></tr><tr><td>0.428</td></tr><tr><td>0.890</td></tr></table>
3ffddc2eb3a94c219a38abf48d0b3018ee3c1a9728bf0c0fd4666188a0d930b9.png
complex
<table><tr><td>Function</td><td>Gene</td><td>Accession no.<sup>&#8727;</sup></td><td colspan="2">Chromosome</td></tr><tr><td></td><td></td><td></td><td><i>T. aestivum</i></td><td><i>Ae. umbellulata</i></td></tr><tr><td>Protein biosynthesis</td><td></td><td></td><td></td><td></td></tr><tr><td>HMW glutenins</td><td>Glu-1Ax1</td><td>X61009</td><td>1A</td><td>1U</td></tr><tr><td></td><td>Glu-1Ax2</td><td>M22208.2</td><td>1A</td><td>1U</td></tr><tr><td></td><td>Glu-B1-1b</td><td>X13927.3</td><td>1B</td><td>1U</td></tr><tr><td></td><td>Glu-1D-1d</td><td>X12928.5</td><td>1D</td><td>1U</td></tr><tr><td></td><td>Glu-D1-2b</td><td>X12929.2</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>X03041.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td>Glu-1Ux</td><td>AF476961.1</td><td>&#8211;</td><td>1U</td></tr><tr><td></td><td>Glu-1Uy</td><td>AF476962.1</td><td>&#8211;</td><td>1U</td></tr><tr><td>LMW glutenins</td><td></td><td>AB062868.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>AB062872.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>JX163862.1</td><td>1B</td><td>1U</td></tr><tr><td></td><td></td><td>HM055909.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>Y17845.1</td><td>1BS</td><td>1U</td></tr><tr><td></td><td></td><td>U86026.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>X13306.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>AB062875.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>U86028.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>X07747.1</td><td>1AS</td><td>1U</td></tr><tr><td></td><td></td><td>AB062873.1</td><td>1DS</td><td>1U</td></tr><tr><td>&#947;-Gliadins</td><td>Group/pattern/subgroup</td><td></td><td></td><td></td></tr><tr><td></td><td>C10/C10-P1/SG-1</td><td>AJ937838.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P2/SG-2</td><td>AF234646.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P3/SG-3</td><td>FJ006638.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-4</td><td>FJ006605.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-6</td><td>AF234647.1</td><td>1BS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-7</td><td>FJ006596.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-8</td><td>AF175312.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-9</td><td>AF120267.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-12</td><td>AF234649.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-13</td><td>AF234643.1</td><td>1AS</td><td>1U</td></tr><tr><td></td><td>C7/C7-P6/SG-14</td><td>AJ416336.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C7/C7-P7/SG-15</td><td>M16064.1</td><td>1DS</td><td>1U</td></tr><tr><td>&#945;-Gliadins</td><td></td><td>AJ133612.1</td><td>6AS</td><td>1U</td></tr><tr><td></td><td></td><td>DQ166377.1</td><td>6AS</td><td>1U</td></tr><tr><td></td><td></td><td>K03074.1</td><td>2BS</td><td>1U</td></tr><tr><td></td><td></td><td>M11075.1</td><td>6AS</td><td>1U, 2U</td></tr><tr><td></td><td></td><td>U08287.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>X01130.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>U50984.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>X02539.1</td><td>6AS</td><td>1U, 3U</td></tr></table>
<table><tr><td>Function</td><td>Gene</td><td>Accession no.∗</td><td colspan="2">Chromosome</td></tr><tr><td></td><td></td><td></td><td>T. aestivum</td><td>Ae. umbellulata</td></tr><tr><td>Protein biosynthesis</td><td></td><td></td><td></td><td></td></tr><tr><td>HMW glutenins</td><td>Glu-1Ax1</td><td>X61009</td><td>1A</td><td>1U</td></tr><tr><td></td><td>Glu-1Ax2</td><td>M22208.2</td><td>1A</td><td>1U</td></tr><tr><td></td><td>Glu-B1-1b</td><td>X13927.3</td><td>1B</td><td>1U</td></tr><tr><td></td><td>Glu-1D-1d</td><td>X12928.5</td><td>1D</td><td>1U</td></tr><tr><td></td><td>Glu-D1-2b</td><td>X12929.2</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>X03041.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td>Glu-1Ux</td><td>AF476961.1</td><td>–</td><td>1U</td></tr><tr><td></td><td>Glu-1Uy</td><td>AF476962.1</td><td>–</td><td>1U</td></tr><tr><td>LMW glutenins</td><td></td><td>AB062868.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>AB062872.1</td><td>1D</td><td>1U</td></tr><tr><td></td><td></td><td>JX163862.1</td><td>1B</td><td>1U</td></tr><tr><td></td><td></td><td>HM055909.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>Y17845.1</td><td>1BS</td><td>1U</td></tr><tr><td></td><td></td><td>U86026.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>X13306.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>AB062875.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>U86028.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td></td><td>X07747.1</td><td>1AS</td><td>1U</td></tr><tr><td></td><td></td><td>AB062873.1</td><td>1DS</td><td>1U</td></tr></table>
<table><tr><td>γ-Gliadins</td><td>Group/pattern/subgroup</td><td></td><td></td><td></td></tr><tr><td></td><td>C10/C10-P1/SG-1</td><td>AJ937838.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P2/SG-2</td><td>AF234646.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P3/SG-3</td><td>FJ006638.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-4</td><td>FJ006605.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-6</td><td>AF234647.1</td><td>1BS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P4/SG-7</td><td>FJ006596.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-8</td><td>AF175312.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-9</td><td>AF120267.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-12</td><td>AF234649.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C8/C8-P5/SG-13</td><td>AF234643.1</td><td>1AS</td><td>1U</td></tr><tr><td></td><td>C7/C7-P6/SG-14</td><td>AJ416336.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C7/C7-P7/SG-15</td><td>M16064.1</td><td>1DS</td><td>1U</td></tr><tr><td>α-Gliadins</td><td></td><td>AJ133612.1</td><td>6AS</td><td>1U</td></tr><tr><td></td><td></td><td>DQ166377.1</td><td>6AS</td><td>1U</td></tr><tr><td></td><td></td><td>K03074.1</td><td>2BS</td><td>1U</td></tr><tr><td></td><td></td><td>M11075.1</td><td>6AS</td><td>1U, 2U</td></tr><tr><td></td><td></td><td>U08287.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>X01130.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>U50984.1</td><td>6AS</td><td>1U, 3U</td></tr><tr><td></td><td></td><td>X02539.1</td><td>6AS</td><td>1U, 3U</td></tr></table>
dee34620c4a39b8a1a618328528c813e5b3176e81f5d82a936727bf51a862d6f.png
simple
<table><tr><td></td><td>RDP (<i>n</i> = 7)</td><td>LDP (<i>n</i> = 21)</td><td><i>P</i> value</td></tr><tr><td>Mean operative time (min)</td><td>368</td><td>210</td><td>0.0002</td></tr><tr><td>Mean blood loss (mL)</td><td>200</td><td>250</td><td>0.451</td></tr><tr><td>Transfusion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr><tr><td>Conversion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr><tr><td>Reverse operation (no. of patients) (%)</td><td>0</td><td>1 (4.7)<sup>a</sup></td><td></td></tr><tr><td>Mean postoperative stay (days)</td><td>8.7</td><td>10.6</td><td>0.004</td></tr><tr><td>Complications (no. of patients) (%)</td><td>2 (28.6)</td><td>7 (33.3)</td><td>0.815</td></tr><tr><td>Grade, Clavien classification</td><td>II (1), III (1)</td><td>I (5), II (1), III (1)</td><td></td></tr><tr><td>Hospital costs ($)</td><td>10,125</td><td>6921</td><td>0.0002</td></tr></table>
<table><tr><td></td><td>RDP (n = 7)</td><td>LDP (n = 21)</td><td>P value</td></tr><tr><td>Mean operative time (min)</td><td>368</td><td>210</td><td>0.0002</td></tr><tr><td>Mean blood loss (mL)</td><td>200</td><td>250</td><td>0.451</td></tr><tr><td>Transfusion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr></table>
<table><tr><td>Conversion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr><tr><td>Reverse operation (no. of patients) (%)</td><td>0</td><td>1 (4.7)a</td><td></td></tr><tr><td>Mean postoperative stay (days)</td><td>8.7</td><td>10.6</td><td>0.004</td></tr><tr><td>Complications (no. of patients) (%)</td><td>2 (28.6)</td><td>7 (33.3)</td><td>0.815</td></tr><tr><td>Grade, Clavien classification</td><td>II (1), III (1)</td><td>I (5), II (1), III (1)</td><td></td></tr><tr><td>Hospital costs ($)</td><td>10,125</td><td>6921</td><td>0.0002</td></tr></table>
c56c1c831ace51c4e392411aa13a46bbefd3a729537a1fea3bfd01d72a73ea33.png
simple
<table><tr><td>Group</td><td>Drug</td><td>Frequency</td><td>Percent (n/N) <sup>b</sup></td></tr><tr><td>&#946;-lactam</td><td></td><td>26</td><td>28.9 (26/90)</td></tr><tr><td> Penicillin</td><td>PenicillinG</td><td>11</td><td>29.0 (11/27)</td></tr><tr><td></td><td>Ampicillin</td><td>12</td><td>32.4 (12/26)</td></tr><tr><td> Cephalosporin</td><td>Cephalothin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Ceftiofur</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td> Combination</td><td>Amoxicillin/Clavulanic acid</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td>Tetracycline</td><td>Doxycycline</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td>Fluoroquinolone</td><td></td><td>6</td><td>8.6 (6/70)</td></tr><tr><td></td><td>Enrofloxacin</td><td>3</td><td>7.9 (3/35)</td></tr><tr><td></td><td>Orbifloxacin</td><td>3</td><td>7.9 (3/35)</td></tr><tr><td>Aminoglycoside</td><td></td><td>4</td><td>3.6 (4/110)</td></tr><tr><td></td><td>Gentamicin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Amikacin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Kanamycin</td><td>2</td><td>5.3 (2/36)</td></tr><tr><td>Potentiated sulfonamide</td><td>Sulfamethoxazole/trimethoprim</td><td>4</td><td>10.5 (4/34)</td></tr><tr><td>Amphenicols</td><td>Chloramphenicol</td><td>2</td><td>5.2 (2/36)</td></tr><tr><td>Lincosamides</td><td>Clindamycin</td><td>13</td><td>34.2 (13/25)</td></tr><tr><td>Aminoglycoside-lincosamide</td><td>Lincospectin</td><td>12</td><td>31.6 (12/26)</td></tr><tr><td>Macrolide</td><td>Tylosin</td><td>2</td><td>5.3 (2/36)</td></tr></table>
<table><tr><td>Group</td><td>Drug</td><td>Frequency</td><td>Percent (n/N) b</td></tr><tr><td>β-lactam</td><td></td><td>26</td><td>28.9 (26/90)</td></tr><tr><td>Penicillin</td><td>PenicillinG</td><td>11</td><td>29.0 (11/27)</td></tr><tr><td></td><td>Ampicillin</td><td>12</td><td>32.4 (12/26)</td></tr><tr><td>Cephalosporin</td><td>Cephalothin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Ceftiofur</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td>Combination</td><td>Amoxicillin/Clavulanic acid</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td>Tetracycline</td><td>Doxycycline</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td>Fluoroquinolone</td><td></td><td>6</td><td>8.6 (6/70)</td></tr><tr><td></td><td>Enrofloxacin</td><td>3</td><td>7.9 (3/35)</td></tr><tr><td></td><td>Orbifloxacin</td><td>3</td><td>7.9 (3/35)</td></tr><tr><td>Aminoglycoside</td><td></td><td>4</td><td>3.6 (4/110)</td></tr><tr><td></td><td>Gentamicin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Amikacin</td><td>1</td><td>2.7 (1/37)</td></tr><tr><td></td><td>Kanamycin</td><td>2</td><td>5.3 (2/36)</td></tr><tr><td>Potentiated sulfonamide</td><td>Sulfamethoxazole/trimethoprim</td><td>4</td><td>10.5 (4/34)</td></tr><tr><td>Amphenicols</td><td>Chloramphenicol</td><td>2</td><td>5.2 (2/36)</td></tr><tr><td>Lincosamides</td><td>Clindamycin</td><td>13</td><td>34.2 (13/25)</td></tr></table>
<table><tr><td>Aminoglycoside-lincosamide</td><td>Lincospectin</td><td>12</td><td>31.6 (12/26)</td></tr><tr><td>Macrolide</td><td>Tylosin</td><td>2</td><td>5.3 (2/36)</td></tr></table>
b08069a254d02a29e242b1f148977fa3100aa37d0d898366a08ff3764f2f2f84.png
complex
<table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>NC</td><td>&#8211;</td><td>4.32 &#177; 0.88</td><td>13.65 &#177; 1.24</td><td>8.94 &#177; 1.47</td><td>4.89 &#177; 0.95</td></tr><tr><td>MC</td><td>&#8211;</td><td>16.04 &#177; 2.15 **</td><td>48.65 &#177; 3.29 **</td><td>42.32 &#177; 4.18 **</td><td>32.74 &#177; 2.82 **</td></tr><tr><td>100-CPOP</td><td>100</td><td>14.42 &#177; 2.07 <sup>#</sup></td><td>42.82 &#177; 2.81 <sup>##</sup></td><td>33.54 &#177; 3.23 <sup>##</sup></td><td>25.06 &#177; 2.67 <sup>##</sup></td></tr><tr><td>200-CPOP</td><td>200</td><td>12.36 &#177; 1.52 <sup>##</sup></td><td>33.98 &#177; 3.61 <sup>##</sup></td><td>24.77 &#177; 2.75 <sup>##</sup></td><td>18.91 &#177; 2.03 <sup>##</sup></td></tr><tr><td>400-CPOP</td><td>400</td><td>10.49 &#177; 1.84 <sup>##</sup></td><td>28.46 &#177; 3.05 <sup>##</sup></td><td>19.35 &#177; 2.36 <sup>##</sup></td><td>14.36 &#177; 1.42 <sup>##</sup></td></tr><tr><td>Glyburide</td><td>25</td><td>8.37 &#177; 1.26 <sup>##</sup></td><td>22.16 &#177; 2.19 <sup>##</sup></td><td>14.82 &#177; 1.63 <sup>##</sup></td><td>10.55 &#177; 1.34 <sup>##</sup></td></tr></table>
<table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>NC</td><td>–</td><td>4.32 ± 0.88</td><td>13.65 ± 1.24</td><td>8.94 ± 1.47</td><td>4.89 ± 0.95</td></tr></table>
<table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>MC</td><td>–</td><td>16.04 ± 2.15 **</td><td>48.65 ± 3.29 **</td><td>42.32 ± 4.18 **</td><td>32.74 ± 2.82 **</td></tr><tr><td>100-CPOP</td><td>100</td><td>14.42 ± 2.07 #</td><td>42.82 ± 2.81 ##</td><td>33.54 ± 3.23 ##</td><td>25.06 ± 2.67 ##</td></tr><tr><td>200-CPOP</td><td>200</td><td>12.36 ± 1.52 ##</td><td>33.98 ± 3.61 ##</td><td>24.77 ± 2.75 ##</td><td>18.91 ± 2.03 ##</td></tr><tr><td>400-CPOP</td><td>400</td><td>10.49 ± 1.84 ##</td><td>28.46 ± 3.05 ##</td><td>19.35 ± 2.36 ##</td><td>14.36 ± 1.42 ##</td></tr><tr><td>Glyburide</td><td>25</td><td>8.37 ± 1.26 ##</td><td>22.16 ± 2.19 ##</td><td>14.82 ± 1.63 ##</td><td>10.55 ± 1.34 ##</td></tr></table>
49ce65355e37577062f7b2ecc5572e2c83cf4597cc0ec5ce5e0d72cd8c9fe952.png
complex
<table><tr><td>Animal ID</td><td>Sex</td><td><i>M</i><sub>b</sub> (kg)</td><td>SL (cm)</td><td>G (cm)</td><td>[Hct]</td><td colspan="2">N</td><td colspan="2"><i>f</i><sub>R</sub> (breaths &#8901; min<sup>-1</sup>)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Air</td><td>Water</td><td>Air</td><td>Water</td></tr><tr><td>Tt19</td><td>M</td><td>294</td><td>256</td><td>142</td><td>54</td><td>104</td><td>17</td><td>3.9</td><td>4.7</td></tr><tr><td>Tt20</td><td>M</td><td>282</td><td>261</td><td>142</td><td>54</td><td>222</td><td>29</td><td>5.8</td><td>9.7</td></tr><tr><td>Tt21</td><td>F</td><td>173</td><td>238</td><td>144</td><td>57</td><td>166</td><td>33</td><td>6.1</td><td>9.6</td></tr><tr><td>Tt22</td><td>M</td><td>282</td><td>251</td><td>144</td><td>59</td><td>127</td><td>24</td><td>4.4</td><td>3.0</td></tr><tr><td>Mean</td><td></td><td>258 &#177; 57</td><td>252 &#177; 10</td><td>143 &#177; 1</td><td>56 &#177; 2</td><td>155 &#177; 52</td><td>26 &#177; 7</td><td>5.1 &#177; 1.0</td><td>6.7 &#177; 3.4</td></tr></table>
<table><tr><td>Animal ID</td><td>Sex</td><td>Mb (kg)</td><td>SL (cm)</td><td>G (cm)</td><td>[Hct]</td><td colspan="2">N</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Air</td><td>Water</td></tr><tr><td>Tt19</td><td>M</td><td>294</td><td>256</td><td>142</td><td>54</td><td>104</td><td>17</td></tr><tr><td>Tt20</td><td>M</td><td>282</td><td>261</td><td>142</td><td>54</td><td>222</td><td>29</td></tr><tr><td>Tt21</td><td>F</td><td>173</td><td>238</td><td>144</td><td>57</td><td>166</td><td>33</td></tr><tr><td>Tt22</td><td>M</td><td>282</td><td>251</td><td>144</td><td>59</td><td>127</td><td>24</td></tr><tr><td>Mean</td><td></td><td>258 ± 57</td><td>252 ± 10</td><td>143 ± 1</td><td>56 ± 2</td><td>155 ± 52</td><td>26 ± 7</td></tr></table>
<table><tr><td colspan="2">fR (breaths ⋅ min-1)</td></tr><tr><td>Air</td><td>Water</td></tr><tr><td>3.9</td><td>4.7</td></tr><tr><td>5.8</td><td>9.7</td></tr><tr><td>6.1</td><td>9.6</td></tr><tr><td>4.4</td><td>3.0</td></tr><tr><td>5.1 ± 1.0</td><td>6.7 ± 3.4</td></tr></table>
5b4729d229730eb04707971603b8a7559b32434812f4ee49e113a02e4a377b53.png
complex
<table><tr><td rowspan="2">Predictor</td><td colspan="4">1 year</td><td colspan="4">2 years</td></tr><tr><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>HAQ score</td><td>1.84 (1.12 to 3.01)</td><td>0.02</td><td>1.87 (1.11 to 3.15)</td><td>0.02</td><td>1.47 (0.94 to 2.29)</td><td>0.09</td><td>1.42 (0.89 to 2.26)</td><td>0.14</td></tr></table>
<table><tr><td rowspan="2">Predictor</td><td colspan="4">1 year</td><td colspan="2">2 years</td></tr><tr><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td><td>Unadjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>HAQ score</td><td>1.84 (1.12 to 3.01)</td><td>0.02</td><td>1.87 (1.11 to 3.15)</td><td>0.02</td><td>1.47 (0.94 to 2.29)</td><td>0.09</td></tr></table>
<table><tr><td colspan="2">2 years</td></tr><tr><td>Adjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>1.42 (0.89 to 2.26)</td><td>0.14</td></tr></table>
e20a62f2968f5a3b6096a5f6ce779091a58acd098fb53b99abffe5ef4eda4403.png
simple
<table><tr><td>Type</td><td>CVID (<i>n</i> = 34)</td><td>IgGSD (<i>n</i> = 398)</td><td>Value of <i>P</i></td></tr><tr><td>B&#8727;07</td><td>29.4 (10)</td><td>22.9 (91)</td><td>0.3866</td></tr><tr><td>B&#8727;08</td><td>38.2 (13)</td><td>25.4 (101)</td><td>0.1025</td></tr><tr><td>B&#8727;13</td><td>0</td><td>4.3 (17)</td><td>0.2414</td></tr><tr><td>B&#8727;14</td><td>2.9 (1)</td><td>9.0 (36)</td><td>0.1874</td></tr><tr><td>B&#8727;15</td><td>11.8 (4)</td><td>14.1 (56)</td><td>0.4757</td></tr><tr><td>B&#8727;18</td><td>8.8 (3)</td><td>7.3 (29)</td><td>0.4708</td></tr><tr><td>B&#8727;27</td><td>2.9 (1)</td><td>6.8 (27)</td><td>0.3322</td></tr><tr><td>B&#8727;35</td><td>8.8 (3)</td><td>14.1 (56)</td><td>0.2888</td></tr><tr><td>B&#8727;37</td><td>2.9 (1)</td><td>2.3 (9)</td><td>0.5634</td></tr><tr><td>B&#8727;38</td><td>8.8 (3)</td><td>2.8 (11)</td><td>0.0891</td></tr><tr><td>B&#8727;39</td><td>0</td><td>3.5 (14)</td><td>0.1681</td></tr><tr><td>B&#8727;40</td><td>17.7 (6)</td><td>8.8 (35)</td><td>0.0894</td></tr><tr><td>B&#8727;41</td><td>0</td><td>1.0 (4)</td><td>0.7196</td></tr><tr><td>B&#8727;44</td><td>44.1 (15)</td><td>30.2 (120)</td><td>0.0917</td></tr><tr><td>B&#8727;45</td><td>0</td><td>2.3 (9)</td><td>0.4747</td></tr><tr><td>B&#8727;47</td><td>0</td><td>1.0 (4)</td><td>0.7196</td></tr><tr><td>B&#8727;48</td><td>0</td><td>0.3 (1)</td><td>0.9213</td></tr><tr><td>B&#8727;49</td><td>0</td><td>3.8 (15)</td><td>0.2863</td></tr><tr><td>B&#8727;50</td><td>0</td><td>2.8 (11)</td><td>0.3705</td></tr><tr><td>B&#8727;51</td><td>14.7 (5)</td><td>8.3 (33)</td><td>0.1673</td></tr><tr><td>B&#8727;52</td><td>0</td><td>2.5 (10)</td><td>0.4366</td></tr><tr><td>B&#8727;53</td><td>2.9 (1)</td><td>1.3 (5)</td><td>0.3903</td></tr><tr><td>B&#8727;55</td><td>0</td><td>3.5 (14)</td><td>0.3116</td></tr><tr><td>B&#8727;56</td><td>0</td><td>1.3 (5)</td><td>0.6624</td></tr><tr><td>B&#8727;57</td><td>2.9 (1)</td><td>7.0 (28)</td><td>0.3127</td></tr><tr><td>B&#8727;58</td><td>0</td><td>0.5 (2)</td><td>0.8486</td></tr><tr><td>B&#8727;60</td><td>0</td><td>1.3 (5)</td><td>0.6624</td></tr><tr><td>B&#8727;62</td><td>2.9 (1)</td><td>0.5 (2)</td><td>0.2185</td></tr></table>
<table><tr><td>Type</td><td>CVID (n = 34)</td><td>IgGSD (n = 398)</td><td>Value of P</td></tr><tr><td>B∗07</td><td>29.4 (10)</td><td>22.9 (91)</td><td>0.3866</td></tr><tr><td>B∗08</td><td>38.2 (13)</td><td>25.4 (101)</td><td>0.1025</td></tr><tr><td>B∗13</td><td>0</td><td>4.3 (17)</td><td>0.2414</td></tr><tr><td>B∗14</td><td>2.9 (1)</td><td>9.0 (36)</td><td>0.1874</td></tr><tr><td>B∗15</td><td>11.8 (4)</td><td>14.1 (56)</td><td>0.4757</td></tr><tr><td>B∗18</td><td>8.8 (3)</td><td>7.3 (29)</td><td>0.4708</td></tr><tr><td>B∗27</td><td>2.9 (1)</td><td>6.8 (27)</td><td>0.3322</td></tr><tr><td>B∗35</td><td>8.8 (3)</td><td>14.1 (56)</td><td>0.2888</td></tr><tr><td>B∗37</td><td>2.9 (1)</td><td>2.3 (9)</td><td>0.5634</td></tr><tr><td>B∗38</td><td>8.8 (3)</td><td>2.8 (11)</td><td>0.0891</td></tr><tr><td>B∗39</td><td>0</td><td>3.5 (14)</td><td>0.1681</td></tr><tr><td>B∗40</td><td>17.7 (6)</td><td>8.8 (35)</td><td>0.0894</td></tr><tr><td>B∗41</td><td>0</td><td>1.0 (4)</td><td>0.7196</td></tr><tr><td>B∗44</td><td>44.1 (15)</td><td>30.2 (120)</td><td>0.0917</td></tr><tr><td>B∗45</td><td>0</td><td>2.3 (9)</td><td>0.4747</td></tr><tr><td>B∗47</td><td>0</td><td>1.0 (4)</td><td>0.7196</td></tr></table>
<table><tr><td>B∗48</td><td>0</td><td>0.3 (1)</td><td>0.9213</td></tr><tr><td>B∗49</td><td>0</td><td>3.8 (15)</td><td>0.2863</td></tr><tr><td>B∗50</td><td>0</td><td>2.8 (11)</td><td>0.3705</td></tr><tr><td>B∗51</td><td>14.7 (5)</td><td>8.3 (33)</td><td>0.1673</td></tr><tr><td>B∗52</td><td>0</td><td>2.5 (10)</td><td>0.4366</td></tr><tr><td>B∗53</td><td>2.9 (1)</td><td>1.3 (5)</td><td>0.3903</td></tr><tr><td>B∗55</td><td>0</td><td>3.5 (14)</td><td>0.3116</td></tr><tr><td>B∗56</td><td>0</td><td>1.3 (5)</td><td>0.6624</td></tr><tr><td>B∗57</td><td>2.9 (1)</td><td>7.0 (28)</td><td>0.3127</td></tr><tr><td>B∗58</td><td>0</td><td>0.5 (2)</td><td>0.8486</td></tr><tr><td>B∗60</td><td>0</td><td>1.3 (5)</td><td>0.6624</td></tr><tr><td>B∗62</td><td>2.9 (1)</td><td>0.5 (2)</td><td>0.2185</td></tr></table>
5876a56e841c3bf7f53a016c7bbe4635a7f206815d4b365a27cf67c8a6f57f1b.png
simple
<table><tr><td>Study Cohort</td><td>Number</td><td>Percentages</td></tr><tr><td>Women</td><td>36</td><td>34</td></tr><tr><td>Men</td><td>71</td><td>66</td></tr><tr><td>Mean Age 64.7 years</td><td></td><td></td></tr><tr><td>(Range 31&#8211;95 years)</td><td></td><td></td></tr><tr><td>Clinical Neuropathic Syndrome</td><td></td><td></td></tr><tr><td>MNM</td><td>1</td><td>1</td></tr><tr><td>DLRPN</td><td>35</td><td>33</td></tr><tr><td>DSPN</td><td>71</td><td>66</td></tr><tr><td>Histological Severity of Neuropathy</td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td>1</td></tr><tr><td>Mild</td><td>17</td><td>16</td></tr><tr><td>Moderate</td><td>54</td><td>50</td></tr><tr><td>Severe</td><td>35</td><td>33</td></tr><tr><td>Teased Fiber/Semithin Section Analysis</td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td>1</td></tr><tr><td>Axonopathy</td><td>45</td><td>65</td></tr><tr><td>Myelinopathy</td><td>23</td><td>35</td></tr><tr><td>Cellular Response</td><td></td><td></td></tr><tr><td>Perivasculitis</td><td>26</td><td>23</td></tr><tr><td>Microvasculitis</td><td>3</td><td>3</td></tr><tr><td>Necrotizing arteritis</td><td>3</td><td>3</td></tr><tr><td>Complement Immunofluorescence</td><td></td><td></td></tr><tr><td>C3 deposition</td><td>70</td><td>67</td></tr><tr><td>C5b-9</td><td>65</td><td>62</td></tr><tr><td>Other Findings</td><td></td><td></td></tr><tr><td>Onion bulb formation</td><td>10</td><td>9</td></tr><tr><td>Epineurial vascular thrombosis</td><td>5</td><td>5</td></tr></table>
<table><tr><td>Study Cohort</td><td>Number</td><td>Percentages</td></tr><tr><td>Women</td><td>36</td><td>34</td></tr><tr><td>Men</td><td>71</td><td>66</td></tr><tr><td>Mean Age 64.7 years</td><td></td><td></td></tr><tr><td>(Range 31–95 years)</td><td></td><td></td></tr><tr><td>Clinical Neuropathic Syndrome</td><td></td><td></td></tr><tr><td>MNM</td><td>1</td><td>1</td></tr><tr><td>DLRPN</td><td>35</td><td>33</td></tr><tr><td>DSPN</td><td>71</td><td>66</td></tr><tr><td>Histological Severity of Neuropathy</td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td>1</td></tr><tr><td>Mild</td><td>17</td><td>16</td></tr></table>
<table><tr><td>Moderate</td><td>54</td><td>50</td></tr><tr><td>Severe</td><td>35</td><td>33</td></tr><tr><td>Teased Fiber/Semithin Section Analysis</td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td>1</td></tr><tr><td>Axonopathy</td><td>45</td><td>65</td></tr><tr><td>Myelinopathy</td><td>23</td><td>35</td></tr><tr><td>Cellular Response</td><td></td><td></td></tr><tr><td>Perivasculitis</td><td>26</td><td>23</td></tr><tr><td>Microvasculitis</td><td>3</td><td>3</td></tr><tr><td>Necrotizing arteritis</td><td>3</td><td>3</td></tr><tr><td>Complement Immunofluorescence</td><td></td><td></td></tr><tr><td>C3 deposition</td><td>70</td><td>67</td></tr><tr><td>C5b-9</td><td>65</td><td>62</td></tr><tr><td>Other Findings</td><td></td><td></td></tr><tr><td>Onion bulb formation</td><td>10</td><td>9</td></tr><tr><td>Epineurial vascular thrombosis</td><td>5</td><td>5</td></tr></table>
2451c38c13d8d4146e1b0623a4cf77f006a9be0cc7e0ec98aa00f22dd7361c9b.png
simple
<table><tr><td>Type</td><td>Strain/<i> Transgene</i><sup>b</sup></td><td>Main pattern<sup>c</sup></td><td>Myoepithelial differentiation<sup>d</sup></td><td>EMT (%)<sup>e</sup></td><td>K1</td><td>K5</td><td>K6</td><td>K8/18</td><td>K10</td><td>K14</td><td>K17</td><td>FLG</td><td>IVL</td><td>LOR</td><td>THH</td><td>SMA</td><td>VIM</td></tr><tr><td>Simple</td><td>FVB-<i>Myc</i></td><td>Glandular</td><td>6/9</td><td>4/9 (&lt;1%)</td><td></td><td>+</td><td>+</td><td>+</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-<i>Notch4</i></td><td>Glandular</td><td>0/6</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C57BL6/J-Tag</td><td>Glandular</td><td>1/5</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ (mostly)</td><td>Papillary, 1 cell thick</td><td>2/6</td><td>0</td><td></td><td>+</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C57BL6/J-Tag</td><td>Papillary</td><td>0/4</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-<i>Myc</i></td><td>Solid</td><td>1/4</td><td>3/4 (&lt;1%)</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-<i>Neu</i></td><td>Solid</td><td>0/10</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Complex</td><td>FVB and B6D2-<i>Tgfa</i></td><td>Macrocyst</td><td>6/8</td><td>0</td><td></td><td>+</td><td>+</td><td>+++</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td></td><td>FVB and B6D2-<i>Tgfa</i></td><td>Lactation plaque</td><td>3/3</td><td>0</td><td></td><td>++</td><td>+</td><td>+++</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td></td><td>BALB/cJ</td><td>Adenomyoepithelioma</td><td>5/5</td><td>0</td><td>+</td><td>+++</td><td>++</td><td>++</td><td></td><td>+++</td><td>++</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ (mostly)</td><td>Adenoacanthoma</td><td>7/7</td><td>0</td><td>++</td><td>++</td><td>++</td><td>++</td><td>++</td><td>+++</td><td>+++</td><td>++</td><td>++</td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td></td><td>C3H/HeJ</td><td>Microacinar</td><td>8/8</td><td>0</td><td></td><td>++</td><td>+</td><td>++</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ, C3H/HeJ</td><td>Papillary, 2 cells thick</td><td>2/2</td><td>0</td><td></td><td>++</td><td></td><td>++</td><td>+</td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td>+++</td><td></td></tr><tr><td></td><td>C3H/HeJ</td><td>Type P tumor</td><td>9/9</td><td>0</td><td></td><td>++</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td>+</td><td></td><td></td><td>+++</td><td></td></tr><tr><td></td><td>FVB-<i>Wnt1</i></td><td>Type P tumor</td><td>6/6</td><td>0</td><td></td><td>++</td><td>++</td><td>+++</td><td></td><td>++</td><td>++</td><td>+</td><td>+</td><td></td><td></td><td>++</td><td></td></tr><tr><td></td><td>B6SJL-<i>Wnt1</i></td><td>Type P tumor</td><td>7/7</td><td>0</td><td></td><td>+</td><td>+</td><td>+</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td>++</td><td></td></tr><tr><td>EMT</td><td>C57BL6/J-Tag</td><td>Glandular with EMT</td><td>2/3</td><td>3/3 (6%)</td><td></td><td></td><td></td><td>+++</td><td></td><td>+++</td><td>++</td><td></td><td></td><td></td><td></td><td>++</td><td>+</td></tr><tr><td></td><td>FVB-<i>Myc</i></td><td>Glandular with EMT</td><td>4/6</td><td>6/6 (20%)</td><td></td><td>+</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td>+</td><td>+</td></tr><tr><td></td><td>PL/J and SJL/J</td><td>Glandular with EMT</td><td>4/4</td><td>4/4 (38%)</td><td></td><td>++</td><td>+</td><td>+++</td><td></td><td>++</td><td>++</td><td></td><td>+</td><td></td><td></td><td>++</td><td>++</td></tr><tr><td></td><td>FVB-<i>Hras</i></td><td>Solid with EMT</td><td>3/4</td><td>3/4 (&lt;1%)</td><td></td><td>+</td><td></td><td>++</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td>+</td></tr></table>
<table><tr><td>Type</td><td>Strain/ Transgeneb</td><td>Main patternc</td><td>Myoepithelial differentiationd</td><td>EMT (%)e</td><td>K1</td><td>K5</td><td>K6</td><td>K8/18</td><td>K10</td><td>K14</td><td>K17</td><td>FLG</td><td>IVL</td><td>LOR</td><td>THH</td><td>SMA</td><td>VIM</td></tr><tr><td>Simple</td><td>FVB-Myc</td><td>Glandular</td><td>6/9</td><td>4/9 (<1%)</td><td></td><td>+</td><td>+</td><td>+</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-Notch4</td><td>Glandular</td><td>0/6</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C57BL6/J-Tag</td><td>Glandular</td><td>1/5</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ (mostly)</td><td>Papillary, 1 cell thick</td><td>2/6</td><td>0</td><td></td><td>+</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C57BL6/J-Tag</td><td>Papillary</td><td>0/4</td><td>0</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-Myc</td><td>Solid</td><td>1/4</td><td>3/4 (<1%)</td><td></td><td></td><td></td><td>+</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>FVB-Neu</td><td>Solid</td><td>0/10</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Complex</td><td>FVB and B6D2-Tgfa</td><td>Macrocyst</td><td>6/8</td><td>0</td><td></td><td>+</td><td>+</td><td>+++</td><td></td><td>+</td><td>+</td><td></td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td></td><td>FVB and B6D2-Tgfa</td><td>Lactation plaque</td><td>3/3</td><td>0</td><td></td><td>++</td><td>+</td><td>+++</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td></td><td>BALB/cJ</td><td>Adenomyoepithelioma</td><td>5/5</td><td>0</td><td>+</td><td>+++</td><td>++</td><td>++</td><td></td><td>+++</td><td>++</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ (mostly)</td><td>Adenoacanthoma</td><td>7/7</td><td>0</td><td>++</td><td>++</td><td>++</td><td>++</td><td>++</td><td>+++</td><td>+++</td><td>++</td><td>++</td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td></td><td>C3H/HeJ</td><td>Microacinar</td><td>8/8</td><td>0</td><td></td><td>++</td><td>+</td><td>++</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>BALB/cJ, C3H/HeJ</td><td>Papillary, 2 cells thick</td><td>2/2</td><td>0</td><td></td><td>++</td><td></td><td>++</td><td>+</td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td>+++</td><td></td></tr><tr><td></td><td>C3H/HeJ</td><td>Type P tumor</td><td>9/9</td><td>0</td><td></td><td>++</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td>+</td><td></td><td></td><td>+++</td><td></td></tr><tr><td></td><td>FVB-Wnt1</td><td>Type P tumor</td><td>6/6</td><td>0</td><td></td><td>++</td><td>++</td><td>+++</td><td></td><td>++</td><td>++</td><td>+</td><td>+</td><td></td><td></td><td>++</td><td></td></tr><tr><td></td><td>B6SJL-Wnt1</td><td>Type P tumor</td><td>7/7</td><td>0</td><td></td><td>+</td><td>+</td><td>+</td><td></td><td>++</td><td>+</td><td></td><td></td><td></td><td></td><td>++</td><td></td></tr><tr><td>EMT</td><td>C57BL6/J-Tag</td><td>Glandular with EMT</td><td>2/3</td><td>3/3 (6%)</td><td></td><td></td><td></td><td>+++</td><td></td><td>+++</td><td>++</td><td></td><td></td><td></td><td></td><td>++</td><td>+</td></tr><tr><td></td><td>FVB-Myc</td><td>Glandular with EMT</td><td>4/6</td><td>6/6 (20%)</td><td></td><td>+</td><td>+</td><td>++</td><td></td><td>++</td><td>++</td><td></td><td></td><td></td><td></td><td>+</td><td>+</td></tr><tr><td></td><td>PL/J and SJL/J</td><td>Glandular with EMT</td><td>4/4</td><td>4/4 (38%)</td><td></td><td>++</td><td>+</td><td>+++</td><td></td><td>++</td><td>++</td><td></td><td>+</td><td></td><td></td><td>++</td><td>++</td></tr></table>
<table><tr><td>Strain/ Transgeneb</td><td>Main patternc</td><td>Myoepithelial differentiationd</td><td>EMT (%)e</td><td>K5</td><td>K8/18</td><td>K14</td><td>K17</td><td>VIM</td></tr><tr><td>FVB-Hras</td><td>Solid with EMT</td><td>3/4</td><td>3/4 (<1%)</td><td>+</td><td>++</td><td>+</td><td>+</td><td>+</td></tr></table>
2ac2c322881f3d9db94e42ef4a4511c8b4121130b88ee846d58ef20c560a15f7.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">HAA intake</td><td></td></tr><tr><td>Low</td><td>Moderate</td><td>High</td><td><i>P</i><sub>interaction</sub></td></tr><tr><td colspan="5"><i>NAT2</i>-imputed phenotype</td></tr><tr><td> Rapid or intermediate acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td> Cases/Controls</td><td>92/124</td><td>100/116</td><td>132/93</td><td></td></tr><tr><td> OR (95% CI)<sup>a</sup></td><td>1.00</td><td>1.17 (0.84&#8211;1.65)</td><td>1.85 (1.34&#8211;2.56)</td><td></td></tr><tr><td> Slow acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td> Cases/Controls</td><td>8/7</td><td>8/8</td><td>11/3</td><td></td></tr><tr><td> OR (95% CI)</td><td>1.43 (0.50&#8211;4.12)</td><td>1.21 (0.56&#8211;2.60)</td><td>5.29 (2.37&#8211;11.80)</td><td>0.004</td></tr><tr><td colspan="5"><i>CYP1A1</i></td></tr><tr><td> AA</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>51/87</td><td>68/82</td><td>88/63</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.00</td><td>1.46 (0.95&#8211;2.24)</td><td>2.41 (1.61&#8211;3.63)</td><td></td></tr><tr><td> GA + GG</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>49/44</td><td>40/42</td><td>55/33</td><td></td></tr><tr><td>OR (95% CI)</td><td>2.05 (1.19&#8211;3.63)</td><td>1.72 (1.07&#8211;2.76)</td><td>2.86 (1.83&#8211;4.47)</td><td>&lt; 0.001</td></tr><tr><td colspan="5"><i>CYP1A2</i></td></tr><tr><td> CC</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>7/17</td><td>14/17</td><td>13/13</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.00</td><td>2.05 (0.73&#8211;5.77)</td><td>2.65 (0.97&#8211;7.29)</td><td></td></tr><tr><td> CA + AA</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>93/114</td><td>94/107</td><td>130/83</td><td></td></tr><tr><td> OR (95% CI)</td><td>2.17 (0.85&#8211;5.59)</td><td>2.34 (0.93&#8211;5.92)</td><td>4.01 (1.60&#8211;10.05)</td><td>0.003</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="3">HAA intake</td><td></td></tr><tr><td>Low</td><td>Moderate</td><td>High</td><td>Pinteraction</td></tr><tr><td colspan="5">NAT2-imputed phenotype</td></tr><tr><td>Rapid or intermediate acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/Controls</td><td>92/124</td><td>100/116</td><td>132/93</td><td></td></tr><tr><td>OR (95% CI)a</td><td>1.00</td><td>1.17 (0.84–1.65)</td><td>1.85 (1.34–2.56)</td><td></td></tr><tr><td>Slow acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/Controls</td><td>8/7</td><td>8/8</td><td>11/3</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.43 (0.50–4.12)</td><td>1.21 (0.56–2.60)</td><td>5.29 (2.37–11.80)</td><td>0.004</td></tr><tr><td colspan="5">CYP1A1</td></tr><tr><td>AA</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>51/87</td><td>68/82</td><td>88/63</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.00</td><td>1.46 (0.95–2.24)</td><td>2.41 (1.61–3.63)</td><td></td></tr><tr><td>GA + GG</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>49/44</td><td>40/42</td><td>55/33</td><td></td></tr><tr><td>OR (95% CI)</td><td>2.05 (1.19–3.63)</td><td>1.72 (1.07–2.76)</td><td>2.86 (1.83–4.47)</td><td>< 0.001</td></tr></table>
<table><tr><td colspan="5">CYP1A2</td></tr><tr><td>CC</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>7/17</td><td>14/17</td><td>13/13</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.00</td><td>2.05 (0.73–5.77)</td><td>2.65 (0.97–7.29)</td><td></td></tr><tr><td>CA + AA</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>93/114</td><td>94/107</td><td>130/83</td><td></td></tr><tr><td>OR (95% CI)</td><td>2.17 (0.85–5.59)</td><td>2.34 (0.93–5.92)</td><td>4.01 (1.60–10.05)</td><td>0.003</td></tr></table>
77ec8ea3f346616ea45d6fc366882b243a2aa12d55e7120ad7f96cc6626718f2.png
complex
<table><tr><td>EORTC QLQ-C30 subscales</td><td>Item</td><td colspan="4">Baseline</td><td colspan="4">2 weeks post-RT</td></tr><tr><td> </td><td> </td><td>IG (n = 89)</td><td>CON (n = 89)</td><td> </td><td> </td><td>IG (n = 89)</td><td>CON (n = 89)</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>Mean(SD)</td><td>Mean(SD)</td><td><i>t</i>value</td><td><i>p</i>value</td><td>Mean(SD)</td><td>Mean(SD)</td><td><i>t</i>value</td><td><i>p</i>value*</td></tr><tr><td>Functioning scales</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Physical functioning PF</td><td>1-5</td><td>77.23(10.19)</td><td>78.91(10.81)</td><td>&#8722;1.067</td><td>0.288</td><td>79.70(9.80)</td><td>75.36(9.71)</td><td>2.970</td><td>0.003</td></tr><tr><td>Role functioning RF</td><td>6,7</td><td>59.55(24.48)</td><td>58.28(24.49)</td><td>0.347</td><td>0.729</td><td>59.18(24.23)</td><td>57.45(21.01)</td><td>0.507</td><td>0.613</td></tr><tr><td>Emotional functioning EF</td><td>21-24</td><td>72.57(12.51)</td><td>70.77(14.71)</td><td>0.874</td><td>0.383</td><td>74.18(11.43)</td><td>66.03(14.00)</td><td>4.251</td><td>&lt;0.001</td></tr><tr><td>Cognitive functioning CF</td><td>20,25</td><td>80.71(11.48)</td><td>81.27(11.46)</td><td>&#8722;0.327</td><td>0.744</td><td>81.09(12.36)</td><td>78.58(10.01)</td><td>1.489</td><td>0.138</td></tr><tr><td>Social functioning SF</td><td>26,27</td><td>75.00(13.82)</td><td>73.43(12.31)</td><td>0.802</td><td>0.424</td><td>74.35(10.67)</td><td>71.33(11.88)</td><td>1.782</td><td>0.076</td></tr><tr><td>Global health status QL</td><td>29,30</td><td>61.31(13.23)</td><td>58.43(12.78)</td><td>1.48</td><td>0.141</td><td>58.80(12.20)</td><td>51.12(12.82)</td><td>4.092</td><td>&lt;0.001</td></tr><tr><td>Symptom scales and/or items</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Fatigue FA</td><td>10,12,18</td><td>28.05(14.75)</td><td>28.63(13.38)</td><td>&#8722;0.276</td><td>0.783</td><td>29.20(11.86)</td><td>32.93(13.78)</td><td>&#8722;1.938</td><td>0.054</td></tr><tr><td>Nausea/vomiting NV</td><td>14,15</td><td>11.05(11.50)</td><td>9.74(9.99)</td><td>0.812</td><td>0.418</td><td>14.61(12.26)</td><td>15.92(10.93)</td><td>&#8722;0.753</td><td>0.452</td></tr><tr><td>Pain PA</td><td>9,19</td><td>31.46(13.86)</td><td>30.52(14.70)</td><td>0.437</td><td>0.662</td><td>28.84(15.64)</td><td>30.90(16.77)</td><td>&#8722;0.847</td><td>0.398</td></tr><tr><td>Dyspnea DY</td><td>8</td><td>12.36(16.19)</td><td>14.79(16.56)</td><td>&#8722;0.992</td><td>0.323</td><td>11.98(16.08)</td><td>12.36(16.95)</td><td>&#8722;0.151</td><td>0.880</td></tr><tr><td>Insomnia SL</td><td>11</td><td>29.21(22.37)</td><td>30.71(21.45)</td><td>&#8722;0.456</td><td>0.649</td><td>27.71(20.25)</td><td>34.08(20.71)</td><td>&#8722;2.074</td><td>0.040</td></tr><tr><td>Appetite loss AP</td><td>13</td><td>23.03(22.96)</td><td>25.09(22.63)</td><td>&#8722;0.603</td><td>0.547</td><td>26.78(21.26)</td><td>28.84(23.13)</td><td>&#8722;0.618</td><td>0.537</td></tr><tr><td>Constipation CO</td><td>16</td><td>16.85(20.18)</td><td>16.10(20.17)</td><td>0.248</td><td>0.805</td><td>18.73(19.43)</td><td>20.97(19.71)</td><td>&#8722;0.766</td><td>0.445</td></tr><tr><td>Diarrhea DI</td><td>17</td><td>10.86(19.32)</td><td>9.36(15.88)</td><td>0.565</td><td>0.573</td><td>13.11(17.13)</td><td>12.36(18.38)</td><td>0.281</td><td>0.779</td></tr><tr><td>Financial difficulties FI</td><td>28</td><td>62.17(29.38)</td><td>61.42(29.26)</td><td>0.170</td><td>0.865</td><td>68.17(30.11)</td><td>67.04(28.65)</td><td>0.255</td><td>0.799</td></tr></table>
<table><tr><td>EORTC QLQ-C30 subscales</td><td>Item</td><td colspan="4">Baseline</td><td colspan="4">2 weeks post-RT</td></tr><tr><td></td><td></td><td>IG (n = 89)</td><td>CON (n = 89)</td><td></td><td></td><td>IG (n = 89)</td><td>CON (n = 89)</td><td></td><td></td></tr><tr><td></td><td></td><td>Mean(SD)</td><td>Mean(SD)</td><td>tvalue</td><td>pvalue</td><td>Mean(SD)</td><td>Mean(SD)</td><td>tvalue</td><td>pvalue*</td></tr></table>
<table><tr><td>Functioning scales</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Physical functioning PF</td><td>1-5</td><td>77.23(10.19)</td><td>78.91(10.81)</td><td>−1.067</td><td>0.288</td><td>79.70(9.80)</td><td>75.36(9.71)</td><td>2.970</td><td>0.003</td></tr><tr><td>Role functioning RF</td><td>6,7</td><td>59.55(24.48)</td><td>58.28(24.49)</td><td>0.347</td><td>0.729</td><td>59.18(24.23)</td><td>57.45(21.01)</td><td>0.507</td><td>0.613</td></tr><tr><td>Emotional functioning EF</td><td>21-24</td><td>72.57(12.51)</td><td>70.77(14.71)</td><td>0.874</td><td>0.383</td><td>74.18(11.43)</td><td>66.03(14.00)</td><td>4.251</td><td><0.001</td></tr><tr><td>Cognitive functioning CF</td><td>20,25</td><td>80.71(11.48)</td><td>81.27(11.46)</td><td>−0.327</td><td>0.744</td><td>81.09(12.36)</td><td>78.58(10.01)</td><td>1.489</td><td>0.138</td></tr><tr><td>Social functioning SF</td><td>26,27</td><td>75.00(13.82)</td><td>73.43(12.31)</td><td>0.802</td><td>0.424</td><td>74.35(10.67)</td><td>71.33(11.88)</td><td>1.782</td><td>0.076</td></tr><tr><td>Global health status QL</td><td>29,30</td><td>61.31(13.23)</td><td>58.43(12.78)</td><td>1.48</td><td>0.141</td><td>58.80(12.20)</td><td>51.12(12.82)</td><td>4.092</td><td><0.001</td></tr><tr><td>Symptom scales and/or items</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Fatigue FA</td><td>10,12,18</td><td>28.05(14.75)</td><td>28.63(13.38)</td><td>−0.276</td><td>0.783</td><td>29.20(11.86)</td><td>32.93(13.78)</td><td>−1.938</td><td>0.054</td></tr><tr><td>Nausea/vomiting NV</td><td>14,15</td><td>11.05(11.50)</td><td>9.74(9.99)</td><td>0.812</td><td>0.418</td><td>14.61(12.26)</td><td>15.92(10.93)</td><td>−0.753</td><td>0.452</td></tr><tr><td>Pain PA</td><td>9,19</td><td>31.46(13.86)</td><td>30.52(14.70)</td><td>0.437</td><td>0.662</td><td>28.84(15.64)</td><td>30.90(16.77)</td><td>−0.847</td><td>0.398</td></tr><tr><td>Dyspnea DY</td><td>8</td><td>12.36(16.19)</td><td>14.79(16.56)</td><td>−0.992</td><td>0.323</td><td>11.98(16.08)</td><td>12.36(16.95)</td><td>−0.151</td><td>0.880</td></tr><tr><td>Insomnia SL</td><td>11</td><td>29.21(22.37)</td><td>30.71(21.45)</td><td>−0.456</td><td>0.649</td><td>27.71(20.25)</td><td>34.08(20.71)</td><td>−2.074</td><td>0.040</td></tr><tr><td>Appetite loss AP</td><td>13</td><td>23.03(22.96)</td><td>25.09(22.63)</td><td>−0.603</td><td>0.547</td><td>26.78(21.26)</td><td>28.84(23.13)</td><td>−0.618</td><td>0.537</td></tr><tr><td>Constipation CO</td><td>16</td><td>16.85(20.18)</td><td>16.10(20.17)</td><td>0.248</td><td>0.805</td><td>18.73(19.43)</td><td>20.97(19.71)</td><td>−0.766</td><td>0.445</td></tr><tr><td>Diarrhea DI</td><td>17</td><td>10.86(19.32)</td><td>9.36(15.88)</td><td>0.565</td><td>0.573</td><td>13.11(17.13)</td><td>12.36(18.38)</td><td>0.281</td><td>0.779</td></tr><tr><td>Financial difficulties FI</td><td>28</td><td>62.17(29.38)</td><td>61.42(29.26)</td><td>0.170</td><td>0.865</td><td>68.17(30.11)</td><td>67.04(28.65)</td><td>0.255</td><td>0.799</td></tr></table>
a4da6baf2a9f4a9ac6462c6e73f82d537be3fee669b49c8626929f23b1502b5b.png
simple
<table><tr><td></td><td>HUS-STEMI I</td><td>HUS-STEMI II</td><td></td></tr><tr><td></td><td>n = 194</td><td>n = 306</td><td></td></tr><tr><td></td><td>%</td><td>%</td><td>p</td></tr><tr><td>Mean age, mean (SD) years</td><td>64.8 (12.9)</td><td>64.3 (14.0)</td><td>0.920</td></tr><tr><td>Age &gt; 75 years</td><td>23.7</td><td>26.1</td><td>0.542</td></tr><tr><td>Male sex</td><td>64.9</td><td>69.0</td><td>0.352</td></tr><tr><td>Diabetes</td><td>15.5</td><td>19.6</td><td>0.240</td></tr><tr><td>Current smoker</td><td>35.6</td><td>39.0</td><td>0.449</td></tr><tr><td>Hypertension</td><td>63.4</td><td>53.3</td><td>0.026</td></tr><tr><td>Dyslipidemia</td><td>44.8</td><td>41.5</td><td>0.462</td></tr><tr><td>Renal dysfunction</td><td>1.5</td><td>4.2</td><td>0.094</td></tr><tr><td>AMI</td><td>18.6</td><td>10.8</td><td>0.014</td></tr><tr><td>Stroke</td><td>8.8</td><td>6.5</td><td>0.354</td></tr><tr><td>CABG</td><td>4.1</td><td>5.2</td><td>0.573</td></tr><tr><td>PCI</td><td>9.8</td><td>13.4</td><td>0.227</td></tr><tr><td>ASA</td><td>23.2</td><td>26.8</td><td>0.367</td></tr><tr><td>P2Y12 inhibitor</td><td>2.1</td><td>3.9</td><td>0.250</td></tr><tr><td>Warfarin</td><td>9.3</td><td>8.8</td><td>0.863</td></tr><tr><td>Anterior infarct</td><td>46.8</td><td>53.6</td><td>0.143</td></tr><tr><td>Killip class 2--4</td><td>12.4</td><td>18.0</td><td>0.096</td></tr><tr><td>Admission at regular hours</td><td>41.5</td><td>40.8</td><td>0.888</td></tr></table>
<table><tr><td></td><td>HUS-STEMI I</td><td>HUS-STEMI II</td><td></td></tr><tr><td></td><td>n = 194</td><td>n = 306</td><td></td></tr><tr><td></td><td>%</td><td>%</td><td>p</td></tr><tr><td>Mean age, mean (SD) years</td><td>64.8 (12.9)</td><td>64.3 (14.0)</td><td>0.920</td></tr><tr><td>Age > 75 years</td><td>23.7</td><td>26.1</td><td>0.542</td></tr><tr><td>Male sex</td><td>64.9</td><td>69.0</td><td>0.352</td></tr><tr><td>Diabetes</td><td>15.5</td><td>19.6</td><td>0.240</td></tr></table>
<table><tr><td>Current smoker</td><td>35.6</td><td>39.0</td><td>0.449</td></tr><tr><td>Hypertension</td><td>63.4</td><td>53.3</td><td>0.026</td></tr><tr><td>Dyslipidemia</td><td>44.8</td><td>41.5</td><td>0.462</td></tr><tr><td>Renal dysfunction</td><td>1.5</td><td>4.2</td><td>0.094</td></tr><tr><td>AMI</td><td>18.6</td><td>10.8</td><td>0.014</td></tr><tr><td>Stroke</td><td>8.8</td><td>6.5</td><td>0.354</td></tr><tr><td>CABG</td><td>4.1</td><td>5.2</td><td>0.573</td></tr><tr><td>PCI</td><td>9.8</td><td>13.4</td><td>0.227</td></tr><tr><td>ASA</td><td>23.2</td><td>26.8</td><td>0.367</td></tr><tr><td>P2Y12 inhibitor</td><td>2.1</td><td>3.9</td><td>0.250</td></tr><tr><td>Warfarin</td><td>9.3</td><td>8.8</td><td>0.863</td></tr><tr><td>Anterior infarct</td><td>46.8</td><td>53.6</td><td>0.143</td></tr><tr><td>Killip class 2--4</td><td>12.4</td><td>18.0</td><td>0.096</td></tr><tr><td>Admission at regular hours</td><td>41.5</td><td>40.8</td><td>0.888</td></tr></table>
e789d6cfa0348cfe1fe0186a8e1a8ef888b34d4c11ed4ee024474fc3d6a5929c.png
simple
<table><tr><td>Category</td><td>All Respondents (n = 769)</td><td>Nurses (n = 527)</td><td>Physicians (n = 238)</td></tr><tr><td>1 Lack of time<sup>a</sup></td><td>33.0% (254)</td><td>27.3% (144)</td><td>46.2% (110)</td></tr><tr><td>2 Behaviours attributed to women living with abuse</td><td>21.5% (165)</td><td>19.9% (105)</td><td>25.2% (60)</td></tr><tr><td>3 Lack of training<sup>a</sup></td><td>16.4% (126)<sup>b</sup></td><td>20.9% (110)</td><td>5.5% (13)</td></tr><tr><td>4 Language/cultural practices<sup>a</sup></td><td>15.5% (119)<sup>c</sup></td><td>18.4% (97)</td><td>8.8% (21)</td></tr><tr><td>5 Partner presence<sup>a</sup></td><td>14.0% (108)</td><td>19.5% (103)</td><td>2.1% (5)</td></tr><tr><td>6 Lack of resources<sup>a</sup></td><td>13.0% (100)</td><td>10.4% (55)</td><td>18.9% (45)</td></tr><tr><td>7 Lack of space/privacy<sup>a</sup></td><td>8.2% (63)</td><td>11.2% (59)</td><td>1.7% (4)</td></tr><tr><td>8 Discomfort with topic</td><td>4.6% (35)</td><td>4.7% (25)</td><td>4.2% (10)</td></tr><tr><td>9 Lack of practitioner knowledge of resources</td><td>2.6% (20)</td><td>2.7% (14)</td><td>2.5% (6)</td></tr></table>
<table><tr><td>Category</td><td>All Respondents (n = 769)</td></tr><tr><td>1 Lack of timea</td><td>33.0% (254)</td></tr><tr><td>2 Behaviours attributed to women living with abuse</td><td>21.5% (165)</td></tr><tr><td>3 Lack of traininga</td><td>16.4% (126)b</td></tr><tr><td>4 Language/cultural practicesa</td><td>15.5% (119)c</td></tr><tr><td>5 Partner presencea</td><td>14.0% (108)</td></tr><tr><td>6 Lack of resourcesa</td><td>13.0% (100)</td></tr><tr><td>7 Lack of space/privacya</td><td>8.2% (63)</td></tr><tr><td>8 Discomfort with topic</td><td>4.6% (35)</td></tr><tr><td>9 Lack of practitioner knowledge of resources</td><td>2.6% (20)</td></tr></table>
<table><tr><td>Nurses (n = 527)</td><td>Physicians (n = 238)</td></tr><tr><td>27.3% (144)</td><td>46.2% (110)</td></tr><tr><td>19.9% (105)</td><td>25.2% (60)</td></tr><tr><td>20.9% (110)</td><td>5.5% (13)</td></tr><tr><td>18.4% (97)</td><td>8.8% (21)</td></tr><tr><td>19.5% (103)</td><td>2.1% (5)</td></tr><tr><td>10.4% (55)</td><td>18.9% (45)</td></tr><tr><td>11.2% (59)</td><td>1.7% (4)</td></tr><tr><td>4.7% (25)</td><td>4.2% (10)</td></tr><tr><td>2.7% (14)</td><td>2.5% (6)</td></tr></table>
20156a01ac3d3b8991a93774f5666df81ea8ddb231b41645d932e8a108c289d5.png
simple
<table><tr><td><i>CHEK2 </i>mutation type</td><td>Controls(<i>n </i>= 1,026)<sup>a</sup></td><td>Allelic frequency in controls</td><td>Cases(<i>n </i>= 1,014)<sup>a</sup></td><td>Allelic frequency in cases</td><td>P value</td><td>OR</td><td>95% CI</td></tr><tr><td>Any <i>CHEK2 </i>mutation</td><td>4</td><td>0.39%</td><td>16</td><td>1.58%</td><td>0.0065</td><td>4.15</td><td>(1.38 to 12.50)</td></tr><tr><td><i>CHEK2 </i>deleterious mutations</td><td>3</td><td>0.29%</td><td>15</td><td>1.48%</td><td>0.0042</td><td>5.18</td><td>(1.49 to 18.00)</td></tr></table>
<table><tr><td>CHEK2 mutation type</td></tr><tr><td>Any CHEK2 mutation</td></tr><tr><td>CHEK2 deleterious mutations</td></tr></table>
<table><tr><td>Controls(n = 1,026)a</td><td>Allelic frequency in controls</td><td>Cases(n = 1,014)a</td><td>Allelic frequency in cases</td><td>P value</td><td>OR</td><td>95% CI</td></tr><tr><td>4</td><td>0.39%</td><td>16</td><td>1.58%</td><td>0.0065</td><td>4.15</td><td>(1.38 to 12.50)</td></tr><tr><td>3</td><td>0.29%</td><td>15</td><td>1.48%</td><td>0.0042</td><td>5.18</td><td>(1.49 to 18.00)</td></tr></table>
34f5bf2176f57cb9e66cb401cb5fdf678bd09c332d50efd8955dc46b41a953a9.png
simple
<table><tr><td>Chr</td><td>SNP</td><td>Position</td><td>Minor allele/major allele</td><td>Association <i>p</i>-value</td><td>Allelic OR (95% CI)</td><td>Bonferroni adjusted <i>p</i>-value</td><td>BH-false discovery rate <i>p</i>-value</td><td>Interaction (ADD &#215; sex) <i>p</i>-value</td></tr><tr><td>1</td><td>rs865682</td><td>223,080,777</td><td>A/G</td><td>4.545 &#215; 10<sup>-6</sup></td><td>0.39(0.26-0.60)</td><td>0.16</td><td>0.16</td><td>-</td></tr><tr><td>2</td><td>rs12477038</td><td>201,518,282</td><td>G/A</td><td>1.038 &#215; 10<sup>-5</sup></td><td>0.47(0.33-0.66)</td><td>0.41</td><td>0.25</td><td>0.09</td></tr><tr><td>3</td><td>rs6775137</td><td>193,649,851</td><td>A/C</td><td>2.124 &#215; 10<sup>-5</sup></td><td>0.65(0.53-0.79)</td><td>0.70</td><td>0.70</td><td>-</td></tr><tr><td>4</td><td>rs512244</td><td>12,775,151</td><td>G/A</td><td>8.362 &#215; 10<sup>-8</sup></td><td>2.2(1.7-3.0)</td><td>0.002</td><td>0.002</td><td>0.14</td></tr><tr><td>5</td><td>rs7726943</td><td>67,854,337</td><td>G/A</td><td>2.991 &#215; 10<sup>-6</sup></td><td>0.62(0.50-0.76)</td><td>0.09</td><td>0.09</td><td>0.21</td></tr><tr><td>6</td><td>rs660895</td><td>32,685,358</td><td>G/A</td><td>8.346 &#215; 10<sup>-24</sup></td><td>3.4(2.7-4.3)</td><td>2.642 &#215; 10<sup>-19</sup></td><td>2.642 &#215; 10<sup>-19</sup></td><td>5.263 &#215; 10<sup>-45</sup></td></tr><tr><td>7</td><td>rs17470799</td><td>100,768,534</td><td>A/G</td><td>6.937 &#215; 10<sup>-6</sup></td><td>0.4(0.27-0.60)</td><td>0.18</td><td>0.12</td><td>1.0</td></tr><tr><td>8</td><td>rs966561</td><td>6,642,801</td><td>A/G</td><td>6.817 &#215; 10<sup>-5</sup></td><td>0.68(0.56-0.82)</td><td>1.0</td><td>0.54</td><td>0.93</td></tr><tr><td>9</td><td>rs306772</td><td>121,171,909</td><td>A/G</td><td>3.559 &#215; 10<sup>-5</sup></td><td>1.7(1.3-2.1)</td><td>0.83</td><td>0.40</td><td>0.09</td></tr><tr><td>10</td><td>rs7072006</td><td>133,595,618</td><td>A/G</td><td>5.309 &#215; 10<sup>-6</sup></td><td>0.48(0.35-0.67)</td><td>0.13</td><td>0.13</td><td>0.78</td></tr><tr><td>11</td><td>rs761453</td><td>31,834,576</td><td>A/G</td><td>3.867 &#215; 10<sup>-5</sup></td><td>0.61(0.48-0.77)</td><td>0.91</td><td>0.46</td><td>0.52</td></tr><tr><td>12</td><td>rs2283275</td><td>2,054,821</td><td>G/A</td><td>4.362 &#215; 10<sup>-6</sup></td><td>0.59(0.47-0.74)</td><td>0.10</td><td>0.10</td><td>0.98</td></tr><tr><td>13</td><td>rs17086849</td><td>28,064,399</td><td>A/G</td><td>3.158 &#215; 10<sup>-6</sup></td><td>0.56(0.44-0.72)</td><td>0.06</td><td>0.06</td><td>0.94</td></tr><tr><td>14</td><td>rs12885166</td><td>92,195,035</td><td>A/C</td><td>1.139 &#215; 10<sup>-5</sup></td><td>1.6(1.3-1.9)</td><td>0.18</td><td>0.18</td><td>0.45</td></tr><tr><td>15</td><td>rs11857639</td><td>71,424,825</td><td>A/G</td><td>1.083 &#215; 10<sup>-5</sup></td><td>0.39(0.25-0.61)</td><td>0.16</td><td>0.16</td><td>1.0</td></tr><tr><td>16</td><td>rs1076251</td><td>73,326,313</td><td>A/C</td><td>6.524 &#215; 10<sup>-6</sup></td><td>0.59(0.46-0.74)</td><td>0.10</td><td>0.10</td><td>0.21</td></tr><tr><td>17</td><td>rs1039519</td><td>3,394,664</td><td>G/A</td><td>7.11 &#215; 10<sup>-5</sup></td><td>1.52(1.2-1.9)</td><td>0.90</td><td>0.60</td><td>-</td></tr><tr><td>18</td><td>rs2174899</td><td>72,420,808</td><td>G/A</td><td>3.671 &#215; 10<sup>-5</sup></td><td>0.57(0.44-0.75)</td><td>0.54</td><td>0.54</td><td>-</td></tr><tr><td>19</td><td>rs9630874</td><td>57,619,851</td><td>A/C</td><td>1.27 &#215; 10<sup>-5</sup></td><td>0.31(0.17-0.54)</td><td>0.10</td><td>0.10</td><td>0.51</td></tr><tr><td>20</td><td>rs1182531</td><td>57,826,397</td><td>A/C</td><td>4.314<sup>-6</sup></td><td>0.56(0.43-0.71)</td><td>0.05</td><td>0.05</td><td>0.17</td></tr><tr><td>21</td><td>rs12626622</td><td>31,981,460</td><td>A/G</td><td>2.063 &#215; 10<sup>-4</sup></td><td>1.8(1.3-2.4)</td><td>1.0</td><td>0.52</td><td>0.20</td></tr><tr><td>22</td><td>rs3830104</td><td>35,033,124</td><td>G/A</td><td>3.974 &#215; 10<sup>-5</sup></td><td>2.3(1.5-3.5)</td><td>0.29</td><td>0.21</td><td>0.73</td></tr></table>
<table><tr><td>Chr</td><td>SNP</td><td>Position</td><td>Minor allele/major allele</td><td>Association p-value</td><td>Allelic OR (95% CI)</td><td>Bonferroni adjusted p-value</td><td>BH-false discovery rate p-value</td><td>Interaction (ADD × sex) p-value</td></tr><tr><td>1</td><td>rs865682</td><td>223,080,777</td><td>A/G</td><td>4.545 × 10-6</td><td>0.39(0.26-0.60)</td><td>0.16</td><td>0.16</td><td>-</td></tr><tr><td>2</td><td>rs12477038</td><td>201,518,282</td><td>G/A</td><td>1.038 × 10-5</td><td>0.47(0.33-0.66)</td><td>0.41</td><td>0.25</td><td>0.09</td></tr><tr><td>3</td><td>rs6775137</td><td>193,649,851</td><td>A/C</td><td>2.124 × 10-5</td><td>0.65(0.53-0.79)</td><td>0.70</td><td>0.70</td><td>-</td></tr><tr><td>4</td><td>rs512244</td><td>12,775,151</td><td>G/A</td><td>8.362 × 10-8</td><td>2.2(1.7-3.0)</td><td>0.002</td><td>0.002</td><td>0.14</td></tr><tr><td>5</td><td>rs7726943</td><td>67,854,337</td><td>G/A</td><td>2.991 × 10-6</td><td>0.62(0.50-0.76)</td><td>0.09</td><td>0.09</td><td>0.21</td></tr><tr><td>6</td><td>rs660895</td><td>32,685,358</td><td>G/A</td><td>8.346 × 10-24</td><td>3.4(2.7-4.3)</td><td>2.642 × 10-19</td><td>2.642 × 10-19</td><td>5.263 × 10-45</td></tr><tr><td>7</td><td>rs17470799</td><td>100,768,534</td><td>A/G</td><td>6.937 × 10-6</td><td>0.4(0.27-0.60)</td><td>0.18</td><td>0.12</td><td>1.0</td></tr><tr><td>8</td><td>rs966561</td><td>6,642,801</td><td>A/G</td><td>6.817 × 10-5</td><td>0.68(0.56-0.82)</td><td>1.0</td><td>0.54</td><td>0.93</td></tr><tr><td>9</td><td>rs306772</td><td>121,171,909</td><td>A/G</td><td>3.559 × 10-5</td><td>1.7(1.3-2.1)</td><td>0.83</td><td>0.40</td><td>0.09</td></tr><tr><td>10</td><td>rs7072006</td><td>133,595,618</td><td>A/G</td><td>5.309 × 10-6</td><td>0.48(0.35-0.67)</td><td>0.13</td><td>0.13</td><td>0.78</td></tr></table>
<table><tr><td>11</td><td>rs761453</td><td>31,834,576</td><td>A/G</td><td>3.867 × 10-5</td><td>0.61(0.48-0.77)</td><td>0.91</td><td>0.46</td><td>0.52</td></tr><tr><td>12</td><td>rs2283275</td><td>2,054,821</td><td>G/A</td><td>4.362 × 10-6</td><td>0.59(0.47-0.74)</td><td>0.10</td><td>0.10</td><td>0.98</td></tr><tr><td>13</td><td>rs17086849</td><td>28,064,399</td><td>A/G</td><td>3.158 × 10-6</td><td>0.56(0.44-0.72)</td><td>0.06</td><td>0.06</td><td>0.94</td></tr><tr><td>14</td><td>rs12885166</td><td>92,195,035</td><td>A/C</td><td>1.139 × 10-5</td><td>1.6(1.3-1.9)</td><td>0.18</td><td>0.18</td><td>0.45</td></tr><tr><td>15</td><td>rs11857639</td><td>71,424,825</td><td>A/G</td><td>1.083 × 10-5</td><td>0.39(0.25-0.61)</td><td>0.16</td><td>0.16</td><td>1.0</td></tr><tr><td>16</td><td>rs1076251</td><td>73,326,313</td><td>A/C</td><td>6.524 × 10-6</td><td>0.59(0.46-0.74)</td><td>0.10</td><td>0.10</td><td>0.21</td></tr><tr><td>17</td><td>rs1039519</td><td>3,394,664</td><td>G/A</td><td>7.11 × 10-5</td><td>1.52(1.2-1.9)</td><td>0.90</td><td>0.60</td><td>-</td></tr><tr><td>18</td><td>rs2174899</td><td>72,420,808</td><td>G/A</td><td>3.671 × 10-5</td><td>0.57(0.44-0.75)</td><td>0.54</td><td>0.54</td><td>-</td></tr><tr><td>19</td><td>rs9630874</td><td>57,619,851</td><td>A/C</td><td>1.27 × 10-5</td><td>0.31(0.17-0.54)</td><td>0.10</td><td>0.10</td><td>0.51</td></tr><tr><td>20</td><td>rs1182531</td><td>57,826,397</td><td>A/C</td><td>4.314-6</td><td>0.56(0.43-0.71)</td><td>0.05</td><td>0.05</td><td>0.17</td></tr><tr><td>21</td><td>rs12626622</td><td>31,981,460</td><td>A/G</td><td>2.063 × 10-4</td><td>1.8(1.3-2.4)</td><td>1.0</td><td>0.52</td><td>0.20</td></tr><tr><td>22</td><td>rs3830104</td><td>35,033,124</td><td>G/A</td><td>3.974 × 10-5</td><td>2.3(1.5-3.5)</td><td>0.29</td><td>0.21</td><td>0.73</td></tr></table>
e6386c1644aa3c1fdb0e75624296aa796c5eddeb85fe3f548a6803754bb699a5.png
simple
<table><tr><td> </td><td>T1</td><td>T2</td><td>T3</td><td><i>P</i> for trend</td></tr><tr><td>Men (<i>n</i>)</td><td>679</td><td>659</td><td>542</td><td> </td></tr><tr><td> Age (yr)</td><td>58.1 &#177; 10.6</td><td>54.5 &#177; 10.3</td><td>51.9 &#177; 9.4</td><td>&lt;0.001</td></tr><tr><td> Weight (kg)</td><td>68.9 &#177; 10.7</td><td>74.5 &#177; 11.0</td><td>80.0 &#177; 11.8</td><td>&lt;0.001</td></tr><tr><td> BMI (kg/m<sup>2</sup>)</td><td>26.5 &#177; 3.9</td><td>26.2 &#177; 3.9</td><td>26.0 &#177; 3.8</td><td>0.048</td></tr><tr><td> Abdominal obesity (%)</td><td>55.2</td><td>62.2</td><td>66.2</td><td>&lt;0.001</td></tr><tr><td> Hypercholesterolemia (%)</td><td>61.9</td><td>61.2</td><td>57.0</td><td>0.093</td></tr><tr><td> Low HDL-C (%)</td><td>61.7</td><td>63.6</td><td>63.5</td><td>0.501</td></tr><tr><td> Hypertriglyceridemia (%)</td><td>54.4</td><td>61.5</td><td>55.3</td><td>0.616</td></tr><tr><td> Hypertension (%)</td><td>33.4</td><td>26.8</td><td>24.8</td><td>&lt;0.001</td></tr><tr><td> Diabetes (%)</td><td>18.6</td><td>17.9</td><td>13.8</td><td>0.037</td></tr><tr><td> Smoking (% current)</td><td>22.6</td><td>28.2</td><td>28.9</td><td>0.011</td></tr><tr><td> Family history of CVD (%)</td><td>11.5</td><td>14.6</td><td>13.5</td><td>0.267</td></tr><tr><td>Women (<i>n</i>)</td><td>795</td><td>725</td><td>710</td><td> </td></tr><tr><td> Age (yr)</td><td>55.7 &#177; 9.6</td><td>52.9 &#177; 8.9</td><td>49.8 &#177; 8.2</td><td>&lt;0.001</td></tr><tr><td> Weight (kg)</td><td>65.1 &#177; 11.2</td><td>70.0 &#177; 11.1</td><td>74.6 &#177; 11.5</td><td>&lt;0.001</td></tr><tr><td> BMI (kg/m<sup>2</sup>)</td><td>29.4 &#177; 5.0</td><td>29.1 &#177; 4.6</td><td>28.7 &#177; 4.3</td><td>0.003</td></tr><tr><td> Abdominal obesity (%)</td><td>57.2</td><td>60.2</td><td>60.0</td><td>0.261</td></tr><tr><td> Hypercholesterolemia (%)</td><td>80.1</td><td>73.9</td><td>69.8</td><td>&lt;0.001</td></tr><tr><td> Low HDL-C (%)</td><td>32.8</td><td>37.8</td><td>41.1</td><td>&lt;0.001</td></tr><tr><td> Hypertriglyceridemia (%)</td><td>62.3</td><td>61.2</td><td>56.3</td><td>0.020</td></tr><tr><td> Hypertension (%)</td><td>38.2</td><td>35.5</td><td>23.3</td><td>&lt;0.001</td></tr><tr><td> Diabetes (%)</td><td>21.2</td><td>23.3</td><td>15.9</td><td>0.314</td></tr><tr><td> Smoking (% current)</td><td>2.5</td><td>2.5</td><td>5.4</td><td>0.003</td></tr><tr><td> Family history of CVD (%)</td><td>19.3</td><td>18.9</td><td>16.8</td><td>0.220</td></tr><tr><td> Menopause (%)</td><td>66.8</td><td>58.2</td><td>45.5</td><td>&lt;0.001</td></tr></table>
<table><tr><td></td><td>T1</td><td>T2</td><td>T3</td><td>P for trend</td></tr><tr><td>Men (n)</td><td>679</td><td>659</td><td>542</td><td></td></tr><tr><td>Age (yr)</td><td>58.1 ± 10.6</td><td>54.5 ± 10.3</td><td>51.9 ± 9.4</td><td><0.001</td></tr></table>
<table><tr><td>Weight (kg)</td><td>68.9 ± 10.7</td><td>74.5 ± 11.0</td><td>80.0 ± 11.8</td><td><0.001</td></tr><tr><td>BMI (kg/m2)</td><td>26.5 ± 3.9</td><td>26.2 ± 3.9</td><td>26.0 ± 3.8</td><td>0.048</td></tr><tr><td>Abdominal obesity (%)</td><td>55.2</td><td>62.2</td><td>66.2</td><td><0.001</td></tr><tr><td>Hypercholesterolemia (%)</td><td>61.9</td><td>61.2</td><td>57.0</td><td>0.093</td></tr><tr><td>Low HDL-C (%)</td><td>61.7</td><td>63.6</td><td>63.5</td><td>0.501</td></tr><tr><td>Hypertriglyceridemia (%)</td><td>54.4</td><td>61.5</td><td>55.3</td><td>0.616</td></tr><tr><td>Hypertension (%)</td><td>33.4</td><td>26.8</td><td>24.8</td><td><0.001</td></tr><tr><td>Diabetes (%)</td><td>18.6</td><td>17.9</td><td>13.8</td><td>0.037</td></tr><tr><td>Smoking (% current)</td><td>22.6</td><td>28.2</td><td>28.9</td><td>0.011</td></tr><tr><td>Family history of CVD (%)</td><td>11.5</td><td>14.6</td><td>13.5</td><td>0.267</td></tr><tr><td>Women (n)</td><td>795</td><td>725</td><td>710</td><td></td></tr><tr><td>Age (yr)</td><td>55.7 ± 9.6</td><td>52.9 ± 8.9</td><td>49.8 ± 8.2</td><td><0.001</td></tr><tr><td>Weight (kg)</td><td>65.1 ± 11.2</td><td>70.0 ± 11.1</td><td>74.6 ± 11.5</td><td><0.001</td></tr><tr><td>BMI (kg/m2)</td><td>29.4 ± 5.0</td><td>29.1 ± 4.6</td><td>28.7 ± 4.3</td><td>0.003</td></tr><tr><td>Abdominal obesity (%)</td><td>57.2</td><td>60.2</td><td>60.0</td><td>0.261</td></tr><tr><td>Hypercholesterolemia (%)</td><td>80.1</td><td>73.9</td><td>69.8</td><td><0.001</td></tr><tr><td>Low HDL-C (%)</td><td>32.8</td><td>37.8</td><td>41.1</td><td><0.001</td></tr><tr><td>Hypertriglyceridemia (%)</td><td>62.3</td><td>61.2</td><td>56.3</td><td>0.020</td></tr><tr><td>Hypertension (%)</td><td>38.2</td><td>35.5</td><td>23.3</td><td><0.001</td></tr><tr><td>Diabetes (%)</td><td>21.2</td><td>23.3</td><td>15.9</td><td>0.314</td></tr><tr><td>Smoking (% current)</td><td>2.5</td><td>2.5</td><td>5.4</td><td>0.003</td></tr><tr><td>Family history of CVD (%)</td><td>19.3</td><td>18.9</td><td>16.8</td><td>0.220</td></tr><tr><td>Menopause (%)</td><td>66.8</td><td>58.2</td><td>45.5</td><td><0.001</td></tr></table>
66f2453f01b391cc55c43f3439d8b4518f3b67d9c547360bd1f63d97d91ad752.png
complex
<table><tr><td>Polysaccharide(s)</td><td>Source(s)</td><td>Animals</td><td>Dose/day</td><td>Duration</td><td>CNS tests performed</td><td>Significant effects</td><td>Reference</td></tr><tr><td rowspan="2">Alpha-glucan (isolichenan)</td><td rowspan="2"><i>Cetrariella islandica</i></td><td>5-week-old &#9794; Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial</td><td>100, 200, or 400 mg/kg p.o. once</td><td>30 minutes before learning trial</td><td>Passive avoidance step through and step down</td><td>All doses reversed ethanol impaired fear memory acquisition; no effects on mice without ethanol exposure</td><td>18</td></tr><tr><td>&#9794; Wistar rats receiving daily i.c.v. injections of A-beta peptide from day 7 to day 4</td><td>100 or 200 mg/kg p.o.</td><td>8 days</td><td>Morris water maze</td><td>100 mg/kg reversed A-beta-induced spatial memory deficits; no effects on rats without A-beta peptide pretreatment</td><td>18</td></tr><tr><td>Arabinoxylan; beta-glucan</td><td><i>Triticum aestivum</i> L.; <i>Hordeum vulgare</i> L.</td><td>&#9794; Sprague&#8211;Dawley rats with bilateral common carotid artery occlusion</td><td>20 mg/kg p.o.</td><td>Days 8&#8211;14 post-surgery; testing on days 22&#8211;26 post-surgery</td><td>Morris water maze; immunohistochemistry and western blot (GFAP, MBP); Luxol fast blue and hematoxylin staining</td><td>Both treatments reversed ischemia-induced spatial memory deficits; arabinoxylan prevented loss of MBP in corpus callosum</td><td>20</td></tr><tr><td>Pectin</td><td>Citrus [peel]</td><td>9&#8211;11-week-old C56BL/6J mice injected i.p. with 100 &#956;g/kg LPS</td><td>10% pectin diet</td><td>6&#8211;8 weeks post-weaning</td><td>Social exploratory behavior of a novel juvenile mouse</td><td>Faster recovery from LPS-induced social withdrawal compared with 5% cellulose diet</td><td>19</td></tr><tr><td>Polysaccharide fraction: PSF (no characterization provided)</td><td><i>Panax ginseng</i></td><td>Adult &#9794; Wistar rats</td><td>4, 20, or 40 mg/kg i.p.</td><td>10 days</td><td>Conditioned Active Escape Response</td><td>All doses differentially improved indications of learning and memory</td><td>22</td></tr><tr><td>Alpha-glucan (FPS)</td><td>Fu Zi (<i>Aconitum carmichaeli</i> Debx)</td><td>8&#8211;11-week-old &#9794; C57BL/6 mice</td><td>5 to 400 mg/kg i.p.</td><td>Varied with assay: 30 minutes, 6 hours, or 1&#8211;4 weeks</td><td>BrdU labeling; forced swim; open-field; novelty-suppressed feeding; chronic social defeat stress; monoamine levels in the frontal cortex; ELISA and Western blot (BDNF)</td><td>10&#8211;400 mg/kg doses increased newborn neurons in the DG; 50 and 100 mg/kg produced AD effects (similar to imipramine); 100 mg/kg increased BDNF expression in the hippocampus; AD and neurogenesis effects were blocked by co-injection with K252a (trkB inhibitor)</td><td>23</td></tr></table>
<table><tr><td>Polysaccharide(s)</td></tr><tr><td rowspan="2">Alpha-glucan (isolichenan)</td></tr><tr></tr><tr><td>Arabinoxylan; beta-glucan</td></tr><tr><td>Pectin</td></tr><tr><td>Polysaccharide fraction: PSF (no characterization provided)</td></tr><tr><td>Alpha-glucan (FPS)</td></tr></table>
<table><tr><td>Source(s)</td><td>Animals</td><td>Dose/day</td><td>Duration</td><td>CNS tests performed</td><td>Significant effects</td><td>Reference</td></tr><tr><td rowspan="2">Cetrariella islandica</td><td>5-week-old ♂ Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial</td><td>100, 200, or 400 mg/kg p.o. once</td><td>30 minutes before learning trial</td><td>Passive avoidance step through and step down</td><td>All doses reversed ethanol impaired fear memory acquisition; no effects on mice without ethanol exposure</td><td>18</td></tr><tr><td>♂ Wistar rats receiving daily i.c.v. injections of A-beta peptide from day 7 to day 4</td><td>100 or 200 mg/kg p.o.</td><td>8 days</td><td>Morris water maze</td><td>100 mg/kg reversed A-beta-induced spatial memory deficits; no effects on rats without A-beta peptide pretreatment</td><td>18</td></tr><tr><td>Triticum aestivum L.; Hordeum vulgare L.</td><td>♂ Sprague–Dawley rats with bilateral common carotid artery occlusion</td><td>20 mg/kg p.o.</td><td>Days 8–14 post-surgery; testing on days 22–26 post-surgery</td><td>Morris water maze; immunohistochemistry and western blot (GFAP, MBP); Luxol fast blue and hematoxylin staining</td><td>Both treatments reversed ischemia-induced spatial memory deficits; arabinoxylan prevented loss of MBP in corpus callosum</td><td>20</td></tr><tr><td>Citrus [peel]</td><td>9–11-week-old C56BL/6J mice injected i.p. with 100 μg/kg LPS</td><td>10% pectin diet</td><td>6–8 weeks post-weaning</td><td>Social exploratory behavior of a novel juvenile mouse</td><td>Faster recovery from LPS-induced social withdrawal compared with 5% cellulose diet</td><td>19</td></tr><tr><td>Panax ginseng</td><td>Adult ♂ Wistar rats</td><td>4, 20, or 40 mg/kg i.p.</td><td>10 days</td><td>Conditioned Active Escape Response</td><td>All doses differentially improved indications of learning and memory</td><td>22</td></tr><tr><td>Fu Zi (Aconitum carmichaeli Debx)</td><td>8–11-week-old ♂ C57BL/6 mice</td><td>5 to 400 mg/kg i.p.</td><td>Varied with assay: 30 minutes, 6 hours, or 1–4 weeks</td><td>BrdU labeling; forced swim; open-field; novelty-suppressed feeding; chronic social defeat stress; monoamine levels in the frontal cortex; ELISA and Western blot (BDNF)</td><td>10–400 mg/kg doses increased newborn neurons in the DG; 50 and 100 mg/kg produced AD effects (similar to imipramine); 100 mg/kg increased BDNF expression in the hippocampus; AD and neurogenesis effects were blocked by co-injection with K252a (trkB inhibitor)</td><td>23</td></tr></table>
d592b6d2899c34ad1c98833a0c1da8b57f8fbdc25558bfe903b7f09eeab19a79.png
complex
<table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td><i>P</i><sub>trend</sub></td></tr><tr><td colspan="6">TyG</td></tr><tr><td> Range</td><td>&lt;8.16</td><td>8.16 to 8.47</td><td>8.48 to 8.81</td><td>&#8805;8.82</td><td></td></tr><tr><td> No. of cases</td><td>18</td><td>35</td><td>52</td><td>88</td><td></td></tr><tr><td> No. of person-years</td><td>8740.50</td><td>8526.83</td><td>8529.25</td><td>8399.50</td><td></td></tr><tr><td> Incidence rate<sup>a</sup></td><td>2.06</td><td>4.10</td><td>6.10</td><td>10.48</td><td>&lt;0.001</td></tr><tr><td> Unadjusted model</td><td>1 (ref)</td><td>2.36 (1.33&#8211;4.16)</td><td>3.58 (2.09&#8211;6.12)</td><td>6.30 (3.78&#8211;10.50)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 1<sup>b</sup></td><td>1 (ref)</td><td>2.38 (1.17&#8211;4.85)</td><td>3.71 (1.89&#8211;7.29)</td><td>5.54 (2.87&#8211;10.71)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 2<sup>c</sup></td><td>1 (ref)</td><td>2.49 (1.22&#8211;5.08)</td><td>3.89 (1.98&#8211;7.65)</td><td>5.69 (2.94&#8211;11.01)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 3<sup>d</sup></td><td>1 (ref)</td><td>2.48 (1.20&#8211;5.11)</td><td>3.77 (1.83&#8211;7.79)</td><td>5.30 (2.21&#8211;12.71)</td><td>&lt;0.001</td></tr><tr><td colspan="6">TyG-D</td></tr><tr><td> Range</td><td>&lt;&#8722;0.27</td><td>&#8722;0.27 to 0</td><td>0.01 to 0.31</td><td>&#8805;0.32</td><td></td></tr><tr><td> No. of cases</td><td>41</td><td>39</td><td>30</td><td>83</td><td></td></tr><tr><td> No. of person-years</td><td>8520.00</td><td>9747.08</td><td>7373.00</td><td>8556.00</td><td></td></tr><tr><td> Incidence rate<sup>a</sup></td><td>4.81</td><td>4.00 </td><td>4.07</td><td>9.70</td><td>&lt;0.001</td></tr><tr><td> Unadjusted model</td><td>1 (ref)</td><td>0.95 (0.58&#8211;1.55)</td><td>1.15 (0.68&#8211;1.93)</td><td>2.19 (1.41&#8211;3.39)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 1<sup>b</sup></td><td>1 (ref)</td><td>0.92 (0.52&#8211;1.63)</td><td>1.09 (0.59&#8211;2.03)</td><td>2.51 (1.50&#8211;4.19)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 2<sup>c</sup></td><td>1 (ref)</td><td>0.92 (0.52&#8211;1.64)</td><td>1.10 (0.59&#8211;2.05)</td><td>2.52 (1.51&#8211;4.22)</td><td>&lt;0.001</td></tr><tr><td> Multivariable adjusted model 3<sup>d</sup></td><td>1 (ref)</td><td>1.14 (0.63&#8211;2.09)</td><td>1.54 (0.80&#8211;2.99)</td><td>3.91 (2.22&#8211;6.87)</td><td>&lt;0.001</td></tr></table>
<table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td>Ptrend</td></tr><tr><td colspan="6">TyG</td></tr><tr><td>Range</td><td><8.16</td><td>8.16 to 8.47</td><td>8.48 to 8.81</td><td>≥8.82</td><td></td></tr><tr><td>No. of cases</td><td>18</td><td>35</td><td>52</td><td>88</td><td></td></tr><tr><td>No. of person-years</td><td>8740.50</td><td>8526.83</td><td>8529.25</td><td>8399.50</td><td></td></tr><tr><td>Incidence ratea</td><td>2.06</td><td>4.10</td><td>6.10</td><td>10.48</td><td><0.001</td></tr><tr><td>Unadjusted model</td><td>1 (ref)</td><td>2.36 (1.33–4.16)</td><td>3.58 (2.09–6.12)</td><td>6.30 (3.78–10.50)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 1b</td><td>1 (ref)</td><td>2.38 (1.17–4.85)</td><td>3.71 (1.89–7.29)</td><td>5.54 (2.87–10.71)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 2c</td><td>1 (ref)</td><td>2.49 (1.22–5.08)</td><td>3.89 (1.98–7.65)</td><td>5.69 (2.94–11.01)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 3d</td><td>1 (ref)</td><td>2.48 (1.20–5.11)</td><td>3.77 (1.83–7.79)</td><td>5.30 (2.21–12.71)</td><td><0.001</td></tr><tr><td colspan="6">TyG-D</td></tr><tr><td>Range</td><td><−0.27</td><td>−0.27 to 0</td><td>0.01 to 0.31</td><td>≥0.32</td><td></td></tr><tr><td>No. of cases</td><td>41</td><td>39</td><td>30</td><td>83</td><td></td></tr><tr><td>No. of person-years</td><td>8520.00</td><td>9747.08</td><td>7373.00</td><td>8556.00</td><td></td></tr><tr><td>Incidence ratea</td><td>4.81</td><td>4.00</td><td>4.07</td><td>9.70</td><td><0.001</td></tr></table>
<table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td>Ptrend</td></tr><tr><td>Unadjusted model</td><td>1 (ref)</td><td>0.95 (0.58–1.55)</td><td>1.15 (0.68–1.93)</td><td>2.19 (1.41–3.39)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 1b</td><td>1 (ref)</td><td>0.92 (0.52–1.63)</td><td>1.09 (0.59–2.03)</td><td>2.51 (1.50–4.19)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 2c</td><td>1 (ref)</td><td>0.92 (0.52–1.64)</td><td>1.10 (0.59–2.05)</td><td>2.52 (1.51–4.22)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 3d</td><td>1 (ref)</td><td>1.14 (0.63–2.09)</td><td>1.54 (0.80–2.99)</td><td>3.91 (2.22–6.87)</td><td><0.001</td></tr></table>
1c161a4d6cb685a7a1bfd07901c96fd8b16410608cca946c49b17c11ad065c39.png
simple
<table><tr><td>Characteristic</td><td>HES APC<sup>a</sup></td><td>England<sup>b</sup></td></tr><tr><td>Finished consultant episodes</td><td>18731964</td><td></td></tr><tr><td>Admissions</td><td>15892434</td><td></td></tr><tr><td>Admission type</td><td></td><td></td></tr><tr><td> Emergency</td><td>5615707 (30.0)</td><td></td></tr><tr><td> Waiting list</td><td>6119234 (32.7)</td><td></td></tr><tr><td> Planned</td><td>2154564 (11.5)</td><td></td></tr><tr><td> Other</td><td>2002929 (10.7)</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td> Male</td><td>8359362 (44.6)</td><td>26773200 (49.3)</td></tr><tr><td> Female</td><td>10370245 (55.4)</td><td>27543400 (50.7)</td></tr><tr><td> Gender unknown</td><td>2357 (0.01)</td><td>&#8211;</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td> 0 years</td><td>1013476 (5.4)</td><td>664183 (1.2)</td></tr><tr><td> 1&#8211;4 years</td><td>454461 (2.4)</td><td>2766774 (5.1)</td></tr><tr><td> 5&#8211;14 years</td><td>568902 (3.0)</td><td>6245420 (11.5)</td></tr><tr><td> 15&#8211;24 years</td><td>1167439 (6.2)</td><td>6837371 (12.6)</td></tr><tr><td> 25&#8211;34 years</td><td>1880715 (10.0)</td><td>7425591 (13.7)</td></tr><tr><td> 35&#8211;44 years</td><td>1573273 (8.4)</td><td>7103408 (13.1)</td></tr><tr><td> 45&#8211;54 years</td><td>1986116 (10.6)</td><td>7635651 (14.1)</td></tr><tr><td> 55&#8211;64 years</td><td>2319214 (12.4)</td><td>6100512 (11.2)</td></tr><tr><td> 65&#8211;74 years</td><td>3013044 (16.1)</td><td>5162873 (9.5)</td></tr><tr><td> 75&#8211;84 years</td><td>2941250 (15.7)</td><td>3099319 (5.7)</td></tr><tr><td> 85+ years</td><td>1711354 (9.1)</td><td>1275516 (2.3)</td></tr><tr><td> Missing</td><td>102720 (0.5)</td><td></td></tr></table>
<table><tr><td>Characteristic</td><td>HES APCa</td><td>Englandb</td></tr><tr><td>Finished consultant episodes</td><td>18731964</td><td></td></tr><tr><td>Admissions</td><td>15892434</td><td></td></tr><tr><td>Admission type</td><td></td><td></td></tr><tr><td>Emergency</td><td>5615707 (30.0)</td><td></td></tr><tr><td>Waiting list</td><td>6119234 (32.7)</td><td></td></tr></table>
<table><tr><td>Characteristic</td><td>HES APCa</td><td>Englandb</td></tr><tr><td>Planned</td><td>2154564 (11.5)</td><td></td></tr><tr><td>Other</td><td>2002929 (10.7)</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td>Male</td><td>8359362 (44.6)</td><td>26773200 (49.3)</td></tr><tr><td>Female</td><td>10370245 (55.4)</td><td>27543400 (50.7)</td></tr><tr><td>Gender unknown</td><td>2357 (0.01)</td><td>–</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td>0 years</td><td>1013476 (5.4)</td><td>664183 (1.2)</td></tr><tr><td>1–4 years</td><td>454461 (2.4)</td><td>2766774 (5.1)</td></tr><tr><td>5–14 years</td><td>568902 (3.0)</td><td>6245420 (11.5)</td></tr><tr><td>15–24 years</td><td>1167439 (6.2)</td><td>6837371 (12.6)</td></tr><tr><td>25–34 years</td><td>1880715 (10.0)</td><td>7425591 (13.7)</td></tr><tr><td>35–44 years</td><td>1573273 (8.4)</td><td>7103408 (13.1)</td></tr><tr><td>45–54 years</td><td>1986116 (10.6)</td><td>7635651 (14.1)</td></tr><tr><td>55–64 years</td><td>2319214 (12.4)</td><td>6100512 (11.2)</td></tr><tr><td>65–74 years</td><td>3013044 (16.1)</td><td>5162873 (9.5)</td></tr><tr><td>75–84 years</td><td>2941250 (15.7)</td><td>3099319 (5.7)</td></tr><tr><td>85+ years</td><td>1711354 (9.1)</td><td>1275516 (2.3)</td></tr><tr><td>Missing</td><td>102720 (0.5)</td><td></td></tr></table>
18a0c09bda3cc11f6eaacc096471a8ed105b481aef3d5fcb7986b2327da527a9.png
complex
<table><tr><td>miRNAs</td><td>Expression in lung cancer</td><td>Cellular processes affected and targets</td><td>Reference</td></tr><tr><td rowspan="3">Let-7 family</td><td rowspan="3">Decreased</td><td>(i) Cell proliferation (KRAS, MYC, and HMGA2)</td><td>[28&#8211;30]</td></tr><tr><td>(ii) miRNA maturation Dicer mediated</td><td>[31]</td></tr><tr><td>(iii) Cell-cycle regulation (CDC25A, CDK6, and cyclin D2)</td><td>[32]</td></tr><tr><td rowspan="2">mir-34 family</td><td rowspan="2">Decreased</td><td>(i) Transcriptionally activated by p53</td><td>[40]</td></tr><tr><td>(ii) TRAIL-induced cell death and cell proliferation (BCL-2, MET, and PDGFR-&#945;/<i>&#946;</i>)</td><td>[41&#8211;43]</td></tr><tr><td rowspan="2">mir-21</td><td rowspan="2">Increased</td><td>(i) Apoptosis, cellular proliferation, and migration (TPM1, PDCD4, and PTEN)</td><td>[50&#8211;53]</td></tr><tr><td>(ii) TKI-treatment resistance</td><td>[54]</td></tr><tr><td rowspan="2">mir-17/92a cluster</td><td rowspan="2">Increased</td><td>(i) Transcriptionally regulated by c-MYC</td><td>[60]</td></tr><tr><td>(ii) Cellular proliferation and cancer development (PTEN, HIF-1a CL2L11, CDKNA, and TSP-1)</td><td>[57, 61&#8211;63]</td></tr><tr><td>mir-15a/16 cluster</td><td>Decreased</td><td>Cell cycle regulation (cyclin D1, D2 and E1)</td><td>[66, 67]</td></tr><tr><td>mir-200 family</td><td>Decreased</td><td>Promotion of EMT and metastasization(ZEB transcription factors,CDH-1, and vimentin)</td><td>[68&#8211;73]</td></tr><tr><td>miRNA-29 family</td><td>Decreased</td><td>Epigenetic regulation of gene expression (DNMT-3A and DNMT-3B)</td><td>[74]</td></tr><tr><td rowspan="2">mir-221/mir-222</td><td rowspan="2">Increased</td><td>(i) TRAIL resistance and cellular migration (PTEN and TIMP3)</td><td>[75, 76]</td></tr><tr><td>(ii) Transcriptionally regulated by EGFR and MET and gefitinib resistance (BIM and APAF1)</td><td>[77]</td></tr><tr><td>mir-548</td><td>Decreased</td><td>Tumor cell growth (CCND, ERBB2, DMNT3A, and DNMT3B)</td><td>[78]</td></tr></table>
<table><tr><td>miRN</td><td>Expression in lun</td><td>Cellular processes affe</td><td>Refe</td></tr></table>
<table><tr><td>As</td><td>g cancer</td><td>cted and targets</td><td>rence</td></tr><tr><td rowspan="3">Let-7 family</td><td rowspan="3">Decreased</td><td>(i) Cell proliferation (KRAS, MYC, and HMGA2)</td><td>[28–30]</td></tr><tr><td>(ii) miRNA maturation Dicer mediated</td><td>[31]</td></tr><tr><td>(iii) Cell-cycle regulation (CDC25A, CDK6, and cyclin D2)</td><td>[32]</td></tr><tr><td rowspan="2">mir-34 family</td><td rowspan="2">Decreased</td><td>(i) Transcriptionally activated by p53</td><td>[40]</td></tr><tr><td>(ii) TRAIL-induced cell death and cell proliferation (BCL-2, MET, and PDGFR-α/β)</td><td>[41–43]</td></tr><tr><td rowspan="2">mir-21</td><td rowspan="2">Increased</td><td>(i) Apoptosis, cellular proliferation, and migration (TPM1, PDCD4, and PTEN)</td><td>[50–53]</td></tr><tr><td>(ii) TKI-treatment resistance</td><td>[54]</td></tr><tr><td rowspan="2">mir-17/92a cluster</td><td rowspan="2">Increased</td><td>(i) Transcriptionally regulated by c-MYC</td><td>[60]</td></tr><tr><td>(ii) Cellular proliferation and cancer development (PTEN, HIF-1a CL2L11, CDKNA, and TSP-1)</td><td>[57, 61–63]</td></tr><tr><td>mir-15a/16 cluster</td><td>Decreased</td><td>Cell cycle regulation (cyclin D1, D2 and E1)</td><td>[66, 67]</td></tr><tr><td>mir-200 family</td><td>Decreased</td><td>Promotion of EMT and metastasization(ZEB transcription factors,CDH-1, and vimentin)</td><td>[68–73]</td></tr><tr><td>miRNA-29 family</td><td>Decreased</td><td>Epigenetic regulation of gene expression (DNMT-3A and DNMT-3B)</td><td>[74]</td></tr><tr><td rowspan="2">mir-221/mir-222</td><td rowspan="2">Increased</td><td>(i) TRAIL resistance and cellular migration (PTEN and TIMP3)</td><td>[75, 76]</td></tr><tr><td>(ii) Transcriptionally regulated by EGFR and MET and gefitinib resistance (BIM and APAF1)</td><td>[77]</td></tr><tr><td>mir-548</td><td>Decreased</td><td>Tumor cell growth (CCND, ERBB2, DMNT3A, and DNMT3B)</td><td>[78]</td></tr></table>
f6b497bcdffbd4a90b146b1b041d931afb38b61e7470ad6e282c9513b11d257b.png
complex
<table><tr><td> </td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td> </td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>Number of patients:</td><td>9</td><td>9</td><td>9</td><td>9</td><td>/</td></tr><tr><td>Total hours:</td><td>/</td><td>194 h</td><td>/</td><td>215 h</td><td>/</td></tr><tr><td>Number of BG measurements:</td><td>46</td><td>91</td><td>44</td><td>205</td><td>/</td></tr><tr><td>BG median [IQR] (mg/dL):</td><td>155.5 [124.0 - 171.0]</td><td>134.0 [117.2 - 150.8]</td><td>136.5 [115.0 - 159.5]</td><td>136.0 [122.5 - 158.0]</td><td>0.27(*)</td></tr><tr><td>% BG within 80&#8211;100 mg/dL</td><td>8.7</td><td>3.3</td><td>6.82</td><td>3.4</td><td>1.00</td></tr><tr><td>% BG within 100&#8211;140 mg/dL</td><td>10.9</td><td>54.9</td><td>43.18</td><td>50.7</td><td>0.53</td></tr><tr><td>% BG within 140&#8211;180 mg/dL</td><td>50.0</td><td>33.0</td><td>36.36</td><td>37.1</td><td>0.51</td></tr><tr><td>% BG &#8805; 180 mg/dL</td><td>19.6</td><td>7.7</td><td>9.09</td><td>8.3</td><td>1.00</td></tr><tr><td>% BG &lt; 90 mg/dL</td><td>19.6</td><td>3.3</td><td>11.4</td><td>2.0</td><td>0.44</td></tr><tr><td>% BG &lt; 80 mg/dL</td><td>10.9</td><td>1.1</td><td>4.55</td><td>0.5</td><td>0.52</td></tr><tr><td>% BG &lt; 40 mg/dL</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>1.00</td></tr><tr><td>Number of patients &lt; 40 mg/dL</td><td>0</td><td>0</td><td>0</td><td>0</td><td>/</td></tr><tr><td>Median insulin rate [IQR] (U/h):</td><td>/</td><td>2.0 [1.0 - 2.5]</td><td>/</td><td>1.5 [0.5 - 3.4]</td><td>0.92(*)</td></tr><tr><td>Median glucose rate [IQR] (g/h):</td><td>/</td><td>0.0 [0.0 - 5.4]</td><td>/</td><td>7.4 [2.0 - 11.2]</td><td>0.00(*)</td></tr></table>
<table><tr><td></td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td></td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>Number of patients:</td><td>9</td><td>9</td><td>9</td><td>9</td><td>/</td></tr><tr><td>Total hours:</td><td>/</td><td>194 h</td><td>/</td><td>215 h</td><td>/</td></tr><tr><td>Number of BG measurements:</td><td>46</td><td>91</td><td>44</td><td>205</td><td>/</td></tr><tr><td>BG median [IQR] (mg/dL):</td><td>155.5 [124.0 - 171.0]</td><td>134.0 [117.2 - 150.8]</td><td>136.5 [115.0 - 159.5]</td><td>136.0 [122.5 - 158.0]</td><td>0.27(*)</td></tr><tr><td>% BG within 80–100 mg/dL</td><td>8.7</td><td>3.3</td><td>6.82</td><td>3.4</td><td>1.00</td></tr></table>
<table><tr><td></td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td></td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>% BG within 100–140 mg/dL</td><td>10.9</td><td>54.9</td><td>43.18</td><td>50.7</td><td>0.53</td></tr><tr><td>% BG within 140–180 mg/dL</td><td>50.0</td><td>33.0</td><td>36.36</td><td>37.1</td><td>0.51</td></tr><tr><td>% BG ≥ 180 mg/dL</td><td>19.6</td><td>7.7</td><td>9.09</td><td>8.3</td><td>1.00</td></tr><tr><td>% BG < 90 mg/dL</td><td>19.6</td><td>3.3</td><td>11.4</td><td>2.0</td><td>0.44</td></tr><tr><td>% BG < 80 mg/dL</td><td>10.9</td><td>1.1</td><td>4.55</td><td>0.5</td><td>0.52</td></tr><tr><td>% BG < 40 mg/dL</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>1.00</td></tr><tr><td>Number of patients < 40 mg/dL</td><td>0</td><td>0</td><td>0</td><td>0</td><td>/</td></tr><tr><td>Median insulin rate [IQR] (U/h):</td><td>/</td><td>2.0 [1.0 - 2.5]</td><td>/</td><td>1.5 [0.5 - 3.4]</td><td>0.92(*)</td></tr><tr><td>Median glucose rate [IQR] (g/h):</td><td>/</td><td>0.0 [0.0 - 5.4]</td><td>/</td><td>7.4 [2.0 - 11.2]</td><td>0.00(*)</td></tr></table>
766345879b0508585a93b51460f720a59c9ac18718f23bd5ae379f69c7c5763a.png
simple
<table><tr><td>Fatty acid</td><td>Name</td><td>Percentage in EVOO</td><td>mg FAME/g sample</td></tr><tr><td>C16:0</td><td>Palmitic acid</td><td>11,27</td><td>125,41</td></tr><tr><td>C16:1n7</td><td>Palmitoleic acid</td><td>0,86</td><td>9,56</td></tr><tr><td>C17:0</td><td>Margaric acid</td><td>0,04</td><td>0,46</td></tr><tr><td>C18:0</td><td>Stearic acid</td><td>3,85</td><td>42,81</td></tr><tr><td>C18:1n7c</td><td><i>Cis</i>-Vaccenic acid</td><td>2,42</td><td>26,92</td></tr><tr><td>C18:1n9c</td><td>Oleic acid</td><td>75,99</td><td>845,97</td></tr><tr><td>C18:2n6c</td><td>Linoleic acid</td><td>4,2</td><td>46,74</td></tr><tr><td>C18:3n3</td><td>&#945;-Linolenic acid</td><td>0,61</td><td>6,81</td></tr><tr><td>C20:0</td><td>Arachidic acid</td><td>0,4</td><td>4,46</td></tr><tr><td>C20:1n9</td><td><i>Cis</i>-11 eicosenoic acid</td><td>0,22</td><td>2,42</td></tr><tr><td>C22:0</td><td>Behenic acid</td><td>0,1</td><td>1,14</td></tr><tr><td>C24:0</td><td>Lignoceric acid</td><td>0,05</td><td>0,544</td></tr><tr><td>Selected phenolic compounds (STP)</td><td></td><td></td><td>&#956;g/g sample</td></tr><tr><td>Hydroxytyrosol</td><td></td><td></td><td>9,31</td></tr><tr><td><i>p</i>-coumaric acid</td><td></td><td></td><td>0,14</td></tr><tr><td>Oleuropein</td><td></td><td></td><td>n.d.</td></tr></table>
<table><tr><td>Fatty acid</td><td>Name</td></tr><tr><td>C16:0</td><td>Palmitic acid</td></tr><tr><td>C16:1n7</td><td>Palmitoleic acid</td></tr><tr><td>C17:0</td><td>Margaric acid</td></tr><tr><td>C18:0</td><td>Stearic acid</td></tr><tr><td>C18:1n7c</td><td>Cis-Vaccenic acid</td></tr><tr><td>C18:1n9c</td><td>Oleic acid</td></tr><tr><td>C18:2n6c</td><td>Linoleic acid</td></tr><tr><td>C18:3n3</td><td>α-Linolenic acid</td></tr><tr><td>C20:0</td><td>Arachidic acid</td></tr><tr><td>C20:1n9</td><td>Cis-11 eicosenoic acid</td></tr><tr><td>C22:0</td><td>Behenic acid</td></tr><tr><td>C24:0</td><td>Lignoceric acid</td></tr><tr><td>Selected phenolic compounds (STP)</td><td></td></tr><tr><td>Hydroxytyrosol</td><td></td></tr><tr><td>p-coumaric acid</td><td></td></tr><tr><td>Oleuropein</td><td></td></tr></table>
<table><tr><td>Percentage in EVOO</td><td>mg FAME/g sample</td></tr><tr><td>11,27</td><td>125,41</td></tr><tr><td>0,86</td><td>9,56</td></tr><tr><td>0,04</td><td>0,46</td></tr><tr><td>3,85</td><td>42,81</td></tr><tr><td>2,42</td><td>26,92</td></tr><tr><td>75,99</td><td>845,97</td></tr><tr><td>4,2</td><td>46,74</td></tr><tr><td>0,61</td><td>6,81</td></tr><tr><td>0,4</td><td>4,46</td></tr><tr><td>0,22</td><td>2,42</td></tr><tr><td>0,1</td><td>1,14</td></tr><tr><td>0,05</td><td>0,544</td></tr><tr><td></td><td>μg/g sample</td></tr><tr><td></td><td>9,31</td></tr><tr><td></td><td>0,14</td></tr><tr><td></td><td>n.d.</td></tr></table>
f5c89fa9ee87ed6e1c5341c6fb8431c1e9b10966a58e580825ab6ef69bafa2a2.png
simple
<table><tr><td>Covariate</td><td>&#967;<sup>2</sup></td><td>P-value</td><td>Hazard ratio</td><td>95% CI</td></tr><tr><td>Adjacent involvement (with vs. without)</td><td>11.841</td><td>0.001</td><td>2.295</td><td>1.430-3.683</td></tr><tr><td>Mitotic rate (&gt; = 5/50 HPF vs. &lt;5/50 HPF)</td><td>8.895</td><td>0.003</td><td>2.406</td><td>1.351-4.284</td></tr><tr><td>Risk grade (high risk vs. non-high risk)</td><td>26.129</td><td>&lt;0.001</td><td>11.794</td><td>4.579-30.379</td></tr></table>
<table><tr><td>Covariate</td><td>χ2</td><td>P-value</td><td>Hazard ratio</td><td>95% CI</td></tr><tr><td>Adjacent involvement (with vs. without)</td><td>11.841</td><td>0.001</td><td>2.295</td><td>1.430-3.683</td></tr><tr><td></td><td>8.89</td><td>0</td><td>2.40</td><td>1</td></tr></table>
<table><tr><td>Mitotic rate (> = 5/50 HPF vs. <5/50 HPF)</td><td>5</td><td>.003</td><td>6</td><td>.351-4.284</td></tr><tr><td>Risk grade (high risk vs. non-high risk)</td><td>26.129</td><td><0.001</td><td>11.794</td><td>4.579-30.379</td></tr></table>
43b89362bb43a1212c966fb255d8031ebe52ba5096ff6e5e18110555db468bd7.png
complex
<table><tr><td rowspan="2">Assessment</td><td rowspan="2">Group</td><td colspan="2">Mean value (95% confidence interval)</td><td>Paired t test</td><td>1-way ANCOVA</td></tr><tr><td>PRE</td><td>POST</td><td>P (Cohen&#8217;s d)</td><td>P (Partial &#951;2)</td></tr><tr><td rowspan="2">FMA<sub>full score</sub></td><td>Clinic</td><td>13.75 (8.09&#8211;19.41)</td><td>30.31 (23.88&#8211;36.75)</td><td>0.000 ( &#8722; 1.45)***</td><td rowspan="2">0.550 (0.012)</td></tr><tr><td>Lab</td><td>17.50 (9.95&#8211;25.05)</td><td>30.88 (23.92&#8211;37.83)</td><td>0.000 ( &#8722; 1.46)***</td></tr><tr><td rowspan="2">FMA<sub>shoulder/elbow</sub></td><td>Clinic</td><td>10.31 (6.28&#8211;14.34)</td><td>20.31 (16.18&#8211;24.44)</td><td>0.000 ( &#8722; 1.35)***</td><td rowspan="2">0.782 (0.003)</td></tr><tr><td>Lab</td><td>12.44 (7.25&#8211;17.63)</td><td>21.06 (16.16&#8211;25.97)</td><td>0.000 ( &#8722; 1.18)***</td></tr><tr><td rowspan="2">FMA<sub>wrist/hand</sub></td><td>Clinic</td><td>3.44 (1.37&#8211;5.51)</td><td>10.00 (7.52&#8211;12.48)</td><td>0.000 ( &#8722; 1.36)***</td><td rowspan="2">0.333 (0.032)</td></tr><tr><td>Lab</td><td>5.06 (2.34&#8211;7.78)</td><td>9.81 (6.75&#8211;12.87)</td><td>0.000 ( &#8722; 1.35)***</td></tr><tr><td rowspan="2">ARAT</td><td>Clinic</td><td>3.81 (&#8722; 0.30 to 7.92)</td><td>14.50 (9.56&#8211;19.44)</td><td>0.000 ( &#8722; 1.22)***</td><td rowspan="2">0.175 (0.063)</td></tr><tr><td>Lab</td><td>11.69 (5.66&#8211;17.72)</td><td>18.06 (11.43&#8211;24.69)</td><td>0.000 ( &#8722; 1.44)***</td></tr><tr><td rowspan="2">FIM</td><td>Clinic</td><td>56.63 (52.05&#8211;61.20)</td><td>62.13 (59.41&#8211;64.84)</td><td>0.004 ( &#8722; 0.86)**</td><td rowspan="2">Nil</td></tr><tr><td>Lab</td><td>58.50 (51.53&#8211;65.47)</td><td>60.00 (53.39&#8211;66.61)</td><td>0.161 ( &#8722; 0.37)</td></tr><tr><td rowspan="2">MAS<sub>Finger</sub></td><td>Clinic</td><td>1.70 (1.32&#8211;2.08)</td><td>0.95 (0.68&#8211;1.22)</td><td>0.000 (1.12)***</td><td rowspan="2">0.622 (0.009)</td></tr><tr><td>Lab</td><td>1.34 (0.81&#8211;1.87)</td><td>0.91 (0.52&#8211;1.31)</td><td>0.085 (0.46)</td></tr><tr><td rowspan="2">MAS<sub>Wrist</sub></td><td>Clinic</td><td>1.65 (1.18&#8211;2.12)</td><td>0.91 (0.56&#8211;1.26)</td><td>0.001 (0.97)***</td><td rowspan="2">0.443 (0.020)</td></tr><tr><td>Lab</td><td>1.10 (0.77&#8211;1.43)</td><td>0.80 (0.45&#8211;1.15)</td><td>0.075 (0.48)</td></tr><tr><td rowspan="2">MAS<sub>Elbow</sub></td><td>Clinic</td><td>1.91 (1.54&#8211;2.28)</td><td>1.18 (0.82&#8211;1.53)</td><td>0.001 (1.08)***</td><td rowspan="2">0.892 (0.001)</td></tr><tr><td>Lab</td><td>1.21 (0.77&#8211;1.66)</td><td>0.76 (0.40&#8211;1.12)</td><td>0.013 (0.71)*</td></tr></table>
<table><tr><td rowspan="2">Assessment</td><td rowspan="2">Group</td><td colspan="2">Mean value (95% confidence interval)</td><td>Paired t test</td><td>1-way ANCOVA</td></tr><tr><td>PRE</td><td>POST</td><td>P (Cohen’s d)</td><td>P (Partial η2)</td></tr><tr><td rowspan="2">FMAfull score</td><td>Clinic</td><td>13.75 (8.09–19.41)</td><td>30.31 (23.88–36.75)</td><td>0.000 ( − 1.45)***</td><td rowspan="2">0.550 (0.012)</td></tr><tr><td>Lab</td><td>17.50 (9.95–25.05)</td><td>30.88 (23.92–37.83)</td><td>0.000 ( − 1.46)***</td></tr><tr><td rowspan="2">FMAshoulder/elbow</td><td>Clinic</td><td>10.31 (6.28–14.34)</td><td>20.31 (16.18–24.44)</td><td>0.000 ( − 1.35)***</td><td rowspan="2">0.782 (0.003)</td></tr><tr><td>Lab</td><td>12.44 (7.25–17.63)</td><td>21.06 (16.16–25.97)</td><td>0.000 ( − 1.18)***</td></tr><tr><td rowspan="2">FMAwrist/hand</td><td>Clinic</td><td>3.44 (1.37–5.51)</td><td>10.00 (7.52–12.48)</td><td>0.000 ( − 1.36)***</td><td rowspan="2">0.333 (0.032)</td></tr><tr><td>Lab</td><td>5.06 (2.34–7.78)</td><td>9.81 (6.75–12.87)</td><td>0.000 ( − 1.35)***</td></tr><tr><td rowspan="2">ARAT</td><td>Clinic</td><td>3.81 (− 0.30 to 7.92)</td><td>14.50 (9.56–19.44)</td><td>0.000 ( − 1.22)***</td><td rowspan="2">0.175 (0.063)</td></tr><tr><td>Lab</td><td>11.69 (5.66–17.72)</td><td>18.06 (11.43–24.69)</td><td>0.000 ( − 1.44)***</td></tr><tr><td rowspan="2">FIM</td><td>Clinic</td><td>56.63 (52.05–61.20)</td><td>62.13 (59.41–64.84)</td><td>0.004 ( − 0.86)**</td><td rowspan="2">Nil</td></tr><tr><td>Lab</td><td>58.50 (51.53–65.47)</td><td>60.00 (53.39–66.61)</td><td>0.161 ( − 0.37)</td></tr><tr><td rowspan="2">MASFinger</td><td>Clinic</td><td>1.70 (1.32–2.08)</td><td>0.95 (0.68–1.22)</td><td>0.000 (1.12)***</td><td rowspan="2">0.622 (0.009)</td></tr><tr><td>Lab</td><td>1.34 (0.81–1.87)</td><td>0.91 (0.52–1.31)</td><td>0.085 (0.46)</td></tr><tr><td rowspan="2">MASWrist</td><td>Clinic</td><td>1.65 (1.18–2.12)</td><td>0.91 (0.56–1.26)</td><td>0.001 (0.97)***</td><td rowspan="2">0.443 (0.020)</td></tr><tr><td>Lab</td><td>1.10 (0.77–1.43)</td><td>0.80 (0.45–1.15)</td><td>0.075 (0.48)</td></tr></table>
<table><tr><td rowspan="2">MASElbow</td><td>Clinic</td><td>1.91 (1.54–2.28)</td><td>1.18 (0.82–1.53)</td><td>0.001 (1.08)***</td><td rowspan="2">0.892 (0.001)</td></tr><tr><td>Lab</td><td>1.21 (0.77–1.66)</td><td>0.76 (0.40–1.12)</td><td>0.013 (0.71)*</td></tr></table>
02a0d2e18f63a62a68e36747766f8a3a3a588b23e55a3df37170224a176f3cf7.png
complex
<table><tr><td> </td><td colspan="2">Validation against our test</td><td colspan="2">Validation against the test in literature</td></tr><tr><td> </td><td>The current experiment (n = 8)</td><td>Predicted value</td><td>Hashemi et al.&#8217;s experiment (n &gt; 4)</td><td>Predicted value</td></tr><tr><td>High density</td><td>2015 &#177; 95.7 N</td><td>2028.8 N</td><td>2132.5 &#177; 119.3 N</td><td>2028.8 N</td></tr><tr><td>Low density</td><td>657 &#177; 69.4 N</td><td>607 N</td><td>688.2 &#177; 91.4 N</td><td>607 N</td></tr></table>
<table><tr><td></td><td colspan="2">Validation against our test</td><td>Validation against the test in literature</td></tr><tr><td></td><td>The current experiment (n = 8)</td><td>Predicted value</td><td>Hashemi et al.’s experiment (n > 4)</td></tr><tr><td>High density</td><td>2015 ± 95.7 N</td><td>2028.8 N</td><td>2132.5 ± 119.3 N</td></tr><tr><td>Low density</td><td>657 ± 69.4 N</td><td>607 N</td><td>688.2 ± 91.4 N</td></tr></table>
<table><tr><td>Validation against the test in literature</td></tr><tr><td>Predicted value</td></tr><tr><td>2028.8 N</td></tr><tr><td>607 N</td></tr></table>
82e0a1442e400a6f6a93cb3aea64a984eb88dbe1e6ee51d0201c8383317325bf.png
simple
<table><tr><td></td><td>n</td><td>%</td></tr><tr><td><i>Gender</i></td><td></td><td></td></tr><tr><td> Male</td><td>432</td><td>49.3</td></tr><tr><td> Female</td><td>444</td><td>50.7</td></tr><tr><td><i>Ethnicity</i></td><td></td><td></td></tr><tr><td> White</td><td>536</td><td>61.2</td></tr><tr><td> Non-white</td><td>340</td><td>38.8</td></tr><tr><td><i>Education</i></td><td></td><td></td></tr><tr><td> Less than college</td><td>421</td><td>48.1</td></tr><tr><td> Some college or higher</td><td>455</td><td>51.9</td></tr><tr><td><i>Household income</i></td><td></td><td></td></tr><tr><td> Less than $20,000</td><td>506</td><td>57.8</td></tr><tr><td> $20,000 or more</td><td>370</td><td>42.2</td></tr><tr><td><i>Marital status</i></td><td></td><td></td></tr><tr><td> Single</td><td>665</td><td>75.9</td></tr><tr><td> Married/living with partner</td><td>211</td><td>24.1</td></tr><tr><td><i>Insurance</i></td><td></td><td></td></tr><tr><td> Managed care (HMO, PPO)</td><td>241</td><td>27.5</td></tr><tr><td> Medicare</td><td>364</td><td>41.6</td></tr><tr><td> Veterans Affairs Medical Center</td><td>41</td><td>4.7</td></tr><tr><td> State Medicaid (MediCal for CA residents)</td><td>350</td><td>40.0</td></tr><tr><td> No health insurance</td><td>61</td><td>7.0</td></tr><tr><td> Don't know</td><td>16</td><td>1.8</td></tr><tr><td><i>Employment</i></td><td></td><td></td></tr><tr><td> Employed full time</td><td>129</td><td>14.7</td></tr><tr><td> Employed part time</td><td>163</td><td>18.6</td></tr><tr><td> Student</td><td>29</td><td>3.3</td></tr><tr><td> Retired</td><td>70</td><td>8.0</td></tr><tr><td> Not employed</td><td>484</td><td>55.3</td></tr><tr><td><i>Atypical Medication</i></td><td></td><td></td></tr><tr><td> On a atypical medication</td><td>628</td><td>71.7</td></tr><tr><td></td><td>Mean</td><td>SD</td></tr><tr><td>Age</td><td>43.03</td><td>11.80</td></tr><tr><td>Number of comorbidities</td><td>1.27</td><td>1.30</td></tr></table>
<table><tr><td></td><td>n</td><td>%</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Male</td><td>432</td><td>49.3</td></tr><tr><td>Female</td><td>444</td><td>50.7</td></tr><tr><td>Ethnicity</td><td></td><td></td></tr><tr><td>White</td><td>536</td><td>61.2</td></tr><tr><td>Non-white</td><td>340</td><td>38.8</td></tr><tr><td>Education</td><td></td><td></td></tr><tr><td>Less than college</td><td>421</td><td>48.1</td></tr><tr><td>Some college or higher</td><td>455</td><td>51.9</td></tr><tr><td>Household income</td><td></td><td></td></tr><tr><td>Less than $20,000</td><td>506</td><td>57.8</td></tr><tr><td>$20,000 or more</td><td>370</td><td>42.2</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>Single</td><td>665</td><td>75.9</td></tr><tr><td>Married/living with partner</td><td>211</td><td>24.1</td></tr><tr><td>Insurance</td><td></td><td></td></tr><tr><td>Managed care (HMO, PPO)</td><td>241</td><td>27.5</td></tr><tr><td>Medicare</td><td>364</td><td>41.6</td></tr><tr><td>Veterans Affairs Medical Center</td><td>41</td><td>4.7</td></tr><tr><td>State Medicaid (MediCal for CA residents)</td><td>350</td><td>40.0</td></tr><tr><td>No health insurance</td><td>61</td><td>7.0</td></tr><tr><td>Don't know</td><td>16</td><td>1.8</td></tr><tr><td>Employment</td><td></td><td></td></tr><tr><td>Employed full time</td><td>129</td><td>14.7</td></tr><tr><td>Employed part time</td><td>163</td><td>18.6</td></tr><tr><td>Student</td><td>29</td><td>3.3</td></tr><tr><td>Retired</td><td>70</td><td>8.0</td></tr><tr><td>Not employed</td><td>484</td><td>55.3</td></tr></table>
<table><tr><td>Atypical Medication</td><td></td><td></td></tr><tr><td>On a atypical medication</td><td>628</td><td>71.7</td></tr><tr><td></td><td>Mean</td><td>SD</td></tr><tr><td>Age</td><td>43.03</td><td>11.80</td></tr><tr><td>Number of comorbidities</td><td>1.27</td><td>1.30</td></tr></table>
03305186bf6e520f92ba4af80eef1384d53b5a71565844067af6a2b2426fb2b1.png
simple
<table><tr><td>Variable</td><td>ROSC</td><td>No ROSC</td><td>P value</td></tr><tr><td>Paramedics with prior OHCA case volume &#8805; 15 (%)</td><td>24.5</td><td>22.7</td><td>&lt;0.01</td></tr><tr><td>Male gender (%)</td><td>60.1</td><td>63.2</td><td>0.01</td></tr><tr><td>Non-Caucasian (%)</td><td>31.7</td><td>29.8</td><td>0.09</td></tr><tr><td>Age in years (mean, &#177; SD)</td><td>65.7</td><td>67.4</td><td>&lt;0.01</td></tr><tr><td>Shockable rhythm (%)</td><td>38.9</td><td>21.2</td><td>&lt;0.01</td></tr><tr><td>Layperson/first responder CPR (%)</td><td>51.8</td><td>36.3</td><td>&lt;0.01</td></tr><tr><td>EMS response time in minutes (mean, &#177; SD)</td><td>7.7</td><td>8.9</td><td>&lt;0.01</td></tr></table>
<table><tr><td>Variable</td></tr><tr><td>Paramedics with prior OHCA case volume ≥ 15 (%)</td></tr><tr><td>Male gender (%)</td></tr><tr><td>Non-Caucasian (%)</td></tr><tr><td>Age in years (mean, ± SD)</td></tr><tr><td>Shockable rhythm (%)</td></tr><tr><td>Layperson/first responder CPR (%)</td></tr><tr><td>EMS response time in minutes (mean, ± SD)</td></tr></table>
<table><tr><td>ROSC</td><td>No ROSC</td><td>P value</td></tr><tr><td>24.5</td><td>22.7</td><td><0.01</td></tr><tr><td>60.1</td><td>63.2</td><td>0.01</td></tr><tr><td>31.7</td><td>29.8</td><td>0.09</td></tr><tr><td>65.7</td><td>67.4</td><td><0.01</td></tr><tr><td>38.9</td><td>21.2</td><td><0.01</td></tr><tr><td>51.8</td><td>36.3</td><td><0.01</td></tr><tr><td>7.7</td><td>8.9</td><td><0.01</td></tr></table>
f3d6dc897b4090bacc78575c48fa0296ea4edf84de7e36e54a454d0d77ae4642.png
simple
<table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td>Physical Activity</td><td></td><td></td></tr><tr><td></td><td>0</td><td>No exercise</td></tr><tr><td></td><td>1</td><td>1&#8211;149 min of moderate exercise or 1&#8211;74 min of vigorous exercise/week</td></tr><tr><td></td><td>2</td><td>150+ minutes of moderate exercise or 75+ minutes of vigorous exercise/week</td></tr><tr><td>Diet<sup>a</sup></td><td></td><td></td></tr><tr><td></td><td>0</td><td>0&#8211;1 components of healthy diet</td></tr><tr><td></td><td>1</td><td>2&#8211;3 components of healthy diet</td></tr><tr><td></td><td>2</td><td>4&#8211;5 components of healthy diet</td></tr><tr><td>Glucose</td><td></td><td></td></tr><tr><td></td><td>0</td><td>&#8805;126 mg/dL fasting</td></tr><tr><td></td><td>1</td><td>100&#8211;125 mg/dL fasting or treated to &lt;100 mg/dL</td></tr><tr><td></td><td>2</td><td>&lt;100 mg/dL fasting, unmedicated</td></tr><tr><td>Blood Pressure</td><td></td><td></td></tr><tr><td></td><td>0</td><td>Systolic blood pressure &#8805;140 mmHg or diastolic blood pressure &#8805;90 mmHg</td></tr><tr><td></td><td>1</td><td>Systolic blood pressure 120&#8211;139 mmHg or diastolic blood pressure 80&#8211;89 mmHg or treated to &lt;120/80 mmHg</td></tr><tr><td></td><td>2</td><td>&lt;120/80 mmHg, unmedicated</td></tr><tr><td>BMI</td><td></td><td></td></tr><tr><td></td><td>0</td><td>&#8805;30 kg/m<sup>2</sup></td></tr><tr><td></td><td>1</td><td>25.0&#8211;29.99 kg/m<sup>2</sup></td></tr><tr><td></td><td>2</td><td>&lt;25.0 kg/m<sup>2</sup></td></tr><tr><td>Cholesterol</td><td></td><td></td></tr><tr><td></td><td>0</td><td>&#8805;240 mg/dL</td></tr><tr><td></td><td>1</td><td>200&#8211;239 mg/dL or treated to &lt;200 mg/dL</td></tr><tr><td></td><td>2</td><td>&lt;200 mg/dL, unmedicated</td></tr><tr><td>Smoking</td><td></td><td></td></tr><tr><td></td><td>0</td><td>Current smoker</td></tr><tr><td></td><td>1</td><td>Former smoker, quit &#8804;12 months ago</td></tr><tr><td></td><td>2</td><td>Never smoker or quit &gt;12 months ago</td></tr></table>
<table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td>Physical Activity</td><td></td><td></td></tr><tr><td></td><td>0</td><td>No exercise</td></tr><tr><td></td><td>1</td><td>1–149 min of moderate exercise or 1–74 min of vigorous exercise/week</td></tr><tr><td></td><td>2</td><td>150+ minutes of moderate exercise or 75+ minutes of vigorous exercise/week</td></tr><tr><td>Dieta</td><td></td><td></td></tr><tr><td></td><td>0</td><td>0–1 components of healthy diet</td></tr><tr><td></td><td>1</td><td>2–3 components of healthy diet</td></tr><tr><td></td><td>2</td><td>4–5 components of healthy diet</td></tr><tr><td>Glucose</td><td></td><td></td></tr><tr><td></td><td>0</td><td>≥126 mg/dL fasting</td></tr><tr><td></td><td>1</td><td>100–125 mg/dL fasting or treated to <100 mg/dL</td></tr><tr><td></td><td>2</td><td><100 mg/dL fasting, unmedicated</td></tr><tr><td>Blood Pressure</td><td></td><td></td></tr><tr><td></td><td>0</td><td>Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg</td></tr><tr><td></td><td>1</td><td>Systolic blood pressure 120–139 mmHg or diastolic blood pressure 80–89 mmHg or treated to <120/80 mmHg</td></tr><tr><td></td><td>2</td><td><120/80 mmHg, unmedicated</td></tr><tr><td>BMI</td><td></td><td></td></tr></table>
<table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td></td><td>0</td><td>≥30 kg/m2</td></tr><tr><td></td><td>1</td><td>25.0–29.99 kg/m2</td></tr><tr><td></td><td>2</td><td><25.0 kg/m2</td></tr><tr><td>Cholesterol</td><td></td><td></td></tr><tr><td></td><td>0</td><td>≥240 mg/dL</td></tr><tr><td></td><td>1</td><td>200–239 mg/dL or treated to <200 mg/dL</td></tr><tr><td></td><td>2</td><td><200 mg/dL, unmedicated</td></tr><tr><td>Smoking</td><td></td><td></td></tr><tr><td></td><td>0</td><td>Current smoker</td></tr><tr><td></td><td>1</td><td>Former smoker, quit ≤12 months ago</td></tr><tr><td></td><td>2</td><td>Never smoker or quit >12 months ago</td></tr></table>
1d4b19eebc8b6a5e56722c8fff8ac365c32c9b934524ea0fb40dbd26ad53378d.png
simple
<table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Breast</td><td>Fernandez et al. (19), Gazit et al. (20)</td></tr><tr><td>Prostate</td><td>Daneshmand et al. (23), Fu et al. (24)</td></tr><tr><td>Gastric</td><td>Song et al. (26)</td></tr><tr><td>Ovarian</td><td>Huang, LW et al. (25)</td></tr><tr><td>Endometrial</td><td>Bifulco et al. (31), Cali&#769; et al. (32)</td></tr><tr><td>Hepatocellular</td><td>Su et al. (27); Shuda (28)</td></tr><tr><td>Esophageal</td><td>Langer et al. (29)</td></tr><tr><td>Fibrosarcoma</td><td>Jamora et al. (35)</td></tr><tr><td>Glioma</td><td>Pyrko et al. (34)</td></tr><tr><td>Melanoma</td><td>Zhuang et al. (33)</td></tr><tr><td>Lung</td><td>Lin et al. (21), Koomagi et al. (22)</td></tr><tr><td>Renal</td><td>Fu et al. (30)</td></tr></table>
<table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Breast</td><td>Fernandez et al. (19), Gazit et al. (20)</td></tr><tr><td>Prostate</td><td>Daneshmand et al. (23), Fu et al. (24)</td></tr><tr><td>Gastric</td><td>Song et al. (26)</td></tr><tr><td>Ovarian</td><td>Huang, LW et al. (25)</td></tr><tr><td>Endometrial</td><td>Bifulco et al. (31), Calí et al. (32)</td></tr><tr><td>Hepatocellular</td><td>Su et al. (27); Shuda (28)</td></tr><tr><td>Esophageal</td><td>Langer et al. (29)</td></tr></table>
<table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Fibrosarcoma</td><td>Jamora et al. (35)</td></tr><tr><td>Glioma</td><td>Pyrko et al. (34)</td></tr><tr><td>Melanoma</td><td>Zhuang et al. (33)</td></tr><tr><td>Lung</td><td>Lin et al. (21), Koomagi et al. (22)</td></tr><tr><td>Renal</td><td>Fu et al. (30)</td></tr></table>
1cc55ecb5c31afc3cf1faddd8d26d60293fa8f811141b488f1bfa172b4fe1c0f.png
complex
<table><tr><td>LN</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan="2">CD63</td><td> </td></tr><tr><td> </td><td> </td><td>Number of patients, <i>n </i>(%)</td><td>Positive, <i>n</i></td><td>Negative, <i>n</i></td><td>P-value</td></tr><tr><td>MDR1</td><td>Positive</td><td>11 (22.9)</td><td>11</td><td>0</td><td> </td></tr><tr><td> </td><td>Negative</td><td>37 (77.1)</td><td>16</td><td>21</td><td>P &lt; 0.05</td></tr></table>
<table><tr><td>LN</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">CD63</td><td></td></tr><tr><td></td><td></td><td>Number of patients, n (%)</td><td>Positive, n</td><td>Negative, n</td><td>P-value</td></tr></table>
<table><tr><td>MDR1</td><td>Positive</td><td>11 (22.9)</td><td>11</td><td>0</td><td></td></tr><tr><td></td><td>Negative</td><td>37 (77.1)</td><td>16</td><td>21</td><td>P < 0.05</td></tr></table>
4a51aa875303d7dd772fae2f8c792a01127204a2d1efa0fcb9880015b1b0ef70.png
complex
<table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) &#177; SD<sup>(a)</sup></td><td><i>F </i> value<sup>(b)</sup></td><td><i>t </i> value<sup>(b)</sup></td><td>Recovery (%) &#177; SD<sup>(a)</sup></td><td><i>F </i> value<sup>(b)</sup></td><td><i>t </i> value<sup>(b)</sup></td></tr><tr><td>Prozac </td><td>99.9 &#177; 1.4</td><td>1.68</td><td>1.17</td><td>99.7 &#177; 1.6</td><td>2.38</td><td>3.00</td></tr><tr><td>Pluzac </td><td>100.1 &#177; 1.3</td><td>2.62</td><td>1.27</td><td>99.2 &#177; 1.5</td><td>1.58</td><td>2.91</td></tr><tr><td>Salipax </td><td>99.8 &#177; 1.3</td><td>1.00</td><td>1.10</td><td>100.8 &#177; 1.8</td><td>1.60</td><td>2.18</td></tr><tr><td>Flutin </td><td>100.1 &#177; 1.6</td><td>1.64</td><td>1.27</td><td>100.1 &#177; 1.3</td><td>0.19</td><td>1.12</td></tr><tr><td>Octozac </td><td>99.8 &#177; 1.2</td><td>2.35</td><td>2.13</td><td>99.4 &#177; 1.5</td><td>1.49</td><td>2.47</td></tr></table>
<table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td></tr><tr><td>Prozac</td><td>99.9 ± 1.4</td><td>1.68</td><td>1.17</td><td>99.7 ± 1.6</td><td>2.38</td><td>3.00</td></tr><tr><td>Pluzac</td><td>100.1 ± 1.3</td><td>2.62</td><td>1.27</td><td>99.2 ± 1.5</td><td>1.58</td><td>2.91</td></tr><tr><td>Sa</td><td>99.8 ± 1</td><td>1</td><td></td><td>100.8</td><td></td><td>2.</td></tr></table>
<table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td></tr><tr><td>lipax</td><td>.3</td><td>.00</td><td>1.10</td><td> ± 1.8</td><td>1.60</td><td>18</td></tr><tr><td>Flutin</td><td>100.1 ± 1.6</td><td>1.64</td><td>1.27</td><td>100.1 ± 1.3</td><td>0.19</td><td>1.12</td></tr><tr><td>Octozac</td><td>99.8 ± 1.2</td><td>2.35</td><td>2.13</td><td>99.4 ± 1.5</td><td>1.49</td><td>2.47</td></tr></table>
f93f11c178fd2f256b7976590aa708fe0443803e1b48fb408f1851c4fc0c4681.png
simple
<table><tr><td></td><td>Age (Years)</td><td>Height (cm)</td><td>Weight (kg)</td></tr><tr><td>CFS</td><td>43 &#177; 4.6</td><td>164 &#177; 7.3</td><td>73 &#177; 21.2</td></tr><tr><td>Control</td><td>43 &#177; 6.5</td><td>167 &#177; 7.0</td><td>70 &#177; 16.7</td></tr></table>
<table><tr><td></td><td>Age (Years)</td><td>Height (cm)</td><td>Weight (kg)</td></tr></table>
<table><tr><td>CFS</td><td>43 ± 4.6</td><td>164 ± 7.3</td><td>73 ± 21.2</td></tr><tr><td>Control</td><td>43 ± 6.5</td><td>167 ± 7.0</td><td>70 ± 16.7</td></tr></table>
c196951cfb266d3655e64d237ae509e40f09f13b9d0c046379bc0e56be472526.png
complex
<table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td colspan="4">&#8216;Type 1&#8217;</td></tr><tr><td> 1a: Emerging female excess</td><td>General health &#8211; Past year General health &#8211; Past month</td><td>High temperature Rash</td><td>Eye infection Ear infection</td></tr><tr><td> 1b: Increasing female excess</td><td></td><td>Earache Stomach-ache Headache Lice/scabies</td><td>Cold sores Urinary infection</td></tr><tr><td> 1c: Disappearing male excess</td><td></td><td>Breathlessness</td><td></td></tr><tr><td colspan="4">&#8216;Type 2&#8217;</td></tr><tr><td> 2a: Consistent female excess</td><td>Health-related days off school</td><td>Constipation Eczema</td><td>Tonsillitis/laryngitis Cold Worm infections</td></tr><tr><td> 2b: Consistent no sex difference</td><td></td><td>Vomiting Cough Ear discharge Food/drink allergies Non-food/drink allergies</td><td>Chicken pox Influenza</td></tr><tr><td> 2c: Consistent male excess</td><td></td><td>Wheezing Asthma Hay fever</td><td>Chest infection</td></tr><tr><td colspan="4">&#8216;Type 3&#8217;</td></tr><tr><td> 3a: Emerging male excess</td><td></td><td>Pain in arms/legs</td><td></td></tr><tr><td> 3b: Increasing male excess</td><td></td><td>Diarrhoea</td><td></td></tr></table>
<table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td colspan="4">‘Type 1’</td></tr><tr><td>1a: Emerging female excess</td><td>General health – Past year General health – Past month</td><td>High temperature Rash</td><td>Eye infection Ear infection</td></tr><tr><td>1b: Increasing female excess</td><td></td><td>Earache Stomach-ache Headache Lice/scabies</td><td>Cold sores Urinary infection</td></tr><tr><td>1c: Disappearing male excess</td><td></td><td>Breathlessness</td><td></td></tr><tr><td colspan="4">‘Type 2’</td></tr><tr><td>2a: Consistent female excess</td><td>Health-related days off school</td><td>Constipation Eczema</td><td>Tonsillitis/laryngitis Cold Worm infections</td></tr><tr><td>2b: Consistent no sex difference</td><td></td><td>Vomiting Cough Ear discharge Food/drink allergies Non-food/drink allergies</td><td>Chicken pox Influenza</td></tr></table>
<table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td>2c: Consistent male excess</td><td></td><td>Wheezing Asthma Hay fever</td><td>Chest infection</td></tr><tr><td colspan="4">‘Type 3’</td></tr><tr><td>3a: Emerging male excess</td><td></td><td>Pain in arms/legs</td><td></td></tr><tr><td>3b: Increasing male excess</td><td></td><td>Diarrhoea</td><td></td></tr></table>
77d3c275275aaebf41c31adfe7c1328f167546d357ec89bf01a45ff6c833d196.png
simple
<table><tr><td>Sample</td><td>ZKR <sup>a</sup>_S1 <sup>b</sup></td><td>ZKR_S2 <sup>b</sup></td><td>ZKR_S3 <sup>b</sup></td><td>QXR <sup>c</sup>_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Raw reads</td><td>100,481,781</td><td>99,812,614</td><td>99,445,825</td><td>100,002,793</td><td>99,887,525</td><td>99,071,615</td></tr><tr><td>Clean reads</td><td>95,660,601</td><td>94,297,177</td><td>90,539,959</td><td>97,386,913</td><td>97,460,159</td><td>91,414,542</td></tr><tr><td>Filtering rate</td><td>93.26%</td><td>92.81%</td><td>90.31%</td><td>95.51%</td><td>95.85%</td><td>91.25%</td></tr><tr><td>Q30</td><td>92.25%</td><td>91.40%</td><td>95.96%</td><td>94.52%</td><td>95.74%</td><td>96.03%</td></tr><tr><td>Total mapped reads</td><td>87,463,758 (91.41%)</td><td>87,557,832(92.85%)</td><td>83,122,460(91.81%)</td><td>89,812,801(92.22%)</td><td>90,465,752(92.82%)</td><td>83,950,965(91.84%)</td></tr><tr><td>Multiple mapped</td><td>10,182,952(10.65%)</td><td>11,506,609(12.20%)</td><td>11,988,424(13.24%)</td><td>10,370,562(10.65%)</td><td>11,019,503(11.30%)</td><td>13,298,066(14.53%)</td></tr><tr><td>Uniquely mapped</td><td>77,280,806(80.77%)</td><td>76,051,223(80.65%)</td><td>71,134,037(78.56%)</td><td>79,442,240(81.58%)</td><td>79,446,249(81.52%)</td><td>70,652,899(77.31%)</td></tr><tr><td>Reads map to &#8216;+&#8217;</td><td>38,609,153(40.35%)</td><td>37,967,782(40.26%)</td><td>35,526,529(39.24%)</td><td>39,685,378(40.75%)</td><td>39,665,757(40.70%)</td><td>35,482,024(38.82%)</td></tr><tr><td>Reads map to &#8216;&#8722;&#8217;</td><td>38,671,654(40.42%)</td><td>38,083,441(40.39%)</td><td>35,607,508(39.33%)</td><td>39,756,861(40.83%)</td><td>39,780,492(40.82%)</td><td>35,170,875(38.49%)</td></tr></table>
<table><tr><td>Sample</td><td>ZKR a_S1 b</td><td>ZKR_S2 b</td><td>ZKR_S3 b</td><td>QXR c_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Raw reads</td><td>100,481,781</td><td>99,812,614</td><td>99,445,825</td><td>100,002,793</td><td>99,887,525</td><td>99,071,615</td></tr></table>
<table><tr><td>Sample</td><td>ZKR a_S1 b</td><td>ZKR_S2 b</td><td>ZKR_S3 b</td><td>QXR c_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Clean reads</td><td>95,660,601</td><td>94,297,177</td><td>90,539,959</td><td>97,386,913</td><td>97,460,159</td><td>91,414,542</td></tr><tr><td>Filtering rate</td><td>93.26%</td><td>92.81%</td><td>90.31%</td><td>95.51%</td><td>95.85%</td><td>91.25%</td></tr><tr><td>Q30</td><td>92.25%</td><td>91.40%</td><td>95.96%</td><td>94.52%</td><td>95.74%</td><td>96.03%</td></tr><tr><td>Total mapped reads</td><td>87,463,758 (91.41%)</td><td>87,557,832(92.85%)</td><td>83,122,460(91.81%)</td><td>89,812,801(92.22%)</td><td>90,465,752(92.82%)</td><td>83,950,965(91.84%)</td></tr><tr><td>Multiple mapped</td><td>10,182,952(10.65%)</td><td>11,506,609(12.20%)</td><td>11,988,424(13.24%)</td><td>10,370,562(10.65%)</td><td>11,019,503(11.30%)</td><td>13,298,066(14.53%)</td></tr><tr><td>Uniquely mapped</td><td>77,280,806(80.77%)</td><td>76,051,223(80.65%)</td><td>71,134,037(78.56%)</td><td>79,442,240(81.58%)</td><td>79,446,249(81.52%)</td><td>70,652,899(77.31%)</td></tr><tr><td>Reads map to ‘+’</td><td>38,609,153(40.35%)</td><td>37,967,782(40.26%)</td><td>35,526,529(39.24%)</td><td>39,685,378(40.75%)</td><td>39,665,757(40.70%)</td><td>35,482,024(38.82%)</td></tr><tr><td>Reads map to ‘−’</td><td>38,671,654(40.42%)</td><td>38,083,441(40.39%)</td><td>35,607,508(39.33%)</td><td>39,756,861(40.83%)</td><td>39,780,492(40.82%)</td><td>35,170,875(38.49%)</td></tr></table>
6665a0f982c5ff2c085761ab7d163538d7cbcf6905b116335f67b2fb06e2359c.png
simple
<table><tr><td>Cross-linked polyurethane</td><td>Macrodiols</td><td>Diisocyanate</td><td>Chain extender</td><td>State at room temperature</td><td>T<sub>g</sub> (&#176;C)</td><td><i>T</i><sub><i>m</i></sub> (&#176;C)</td></tr><tr><td>CPU 1</td><td>PCEG 1</td><td>HDI</td><td>TMP</td><td>Hard</td><td>&#8722;45</td><td>46</td></tr><tr><td>CPU 2</td><td>PCEG 2</td><td>HDI</td><td>TMP</td><td>Frangibility</td><td>&#8722;48</td><td>44</td></tr><tr><td>CPU 3</td><td>PCEG 3</td><td>HDI</td><td>TMP</td><td>Elasticity</td><td>&#8722;51</td><td>38</td></tr></table>
<table><tr><td>Cross-linked polyurethane</td><td>Macrodiols</td><td>Diisocyanate</td><td>Chain extender</td><td>State at room temperature</td></tr><tr><td>CPU 1</td><td>PCEG 1</td><td>HDI</td><td>TMP</td><td>Hard</td></tr><tr><td>CPU 2</td><td>PCEG 2</td><td>HDI</td><td>TMP</td><td>Frangibility</td></tr><tr><td>CPU 3</td><td>PCEG 3</td><td>HDI</td><td>TMP</td><td>Elasticity</td></tr></table>
<table><tr><td>Tg (°C)</td><td>Tm (°C)</td></tr><tr><td>−45</td><td>46</td></tr><tr><td>−48</td><td>44</td></tr><tr><td>−51</td><td>38</td></tr></table>
1e1bf45acf4127fec4c2715a7a3ab139b4533f2c18f001ba374498778fab92ed.png
simple
<table><tr><td>Striatal Region<sup>&#968;</sup></td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.416% (0.400 &#8211; 0.433)</td><td>0.468% (0.443 &#8211; 0.493)</td><td>11.38</td><td>0.001</td><td>&#8722;0.80</td></tr><tr><td>Normalized Putamen</td><td>0.422% (0.405 &#8211; 0.440)</td><td>0.459% (0.432 &#8211; 0.442)</td><td>5.22</td><td>0.03</td><td>&#8722;0.52</td></tr><tr><td>Gender effects<sup>&#968;</sup></td><td>Male (n = 67)</td><td>Female (n = 25)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.423% (0.407 &#8211; 0.439)</td><td>0.461% (0.435 &#8211; 0.487)</td><td>6.2</td><td>0.02</td><td>&#8722;0.59</td></tr><tr><td>Normalized Putamen</td><td>0.425% (0.408 &#8211; 0.442)</td><td>0.456% (0.429 &#8211; 0.483)</td><td>3.8</td><td>0.05</td><td>&#8722;0.47</td></tr><tr><td>Caudate sub-regions<sup>&#950;</sup></td><td>PD (n = 58)</td><td>Healthy Controls (n = 25)</td><td>F(1,82)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Head</td><td>0.351% (0.338 &#8211; 0.363)</td><td>0.381% (0.363 &#8211; 0.399)</td><td>7.4</td><td>0.008</td><td>&#8722;0.66</td></tr><tr><td>Normalized Body</td><td>0.071% (0.064 &#8211; 0.077)</td><td>0.078% (0.070 &#8211; 0.086)</td><td>2.0</td><td>0.16</td><td>&#8722;0.32</td></tr><tr><td>Cognitively normal comparison<sup>*</sup></td><td>PD normal cognition (n = 41)</td><td>Healthy Controls (n = 27)</td><td>F(1,67)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.424% (0.401 &#8211; 0.446)</td><td>0.470% (0.442 &#8211; 0.497)</td><td>6.0</td><td>0.02</td><td>&#8722;0.65</td></tr><tr><td>Normalized Putamen</td><td>0.429% (0.406 &#8211; 0.453)</td><td>0.465% (0.437 &#8211; 0.494)</td><td>3.9</td><td>0.05</td><td>&#8722;0.48</td></tr></table>
<table><tr><td>Striatal Regionψ</td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.416% (0.400 – 0.433)</td><td>0.468% (0.443 – 0.493)</td><td>11.38</td><td>0.001</td><td>−0.80</td></tr><tr><td>Normalized Putamen</td><td>0.422% (0.405 – 0.440)</td><td>0.459% (0.432 – 0.442)</td><td>5.22</td><td>0.03</td><td>−0.52</td></tr><tr><td>Gender effectsψ</td><td>Male (n = 67)</td><td>Female (n = 25)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.423% (0.407 – 0.439)</td><td>0.461% (0.435 – 0.487)</td><td>6.2</td><td>0.02</td><td>−0.59</td></tr><tr><td>Normalized Putamen</td><td>0.425% (0.408 – 0.442)</td><td>0.456% (0.429 – 0.483)</td><td>3.8</td><td>0.05</td><td>−0.47</td></tr><tr><td>Caudate sub-regionsζ</td><td>PD (n = 58)</td><td>Healthy Controls (n = 25)</td><td>F(1,82)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Head</td><td>0.351% (0.338 – 0.363)</td><td>0.381% (0.363 – 0.399)</td><td>7.4</td><td>0.008</td><td>−0.66</td></tr></table>
<table><tr><td>Striatal Regionψ</td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Body</td><td>0.071% (0.064 – 0.077)</td><td>0.078% (0.070 – 0.086)</td><td>2.0</td><td>0.16</td><td>−0.32</td></tr><tr><td>Cognitively normal comparison*</td><td>PD normal cognition (n = 41)</td><td>Healthy Controls (n = 27)</td><td>F(1,67)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.424% (0.401 – 0.446)</td><td>0.470% (0.442 – 0.497)</td><td>6.0</td><td>0.02</td><td>−0.65</td></tr><tr><td>Normalized Putamen</td><td>0.429% (0.406 – 0.453)</td><td>0.465% (0.437 – 0.494)</td><td>3.9</td><td>0.05</td><td>−0.48</td></tr></table>
6e035626f5a47ae6f104402e41d320be8429886195e981df220695af37107f1e.png
complex
<table><tr><td></td><td colspan="4">Aerobe genomes</td><td colspan="4">Anaerobe genomes</td><td colspan="4">Facultative genomes</td></tr><tr><td rowspan="3">Predictions</td><td>Aerobe</td><td>137</td><td>87</td><td>%</td><td>Aerobe</td><td>6</td><td>6</td><td>%</td><td>Aerobe</td><td>43</td><td>44</td><td>%</td></tr><tr><td>Anaerobe</td><td>3</td><td>2</td><td>%</td><td>Anaerobe</td><td>95</td><td>88</td><td>%</td><td>Anaerobe</td><td>21</td><td>21</td><td>%</td></tr><tr><td>Facultative</td><td>17</td><td>11</td><td>%</td><td>Facultative</td><td>7</td><td>6</td><td>%</td><td>Facultative</td><td>34</td><td>35</td><td>%</td></tr></table>
<table><tr><td></td></tr><tr><td rowspan="3">Predictions</td></tr><tr></tr><tr></tr></table>
<table><tr><td colspan="4">Aerobe genomes</td><td colspan="4">Anaerobe genomes</td><td colspan="4">Facultative genomes</td></tr><tr><td>Aerobe</td><td>137</td><td>87</td><td>%</td><td>Aerobe</td><td>6</td><td>6</td><td>%</td><td>Aerobe</td><td>43</td><td>44</td><td>%</td></tr><tr><td>Anaerobe</td><td>3</td><td>2</td><td>%</td><td>Anaerobe</td><td>95</td><td>88</td><td>%</td><td>Anaerobe</td><td>21</td><td>21</td><td>%</td></tr><tr><td>Facultative</td><td>17</td><td>11</td><td>%</td><td>Facultative</td><td>7</td><td>6</td><td>%</td><td>Facultative</td><td>34</td><td>35</td><td>%</td></tr></table>
cf56af6e2298c40519a3b8aad02e71641bb5cf99809cb5ccf344ae094f6c563e.png
complex
<table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td>Characteristics</td><td>Cases (n = 296)</td><td>Controls (n = 296)</td></tr><tr><td></td><td>n* (%)</td><td>n* (%)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>- Married</td><td>227 (76.69%)</td><td>251 (84.80%)</td></tr><tr><td>Family type</td><td></td><td></td></tr><tr><td>- Nuclear family</td><td>207 (70.61%)</td><td>175 (59.12%)</td></tr><tr><td>- Extended family</td><td>87 (29.39%)</td><td>121 (40.88%)</td></tr><tr><td>Socioeconomic status</td><td></td><td></td></tr><tr><td>- Lowest</td><td>91 (30.74%)</td><td>85 (28.72%)</td></tr><tr><td>- Middle</td><td>145 (48.99%)</td><td>165 (55.74%)</td></tr><tr><td>- Upper</td><td>60 (20.27%)</td><td>46 (15.54%)</td></tr><tr><td>Occupation</td><td></td><td></td></tr><tr><td>- Salaried workers</td><td>29 (9.8%)</td><td>23 (7.77%)</td></tr><tr><td>- Daily wages laborer</td><td>31 (10.47%)</td><td>36 (12.16%)</td></tr><tr><td>- Not working</td><td>236 (79.73%)</td><td>237(80.07%)</td></tr><tr><td>House ownership</td><td></td><td></td></tr><tr><td>- Shared accommodation</td><td>15 (5.07%)</td><td>11 (3.72%)</td></tr><tr><td>- On rent</td><td>122 (41.21%)</td><td>114 (38.51%)</td></tr><tr><td>- Own house</td><td>159 (53.72%)</td><td>171 (57.77%)</td></tr><tr><td>Illiterate</td><td>150 (50.68%)</td><td>160 (54.05%)</td></tr><tr><td>H/o smoking</td><td>21 (7.09%)</td><td>20 (6.76%)</td></tr><tr><td>H/o high cholesterol</td><td>16 (5.41%)</td><td>12 (4.05%)</td></tr><tr><td>H/o exercise</td><td>51 (17.23%)</td><td>35 (11.83%)</td></tr><tr><td>Past h/o depression</td><td>49 (16.55%)</td><td>41 (13.85%)</td></tr></table>
<table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td>Characteristics</td><td>Cases (n = 296)</td><td>Controls (n = 296)</td></tr></table>
<table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td></td><td>n* (%)</td><td>n* (%)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>- Married</td><td>227 (76.69%)</td><td>251 (84.80%)</td></tr><tr><td>Family type</td><td></td><td></td></tr><tr><td>- Nuclear family</td><td>207 (70.61%)</td><td>175 (59.12%)</td></tr><tr><td>- Extended family</td><td>87 (29.39%)</td><td>121 (40.88%)</td></tr><tr><td>Socioeconomic status</td><td></td><td></td></tr><tr><td>- Lowest</td><td>91 (30.74%)</td><td>85 (28.72%)</td></tr><tr><td>- Middle</td><td>145 (48.99%)</td><td>165 (55.74%)</td></tr><tr><td>- Upper</td><td>60 (20.27%)</td><td>46 (15.54%)</td></tr><tr><td>Occupation</td><td></td><td></td></tr><tr><td>- Salaried workers</td><td>29 (9.8%)</td><td>23 (7.77%)</td></tr><tr><td>- Daily wages laborer</td><td>31 (10.47%)</td><td>36 (12.16%)</td></tr><tr><td>- Not working</td><td>236 (79.73%)</td><td>237(80.07%)</td></tr><tr><td>House ownership</td><td></td><td></td></tr><tr><td>- Shared accommodation</td><td>15 (5.07%)</td><td>11 (3.72%)</td></tr><tr><td>- On rent</td><td>122 (41.21%)</td><td>114 (38.51%)</td></tr><tr><td>- Own house</td><td>159 (53.72%)</td><td>171 (57.77%)</td></tr><tr><td>Illiterate</td><td>150 (50.68%)</td><td>160 (54.05%)</td></tr><tr><td>H/o smoking</td><td>21 (7.09%)</td><td>20 (6.76%)</td></tr><tr><td>H/o high cholesterol</td><td>16 (5.41%)</td><td>12 (4.05%)</td></tr><tr><td>H/o exercise</td><td>51 (17.23%)</td><td>35 (11.83%)</td></tr><tr><td>Past h/o depression</td><td>49 (16.55%)</td><td>41 (13.85%)</td></tr></table>
f9b0ce1a3f23941778e9cc1a8bd85d0a0ffb7ec75c1ccd297044c0c4816d9515.png
simple
<table><tr><td>Annotation type</td><td>Content</td><td>Elements involved</td></tr><tr><td>Curatorial</td><td>Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed</td><td>All elements of the curated annotation</td></tr><tr><td>Batch</td><td>Meta annotation linking identical annotations referring to different annotated records</td><td>All elements of the linked annotation(s)</td></tr><tr><td>CuratorialBatch</td><td>Meta annotation referring to all curated annotations of a Batch and its annotation type. Each annotated value can be accepted, rejected or commented by the curator for all annotations linked by the referred Batch</td><td>All elements of the curated BatchAnnotations</td></tr></table>
<table><tr><td>Annotation type</td><td>Content</td><td>Elements involved</td></tr></table>
<table><tr><td>Curatorial</td><td>Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed</td><td>All elements of the curated annotation</td></tr><tr><td>Batch</td><td>Meta annotation linking identical annotations referring to different annotated records</td><td>All elements of the linked annotation(s)</td></tr><tr><td>CuratorialBatch</td><td>Meta annotation referring to all curated annotations of a Batch and its annotation type. Each annotated value can be accepted, rejected or commented by the curator for all annotations linked by the referred Batch</td><td>All elements of the curated BatchAnnotations</td></tr></table>
2b1a745200d190df21a1016c35a1d76eae98b44e46693ab4858b5681af51e1a6.png
simple
<table><tr><td>Outcome</td><td>Persons with symptomatic RHOA (<i>n</i> = 718), mean (s.d.)</td><td>Persons with EOA (<i>n</i> = 80), mean (s.d.)</td><td>Adjusted mean difference<sup>a</sup> (95% CI)</td></tr><tr><td>Female, <i>n</i> (%)</td><td>442 (62)</td><td>67 (84)</td><td>22.2 (13.4, 31.0)</td></tr><tr><td>Age, years</td><td>66.1 (8.1)</td><td>69.2 (7.8)</td><td>3.1 (1.3, 5.0)</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>29.3 (5.1)</td><td>28.7 (5.1)</td><td>&#8722;0.6 (&#8722;1.7, 0.6)</td></tr><tr><td>AUSCAN pain</td><td>6.6 (4.2)</td><td>8.0 (4.2)</td><td>1.3 (0.3, 2.3)</td></tr><tr><td>AUSCAN stiffness</td><td>1.1 (0.9)</td><td>1.5 (1.0)</td><td>0.3 (0.1, 0.6)</td></tr><tr><td>AUSCAN function</td><td>10.4 (8.1)</td><td>13.8 (8.0)</td><td>2.3 (0.4, 4.2)</td></tr><tr><td>AIMS-2 pain subscale</td><td>3.8 (2.3)</td><td>4.7 (2.6)</td><td>0.8 (0.3, 1.4)</td></tr><tr><td>AIMS-2 hand/finger function</td><td>2.2 (2.1)</td><td>3.1 (2.4)</td><td>0.8 (0.2, 1.3)</td></tr><tr><td>AIMS-2 impact subscale</td><td>2.2 (2.1)</td><td>2.6 (2.2)</td><td>0.5 (&#8722;0.05, 1.0)</td></tr><tr><td>Power grip, lbs</td><td>50.7 (25.6)</td><td>37.4 (18.9)</td><td>&#8722;3.0 (&#8722;7.1, 1.1)</td></tr><tr><td>Pulp pinch, lbs</td><td>10.3 (4.1)</td><td>8.4 (2.7)</td><td>&#8722;0.3 (&#8722;1.0, 0.4)</td></tr><tr><td>GAT</td><td>31.8 (12.9)</td><td>32.3 (9.8)</td><td>&#8722;0.7 (&#8722;4.7, 3.4)</td></tr><tr><td>SF-12 PCS</td><td>37.6 (11.8)</td><td>37.0 (11.3)</td><td>0.5 (&#8722;2.4, 3.4)</td></tr><tr><td>SF-12 MCS</td><td>50.4 (10.8)</td><td>53.0 (9.3)</td><td>2.9 (0.2, 5.5)</td></tr><tr><td>MHQ aesthetics subscale</td><td>72.2 (20.5)</td><td>52.2 (23.7)</td><td>&#8722;17.6 (&#8722;22.8, &#8722;12.5)</td></tr></table>
<table><tr><td>Outcome</td><td>Persons with symptomatic RHOA (n = 718), mean (s.d.)</td></tr><tr><td>Female, n (%)</td><td>442 (62)</td></tr><tr><td>Age, years</td><td>66.1 (8.1)</td></tr><tr><td>BMI, kg/m2</td><td>29.3 (5.1)</td></tr><tr><td>AUSCAN pain</td><td>6.6 (4.2)</td></tr><tr><td>AUSCAN stiffness</td><td>1.1 (0.9)</td></tr><tr><td>AUSCAN function</td><td>10.4 (8.1)</td></tr><tr><td>AIMS-2 pain subscale</td><td>3.8 (2.3)</td></tr><tr><td>AIMS-2 hand/finger function</td><td>2.2 (2.1)</td></tr><tr><td>AIMS-2 impact subscale</td><td>2.2 (2.1)</td></tr><tr><td>Power grip, lbs</td><td>50.7 (25.6)</td></tr><tr><td>Pulp pinch, lbs</td><td>10.3 (4.1)</td></tr><tr><td>GAT</td><td>31.8 (12.9)</td></tr><tr><td>SF-12 PCS</td><td>37.6 (11.8)</td></tr><tr><td>SF-12 MCS</td><td>50.4 (10.8)</td></tr><tr><td>MHQ aesthetics subscale</td><td>72.2 (20.5)</td></tr></table>
<table><tr><td>Persons with EOA (n = 80), mean (s.d.)</td><td>Adjusted mean differencea (95% CI)</td></tr><tr><td>67 (84)</td><td>22.2 (13.4, 31.0)</td></tr><tr><td>69.2 (7.8)</td><td>3.1 (1.3, 5.0)</td></tr><tr><td>28.7 (5.1)</td><td>−0.6 (−1.7, 0.6)</td></tr><tr><td>8.0 (4.2)</td><td>1.3 (0.3, 2.3)</td></tr><tr><td>1.5 (1.0)</td><td>0.3 (0.1, 0.6)</td></tr><tr><td>13.8 (8.0)</td><td>2.3 (0.4, 4.2)</td></tr><tr><td>4.7 (2.6)</td><td>0.8 (0.3, 1.4)</td></tr><tr><td>3.1 (2.4)</td><td>0.8 (0.2, 1.3)</td></tr><tr><td>2.6 (2.2)</td><td>0.5 (−0.05, 1.0)</td></tr><tr><td>37.4 (18.9)</td><td>−3.0 (−7.1, 1.1)</td></tr><tr><td>8.4 (2.7)</td><td>−0.3 (−1.0, 0.4)</td></tr><tr><td>32.3 (9.8)</td><td>−0.7 (−4.7, 3.4)</td></tr><tr><td>37.0 (11.3)</td><td>0.5 (−2.4, 3.4)</td></tr><tr><td>53.0 (9.3)</td><td>2.9 (0.2, 5.5)</td></tr><tr><td>52.2 (23.7)</td><td>−17.6 (−22.8, −12.5)</td></tr></table>
7850b0b1fa83529112d7eabd9cd86f04d1b95a3a2a285d6157eeda65b48973f1.png
complex
<table><tr><td rowspan="2">Eikelboom morphotype<sup>a</sup></td><td rowspan="2">Taxonomy</td><td colspan="5">Classification</td></tr><tr><td>Phylum</td><td>Class</td><td>Order</td><td>Family</td><td>Genus</td></tr><tr><td rowspan="4">0092 (30)</td><td>RDP<sup>b</sup></td><td><i>Chloroflexi</i></td><td><i>Anaerolineae</i></td><td><i>Anaerolineales</i></td><td><i>Anaerolineaceae</i></td><td></td></tr><tr><td>Greengenes<sup>c</sup></td><td><i>Chloroflexi</i></td><td><i>Anaerolineae</i></td><td>DRC31</td><td></td><td></td></tr><tr><td>SILVA<sup>d</sup></td><td><i>Chloroflexi</i></td><td><i>Ardenticatenia</i></td><td></td><td></td><td></td></tr><tr><td>MiDAS<sup>e</sup></td><td><i>Chloroflexi</i></td><td><i>Ardenticatenia</i></td><td>419</td><td>2-1</td><td>B45</td></tr><tr><td rowspan="4">0803 (27)</td><td>RDP</td><td><i>Chloroflexi</i></td><td><i>Caldilineae</i></td><td><i>Caldilineales</i></td><td><i>Caldilineaceae</i></td><td><i>Caldilinea</i></td></tr><tr><td>Greengenes</td><td><i>Chloroflexi</i></td><td><i>Anaerolineae</i></td><td><i>Caldilineales</i></td><td><i>Caldilineaceae</i></td><td><i>Caldilinea</i></td></tr><tr><td>SILVA</td><td><i>Chloroflexi</i></td><td><i>Caldilineae</i></td><td><i>Caldilineales</i></td><td><i>Caldilineaceae</i></td><td></td></tr><tr><td>MiDAS</td><td><i>Chloroflexi</i></td><td><i>Caldilineae</i></td><td><i>Caldilineales</i></td><td><i>Caldilineaceae</i></td><td>P2CN44</td></tr><tr><td rowspan="4">0914 (31)</td><td>RDP</td><td><i>Chloroflexi</i></td><td><i>Caldilineae</i></td><td><i>Caldilineales</i></td><td><i>Caldilineaceae</i></td><td></td></tr><tr><td>Greengenes</td><td><i>Chloroflexi</i></td><td><i>Anaerolinea</i></td><td>SHA-20</td><td></td><td></td></tr><tr><td>SILVA</td><td><i>Chloroflexi</i></td><td></td><td></td><td></td><td></td></tr><tr><td>MiDAS</td><td><i>Chloroflexi</i></td><td>SJA-15</td><td>1-20</td><td>1-20</td><td><i>Ca.</i> Sarcinathrix</td></tr><tr><td rowspan="4">1851 (28, 32)</td><td>RDP</td><td><i>Chloroflexi</i></td><td><i>Chloroflexia</i></td><td><i>Chloroflexales</i></td><td><i>Chloroflexineae</i></td><td><i>Roseiflexus</i></td></tr><tr><td>Greengenes</td><td><i>Chloroflexi</i></td><td><i>Chloroflexi</i></td><td><i>Roseiflexales</i></td><td><i>Kouleothrixaceae</i></td><td><i>Kouleothrix</i></td></tr><tr><td>SILVA</td><td><i>Chloroflexi</i></td><td><i>Chloroflexia</i></td><td><i>Chloroflexales</i></td><td><i>Roseiflexaceae</i></td><td><i>Roseiflexus</i></td></tr><tr><td>MiDAS</td><td><i>Chloroflexi</i></td><td><i>Chloroflexia</i></td><td><i>Chloroflexales</i></td><td><i>Roseiflexaceae</i></td><td><i>Kouleothrix</i></td></tr></table>
<table><tr><td rowspan="2">Eikelboom morphotypea</td><td rowspan="2">Taxonomy</td><td colspan="3">Classification</td></tr><tr><td>Phylum</td><td>Class</td><td>Order</td></tr><tr><td rowspan="4">0092 (30)</td><td>RDPb</td><td>Chloroflexi</td><td>Anaerolineae</td><td>Anaerolineales</td></tr><tr><td>Greengenesc</td><td>Chloroflexi</td><td>Anaerolineae</td><td>DRC31</td></tr><tr><td>SILVAd</td><td>Chloroflexi</td><td>Ardenticatenia</td><td></td></tr><tr><td>MiDASe</td><td>Chloroflexi</td><td>Ardenticatenia</td><td>419</td></tr><tr><td rowspan="4">0803 (27)</td><td>RDP</td><td>Chloroflexi</td><td>Caldilineae</td><td>Caldilineales</td></tr><tr><td>Greengenes</td><td>Chloroflexi</td><td>Anaerolineae</td><td>Caldilineales</td></tr><tr><td>SILVA</td><td>Chloroflexi</td><td>Caldilineae</td><td>Caldilineales</td></tr><tr><td>MiDAS</td><td>Chloroflexi</td><td>Caldilineae</td><td>Caldilineales</td></tr><tr><td rowspan="4">0914 (31)</td><td>RDP</td><td>Chloroflexi</td><td>Caldilineae</td><td>Caldilineales</td></tr><tr><td>Greengenes</td><td>Chloroflexi</td><td>Anaerolinea</td><td>SHA-20</td></tr><tr><td>SILVA</td><td>Chloroflexi</td><td></td><td></td></tr><tr><td>MiDAS</td><td>Chloroflexi</td><td>SJA-15</td><td>1-20</td></tr><tr><td rowspan="4">1851 (28, 32)</td><td>RDP</td><td>Chloroflexi</td><td>Chloroflexia</td><td>Chloroflexales</td></tr><tr><td>Greengenes</td><td>Chloroflexi</td><td>Chloroflexi</td><td>Roseiflexales</td></tr><tr><td>SILVA</td><td>Chloroflexi</td><td>Chloroflexia</td><td>Chloroflexales</td></tr><tr><td>MiDAS</td><td>Chloroflexi</td><td>Chloroflexia</td><td>Chloroflexales</td></tr></table>
<table><tr><td colspan="2">Classification</td></tr><tr><td>Family</td><td>Genus</td></tr><tr><td>Anaerolineaceae</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>2-1</td><td>B45</td></tr><tr><td>Caldilineaceae</td><td>Caldilinea</td></tr><tr><td>Caldilineaceae</td><td>Caldilinea</td></tr><tr><td>Caldilineaceae</td><td></td></tr><tr><td>Caldilineaceae</td><td>P2CN44</td></tr><tr><td>Caldilineaceae</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>1-20</td><td>Ca. Sarcinathrix</td></tr><tr><td>Chloroflexineae</td><td>Roseiflexus</td></tr><tr><td>Kouleothrixaceae</td><td>Kouleothrix</td></tr><tr><td>Roseiflexaceae</td><td>Roseiflexus</td></tr><tr><td>Roseiflexaceae</td><td>Kouleothrix</td></tr></table>
988f48ec6a8f2b5e942d940a233944d094ce872c4535b64cc80d855b20e8af21.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="3">Codes</td></tr><tr><td>&#8722;1</td><td>0</td><td>+1</td></tr><tr><td>Frying temperature (<sup>&#176;</sup>C)</td><td>140</td><td>150</td><td>160</td></tr><tr><td>Frying time (min)</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Level of BSCF (%)</td><td>20</td><td>30</td><td>40</td></tr><tr><td>Thickness (mm)</td><td>2</td><td>3</td><td>4</td></tr></table>
<table><tr><td rowspan="2">Variables</td><td>Codes</td></tr><tr><td>−1</td></tr><tr><td>Frying temperature (°C)</td><td>140</td></tr><tr><td>Frying time (min)</td><td>2</td></tr><tr><td>Level of BSCF (%)</td><td>20</td></tr><tr><td>Thickness (mm)</td><td>2</td></tr></table>
<table><tr><td colspan="2">Codes</td></tr><tr><td>0</td><td>+1</td></tr><tr><td>150</td><td>160</td></tr><tr><td>3</td><td>4</td></tr><tr><td>30</td><td>40</td></tr><tr><td>3</td><td>4</td></tr></table>
f2f56fe2f4e1d83525dd921516d6e4c78845b885f3b1065923b9c4522a97de87.png
simple
<table><tr><td>Material</td><td>Element type</td><td>Constitutive relation</td><td>Material properties</td></tr><tr><td>Bony structures</td><td></td><td></td><td></td></tr><tr><td>Vertebral cortical bone, endplates, and posterior cortical bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td><i>E</i> = 12,000 MPa &#957; = 0.3</td></tr><tr><td>Vertebral cancellous bone and posterior cancellous bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td><i>E</i> = 100 MPa &#957; = 0.2</td></tr><tr><td>Ligaments</td><td></td><td></td><td>Elastic modulus MPa (strain %)</td></tr><tr><td>Anterior longitudinal</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>7.8 (&lt;12%), 20.0 (&gt;12%) &#957; = 0.3</td></tr><tr><td>Posterior longitudinal</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (&lt;11%), 20.0 (&gt;11%) &#957; = 0.3</td></tr><tr><td>Ligamentum flavum</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>15.0 (&lt;6.2%), 19.5 (&gt;6.2%) &#957; = 0.3</td></tr><tr><td>Intertransverse</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (&lt;18%), 58.7 (&gt;18%) &#957; = 0.3</td></tr><tr><td>Interspinous</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (&lt;14%), 11.6 (&gt;14%) &#957; = 0.3</td></tr><tr><td>Supraspinous</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>8.0 (&lt;20%), 15.0 (&gt;20%) &#957; = 0.3</td></tr><tr><td>Capsular</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>7.5 (&lt;25%), 32.9 (&gt;25%) &#957; = 0.3</td></tr><tr><td>Intervertebral disk</td><td></td><td></td><td></td></tr><tr><td>Nucleus pulposus</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td><i>E</i> = 2 MPa &#957; = 0.499</td></tr><tr><td>Annulus fibrosus</td><td>8 Nodes brick element (C3D8)</td><td>Hyperelastic anisotropic (HGO)</td><td>Table 2</td></tr><tr><td>Apophyseal joints</td><td>GAPUNI elements</td><td>Non-linear soft contact</td><td>Pressure overclosure = 12,000 MPa</td></tr></table>
<table><tr><td>Material</td><td>Element type</td><td>Constitutive relation</td><td>Material properties</td></tr><tr><td>Bony structures</td><td></td><td></td><td></td></tr><tr><td>Vertebral cortical bone, endplates, and posterior cortical bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td>E = 12,000 MPa ν = 0.3</td></tr><tr><td>Vertebral cancellous bone and posterior cancellous bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td>E = 100 MPa ν = 0.2</td></tr><tr><td>Ligaments</td><td></td><td></td><td>Elastic modulus MPa (strain %)</td></tr><tr><td>Anterior longitudinal</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>7.8 (<12%), 20.0 (>12%) ν = 0.3</td></tr><tr><td>Posterior longitudinal</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (<11%), 20.0 (>11%) ν = 0.3</td></tr><tr><td>Ligamentum flavum</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>15.0 (<6.2%), 19.5 (>6.2%) ν = 0.3</td></tr><tr><td>Intertransverse</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (<18%), 58.7 (>18%) ν = 0.3</td></tr><tr><td>Interspinous</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>10.0 (<14%), 11.6 (>14%) ν = 0.3</td></tr><tr><td>Supraspinous</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>8.0 (<20%), 15.0 (>20%) ν = 0.3</td></tr><tr><td>Capsular</td><td>Tension-only, truss elements (T3D2)</td><td>Hypoelastic</td><td>7.5 (<25%), 32.9 (>25%) ν = 0.3</td></tr></table>
<table><tr><td>Intervertebral disk</td><td></td><td></td><td></td></tr><tr><td>Nucleus pulposus</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td>E = 2 MPa ν = 0.499</td></tr><tr><td>Annulus fibrosus</td><td>8 Nodes brick element (C3D8)</td><td>Hyperelastic anisotropic (HGO)</td><td>Table 2</td></tr><tr><td>Apophyseal joints</td><td>GAPUNI elements</td><td>Non-linear soft contact</td><td>Pressure overclosure = 12,000 MPa</td></tr></table>
e1c384ef4948a16d4e6c1305ffb1b27556cf160551dd5dc8c81bcdd02873d841.png
complex
<table><tr><td></td><td colspan="6">Men</td><td colspan="8">Women</td></tr><tr><td></td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3b</td></tr><tr><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td></tr><tr><td>Intercept</td><td>0.21</td><td>***</td><td>0.07</td><td>***</td><td>0.07</td><td>***</td><td>0.18</td><td>***</td><td>0.08</td><td>***</td><td>0.09</td><td>***</td><td>0.09</td><td>***</td></tr><tr><td> (1) Individual variables<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Education Level (ref. University Studies)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate, no diploma, or primary education</td><td></td><td></td><td>1.41</td><td>***</td><td>1.40</td><td>***</td><td></td><td></td><td>1.67</td><td>***</td><td>1.70</td><td>***</td><td>1.71</td><td>***</td></tr><tr><td>Lower Secondary</td><td></td><td></td><td>1.21</td><td>**</td><td>1.20</td><td>**</td><td></td><td></td><td>1.35</td><td>***</td><td>1.37</td><td>***</td><td>1.38</td><td>***</td></tr><tr><td>Upper Secondary</td><td></td><td></td><td>1.19</td><td>*</td><td>1.19</td><td>**</td><td></td><td></td><td>1.28</td><td>**</td><td>1.30</td><td>***</td><td>1.26</td><td>**</td></tr><tr><td>Higher technical education</td><td></td><td></td><td>1.04</td><td></td><td>1.04</td><td></td><td></td><td></td><td>1.26</td><td>*</td><td>1.26</td><td>*</td><td>1.25</td><td>*</td></tr><tr><td> (2) Period Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Period (ref. 2006)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2009</td><td></td><td></td><td>1.01</td><td></td><td>1.04</td><td></td><td></td><td></td><td>1.05</td><td></td><td>0.94</td><td></td><td>0.93</td><td></td></tr><tr><td>2011</td><td></td><td></td><td>1.13</td><td>*</td><td>0.96</td><td></td><td></td><td></td><td>1.14</td><td>**</td><td>0.99</td><td></td><td>1.00</td><td></td></tr><tr><td>Change in real GDP growth rate</td><td></td><td></td><td></td><td></td><td>1.01</td><td></td><td></td><td></td><td></td><td></td><td>0.95</td><td></td><td>0.94</td><td></td></tr><tr><td>Change in low work intensity indicator</td><td></td><td></td><td></td><td></td><td>1.04</td><td>**</td><td></td><td></td><td></td><td></td><td>0.99</td><td></td><td>0.97</td><td></td></tr><tr><td> (3) Context Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean real GDP growth rate</td><td></td><td></td><td></td><td></td><td>0.96</td><td></td><td></td><td></td><td></td><td></td><td>0.98</td><td></td><td>0.97</td><td></td></tr><tr><td>Mean low work intensity indicator</td><td></td><td></td><td></td><td></td><td>1.02</td><td>*</td><td></td><td></td><td></td><td></td><td>1.04</td><td>**</td><td>1.04</td><td>**</td></tr><tr><td> (1) Education level* (2) Period Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate, no diploma, or primary education* Change in Low work intensity indicator</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1.03</td><td>+</td></tr><tr><td>Variance</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Region</td><td>0.013</td><td>(0.013)</td><td>0.025</td><td>(0.023)</td><td>0.019</td><td>(0.019)</td><td>0.054</td><td>(0.030)</td><td>0.066</td><td>(0.048)</td><td>0.026</td><td>(0.028)</td><td>0.030</td><td>(0.028)</td></tr><tr><td> Period</td><td>0.034</td><td>(0.019)</td><td>0.016</td><td>(0.020)</td><td>0.010</td><td>(0.012)</td><td>0.007</td><td>(0.007)</td><td>0.005</td><td>(0.007)</td><td>0.006</td><td>(0.007)</td><td>0.005</td><td>(0.007)</td></tr><tr><td>VPC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Region<sup>b</sup></td><td colspan="2">0.4 %</td><td colspan="2">0.8 %</td><td colspan="2">0.6 %</td><td colspan="2">1.6 %</td><td colspan="2">2.0 %</td><td colspan="2">0.8 %</td><td colspan="2">0.9 %</td></tr><tr><td> Period<sup>c</sup></td><td colspan="2">1.0 %</td><td colspan="2">0.5 %</td><td colspan="2">0.3 %</td><td colspan="2">0.2 %</td><td colspan="2">0.1 %</td><td colspan="2">0.2 %</td><td colspan="2">0.2 %</td></tr><tr><td>VPC at higher levels (Region + Period)</td><td colspan="2">1.4 %</td><td colspan="2">1.2 %</td><td colspan="2">0.9 %</td><td colspan="2">1.8 %</td><td colspan="2">2.1 %</td><td colspan="2">1.0 %</td><td colspan="2">1.1 %</td></tr><tr><td>DIC:</td><td colspan="2">8762.19</td><td colspan="2">7419.424</td><td colspan="2">7412.147</td><td colspan="2">8950.835</td><td colspan="2">7963.463</td><td colspan="2">7964.03</td><td colspan="2">7960.65</td></tr><tr><td> Units: Region</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td></tr><tr><td> Units: Period</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td></tr><tr><td> Units: Individuals</td><td colspan="2">21,260</td><td colspan="2">21,052</td><td colspan="2">21,052</td><td colspan="2">26,182</td><td colspan="2">25,919</td><td colspan="2">25,919</td><td colspan="2">25,919</td></tr></table>
<table><tr><td></td><td colspan="6">Men</td><td colspan="8">Women</td></tr><tr><td></td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3b</td></tr><tr><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td><td>OR</td><td></td></tr><tr><td>Intercept</td><td>0.21</td><td>***</td><td>0.07</td><td>***</td><td>0.07</td><td>***</td><td>0.18</td><td>***</td><td>0.08</td><td>***</td><td>0.09</td><td>***</td><td>0.09</td><td>***</td></tr><tr><td>(1) Individual variablesa</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Education Level (ref. University Studies)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>Illiterate, no diploma, or primary education</td><td></td><td></td><td>1.41</td><td>***</td><td>1.40</td><td>***</td><td></td><td></td><td>1.67</td><td>***</td><td>1.70</td><td>***</td><td>1.71</td><td>***</td></tr><tr><td>Lower Secondary</td><td></td><td></td><td>1.21</td><td>**</td><td>1.20</td><td>**</td><td></td><td></td><td>1.35</td><td>***</td><td>1.37</td><td>***</td><td>1.38</td><td>***</td></tr><tr><td>Upper Secondary</td><td></td><td></td><td>1.19</td><td>*</td><td>1.19</td><td>**</td><td></td><td></td><td>1.28</td><td>**</td><td>1.30</td><td>***</td><td>1.26</td><td>**</td></tr><tr><td>Higher technical education</td><td></td><td></td><td>1.04</td><td></td><td>1.04</td><td></td><td></td><td></td><td>1.26</td><td>*</td><td>1.26</td><td>*</td><td>1.25</td><td>*</td></tr><tr><td>(2) Period Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Period (ref. 2006)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2009</td><td></td><td></td><td>1.01</td><td></td><td>1.04</td><td></td><td></td><td></td><td>1.05</td><td></td><td>0.94</td><td></td><td>0.93</td><td></td></tr><tr><td>2011</td><td></td><td></td><td>1.13</td><td>*</td><td>0.96</td><td></td><td></td><td></td><td>1.14</td><td>**</td><td>0.99</td><td></td><td>1.00</td><td></td></tr><tr><td>Change in real GDP growth rate</td><td></td><td></td><td></td><td></td><td>1.01</td><td></td><td></td><td></td><td></td><td></td><td>0.95</td><td></td><td>0.94</td><td></td></tr><tr><td>Change in low work intensity indicator</td><td></td><td></td><td></td><td></td><td>1.04</td><td>**</td><td></td><td></td><td></td><td></td><td>0.99</td><td></td><td>0.97</td><td></td></tr><tr><td>(3) Context Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean real GDP growth rate</td><td></td><td></td><td></td><td></td><td>0.96</td><td></td><td></td><td></td><td></td><td></td><td>0.98</td><td></td><td>0.97</td><td></td></tr><tr><td>Mean low work intensity indicator</td><td></td><td></td><td></td><td></td><td>1.02</td><td>*</td><td></td><td></td><td></td><td></td><td>1.04</td><td>**</td><td>1.04</td><td>**</td></tr><tr><td>(1) Education level* (2) Period Variables</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Illiterate, no diploma, or primary education* Change in Low work intensity indicator</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1.03</td><td>+</td></tr><tr><td>Variance</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Region</td><td>0.013</td><td>(0.013)</td><td>0.025</td><td>(0.023)</td><td>0.019</td><td>(0.019)</td><td>0.054</td><td>(0.030)</td><td>0.066</td><td>(0.048)</td><td>0.026</td><td>(0.028)</td><td>0.030</td><td>(0.028)</td></tr><tr><td>Period</td><td>0.034</td><td>(0.019)</td><td>0.016</td><td>(0.020)</td><td>0.010</td><td>(0.012)</td><td>0.007</td><td>(0.007)</td><td>0.005</td><td>(0.007)</td><td>0.006</td><td>(0.007)</td><td>0.005</td><td>(0.007)</td></tr><tr><td>VPC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Regionb</td><td colspan="2">0.4 %</td><td colspan="2">0.8 %</td><td colspan="2">0.6 %</td><td colspan="2">1.6 %</td><td colspan="2">2.0 %</td><td colspan="2">0.8 %</td><td colspan="2">0.9 %</td></tr><tr><td>Periodc</td><td colspan="2">1.0 %</td><td colspan="2">0.5 %</td><td colspan="2">0.3 %</td><td colspan="2">0.2 %</td><td colspan="2">0.1 %</td><td colspan="2">0.2 %</td><td colspan="2">0.2 %</td></tr><tr><td>VPC at higher levels (Region + Period)</td><td colspan="2">1.4 %</td><td colspan="2">1.2 %</td><td colspan="2">0.9 %</td><td colspan="2">1.8 %</td><td colspan="2">2.1 %</td><td colspan="2">1.0 %</td><td colspan="2">1.1 %</td></tr><tr><td>DIC:</td><td colspan="2">8762.19</td><td colspan="2">7419.424</td><td colspan="2">7412.147</td><td colspan="2">8950.835</td><td colspan="2">7963.463</td><td colspan="2">7964.03</td><td colspan="2">7960.65</td></tr><tr><td>Units: Region</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td><td colspan="2">17</td></tr><tr><td>Units: Period</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td><td colspan="2">51</td></tr><tr><td>Units: Individuals</td><td colspan="2">21,260</td><td colspan="2">21,052</td><td colspan="2">21,052</td><td colspan="2">26,182</td><td colspan="2">25,919</td><td colspan="2">25,919</td><td colspan="2">25,919</td></tr></table>
cdf6bb3fba2f442abd2d00d2939009991eeb2a10ee73d5a624cac4bb302b723b.png
complex
<table><tr><td></td><td colspan="3">Frequency</td></tr><tr><td></td><td>Current employment</td><td>Not working as nurses</td><td>Total</td></tr><tr><td>1994</td><td>18</td><td>5</td><td>23</td></tr><tr><td>1995</td><td>13</td><td>5</td><td>18</td></tr><tr><td>1996</td><td>15</td><td>6</td><td>21</td></tr><tr><td>1997</td><td>23</td><td>2</td><td>25</td></tr><tr><td>2001</td><td>20</td><td>4</td><td>24</td></tr><tr><td>2002</td><td>22</td><td>3</td><td>25</td></tr><tr><td>2005</td><td>23</td><td>3</td><td>26</td></tr><tr><td>2006</td><td>16</td><td>0</td><td>16</td></tr><tr><td>2007</td><td>19</td><td>2</td><td>21</td></tr><tr><td>2009</td><td>20</td><td>1</td><td>21</td></tr><tr><td>2011</td><td>11</td><td>1</td><td>12</td></tr><tr><td>Total</td><td>200</td><td>33</td><td>233</td></tr></table>
<table><tr><td></td></tr><tr><td></td></tr><tr><td>1994</td></tr><tr><td>1995</td></tr><tr><td>1996</td></tr><tr><td>1997</td></tr><tr><td>2001</td></tr><tr><td>2002</td></tr><tr><td>2005</td></tr><tr><td>2006</td></tr><tr><td>2007</td></tr><tr><td>2009</td></tr><tr><td>2011</td></tr><tr><td>Total</td></tr></table>
<table><tr><td colspan="3">Frequency</td></tr><tr><td>Current employment</td><td>Not working as nurses</td><td>Total</td></tr><tr><td>18</td><td>5</td><td>23</td></tr><tr><td>13</td><td>5</td><td>18</td></tr><tr><td>15</td><td>6</td><td>21</td></tr><tr><td>23</td><td>2</td><td>25</td></tr><tr><td>20</td><td>4</td><td>24</td></tr><tr><td>22</td><td>3</td><td>25</td></tr><tr><td>23</td><td>3</td><td>26</td></tr><tr><td>16</td><td>0</td><td>16</td></tr><tr><td>19</td><td>2</td><td>21</td></tr><tr><td>20</td><td>1</td><td>21</td></tr><tr><td>11</td><td>1</td><td>12</td></tr><tr><td>200</td><td>33</td><td>233</td></tr></table>
cc785b8e4b63f2da04ed6dd945fcb283d124876c6a3f46481f0838000a00306f.png
complex
<table><tr><td colspan="2"> </td><td>LFI strip test</td><td>DAS ELISA (OD)</td></tr><tr><td rowspan="3">Pig 77</td><td>Swap 1</td><td>+</td><td>1.717</td></tr><tr><td>Swap 2</td><td>+</td><td>1.3</td></tr><tr><td>Swap 3</td><td>+</td><td>0.307</td></tr><tr><td>Pig 78</td><td>Swap 1</td><td>+</td><td>0.604</td></tr><tr><td rowspan="3">Pig 79</td><td>Swap 1</td><td>+</td><td>1.589</td></tr><tr><td>Swap 2</td><td>+</td><td>0.833</td></tr><tr><td>Swap 3</td><td>+</td><td>2.04</td></tr><tr><td rowspan="3">Pig 80</td><td>Swap 1</td><td>+</td><td>3.079</td></tr><tr><td>Swap 2</td><td>+</td><td>3.372</td></tr><tr><td>Swap 3</td><td>+</td><td>2.713</td></tr><tr><td> </td><td>Swap 4</td><td>+</td><td>2.918</td></tr></table>
<table><tr><td colspan="2"></td><td>LFI strip test</td><td>DAS ELISA (OD)</td></tr><tr><td rowspan="3">Pig 77</td><td>Swap 1</td><td>+</td><td>1.717</td></tr><tr><td>Swap 2</td><td>+</td><td>1.3</td></tr><tr><td>Swap 3</td><td>+</td><td>0.307</td></tr><tr><td>Pig 78</td><td>Swap 1</td><td>+</td><td>0.604</td></tr><tr><td>Pig 79</td><td>Swap 1</td><td>+</td><td>1.589</td></tr></table>
<table><tr><td rowspan="2">Pig 79</td><td>Swap 2</td><td>+</td><td>0.833</td></tr><tr><td>Swap 3</td><td>+</td><td>2.04</td></tr><tr><td rowspan="3">Pig 80</td><td>Swap 1</td><td>+</td><td>3.079</td></tr><tr><td>Swap 2</td><td>+</td><td>3.372</td></tr><tr><td>Swap 3</td><td>+</td><td>2.713</td></tr><tr><td></td><td>Swap 4</td><td>+</td><td>2.918</td></tr></table>
aa78872c4cd7038e9abbe4ca9c8794f460065d0b3e3c24f1225e9dfcb3a0dfe6.png
simple
<table><tr><td>Causes of pulmonary hypertension in ICU</td><td>Causes of RV failure in ICU</td></tr><tr><td>1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)</td><td>1) RV Pressure overload, pulmonary hypertension, any cause</td></tr><tr><td>2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/cardiomyopathy; mitral regurgitation; pulmonary stenosis)</td><td>2) Reduced RV contractility</td></tr><tr><td>3) PH due to hypoxia: acute (for example, ARDS)/preexisting lung disease (for example, COPD, IPF)</td><td> RV infarction; sepsis; RV cardiomyopathy; myocarditis; pericardial disease; LVAD; after CPB; after cardiac surgery/transplantation</td></tr><tr><td>4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement)</td><td>3) RV-volume overload</td></tr><tr><td>5) Mechanical (for example, increased Pplat - IPPV</td><td> Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts</td></tr></table>
<table><tr><td>Causes of pulmonary hypertension in ICU</td><td>Causes of RV failure in ICU</td></tr><tr><td>1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)</td><td>1) RV Pressure overload, pulmonary hypertension, any cause</td></tr><tr><td>2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/cardiomyopathy; mitral regurgitation; pulmonary stenosis)</td><td>2) Reduced RV contractility</td></tr><tr><td>3) PH due to hypoxia: acute (for example, ARDS)/preexisting lung disease (for example, COPD, IPF)</td><td>RV infarction; sepsis; RV cardiomyopathy; myocarditis; pericardial disease; LVAD; after CPB; after cardiac surgery/transplantation</td></tr></table>
<table><tr><td>4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement)</td><td>3) RV-volume overload</td></tr><tr><td>5) Mechanical (for example, increased Pplat - IPPV</td><td>Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts</td></tr></table>
252f68b4abf65d5b82890d0191c25cd3710fcfcb5a7232245751f5206413049a.png
complex
<table><tr><td>Gene</td><td>5&#8242;&#8211;3&#8242; sequence</td></tr><tr><td rowspan="2"><i>P5CS1</i></td><td>F&#8208;GTAGACGACGACGACGATAATG</td></tr><tr><td>R&#8208;ACTGCTGTCCCAACCTTAAC</td></tr><tr><td rowspan="2"><i>P5CS2</i></td><td>F&#8208;GGTGCTGAGGTGGGAATAAG</td></tr><tr><td>R&#8208;ACTTGTCCCTTTCCTCTCATTATC</td></tr><tr><td rowspan="2"><i>P5CR</i></td><td>F&#8208;GAGGAGTAGCTGCTGGTTTAC</td></tr><tr><td>R&#8208;CCTGGATGCTTCCCAGTTT</td></tr><tr><td rowspan="2"><i>OAT</i></td><td>F&#8208;TGCTTGAGCTTGAAGGAGAG</td></tr><tr><td>R&#8208;GATCCATCTCGGAGTTCATCAG</td></tr><tr><td rowspan="2"><i>PDH1</i></td><td>F&#8208;AGCAGCTCATGGAAGGATTC</td></tr><tr><td>R&#8208;GGGTTGGAGGATTGTGTCTT</td></tr><tr><td rowspan="2"><i>PDH2</i></td><td>F&#8208;GCGTAGAACACGCTGAAGA</td></tr><tr><td>R&#8208;GCTTAAGTGAGACGAAGGTAGG</td></tr><tr><td rowspan="2"><i>P5CDH</i></td><td>F&#8208;AGGATGCACGCTCATCTAAC</td></tr><tr><td>R&#8208;CCAGCATATGTAGTCCCATTCA</td></tr><tr><td rowspan="2"><i>GAPDH</i></td><td>F&#8208;TTGTTGTTGAGTCCACTG</td></tr><tr><td>R&#8208;CTTGTATTCCTTCTCGTTGA</td></tr></table>
<table><tr><td>Gene</td></tr><tr><td rowspan="2">P5CS1</td></tr><tr></tr><tr><td rowspan="2">P5CS2</td></tr><tr></tr><tr><td rowspan="2">P5CR</td></tr><tr></tr><tr><td rowspan="2">OAT</td></tr><tr></tr><tr><td rowspan="2">PDH1</td></tr><tr></tr><tr><td rowspan="2">PDH2</td></tr><tr></tr><tr><td rowspan="2">P5CDH</td></tr><tr></tr><tr><td rowspan="2">GAPDH</td></tr><tr></tr></table>
<table><tr><td>5′–3′ sequence</td></tr><tr><td>F‐GTAGACGACGACGACGATAATG</td></tr><tr><td>R‐ACTGCTGTCCCAACCTTAAC</td></tr><tr><td>F‐GGTGCTGAGGTGGGAATAAG</td></tr><tr><td>R‐ACTTGTCCCTTTCCTCTCATTATC</td></tr><tr><td>F‐GAGGAGTAGCTGCTGGTTTAC</td></tr><tr><td>R‐CCTGGATGCTTCCCAGTTT</td></tr><tr><td>F‐TGCTTGAGCTTGAAGGAGAG</td></tr><tr><td>R‐GATCCATCTCGGAGTTCATCAG</td></tr><tr><td>F‐AGCAGCTCATGGAAGGATTC</td></tr><tr><td>R‐GGGTTGGAGGATTGTGTCTT</td></tr><tr><td>F‐GCGTAGAACACGCTGAAGA</td></tr><tr><td>R‐GCTTAAGTGAGACGAAGGTAGG</td></tr><tr><td>F‐AGGATGCACGCTCATCTAAC</td></tr><tr><td>R‐CCAGCATATGTAGTCCCATTCA</td></tr><tr><td>F‐TTGTTGTTGAGTCCACTG</td></tr><tr><td>R‐CTTGTATTCCTTCTCGTTGA</td></tr></table>
042e505ba6e8f03c5791843f32348c38822664c70bae401c94f3ede5f2473f9d.png
simple
<table><tr><td></td><td>First quartile</td><td>Third quartile</td></tr><tr><td>Shortwave radiation</td><td>164.97 (1.41)*</td><td>141.35(1.14)</td></tr><tr><td>HDD</td><td>134.62(1.22)</td><td>168.11(1.39)</td></tr><tr><td>Snowfall</td><td>135.04(1.24)</td><td>163.66(1.42)</td></tr><tr><td>Rainfall</td><td>164.69 (1.60)</td><td>131.82(1.32)</td></tr><tr><td>Permitted air emissions</td><td>142.96(1.09)</td><td>149.01(1.12)</td></tr><tr><td>Acres of land used to grow crops</td><td>142.09(1.29)</td><td>157.14(1.53)</td></tr></table>
<table><tr><td></td><td>First quartile</td><td>Third quartile</td></tr><tr><td>Shortwave radiation</td><td>164.97 (1.41)*</td><td>141.35(1.14)</td></tr><tr><td>HDD</td><td>134.62(1.22)</td><td>168.11(1.39)</td></tr><tr><td>Snowfall</td><td>135.04(1.24)</td><td>163.66(1.42)</td></tr><tr><td>Rainfall</td><td>164.69 (1.60</td><td>131.</td></tr></table>
<table><tr><td></td><td>)</td><td>82(1.32)</td></tr><tr><td>Permitted air emissions</td><td>142.96(1.09)</td><td>149.01(1.12)</td></tr><tr><td>Acres of land used to grow crops</td><td>142.09(1.29)</td><td>157.14(1.53)</td></tr></table>
dfd2f0a62259c18dc1176048b31b767b26be7c4be92ee1bc7904cadc8fef3f99.png
simple
<table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td>Moore RG <i>et al</i>. [5]</td><td>USA</td><td>2008</td><td>prospective/retrospective</td><td>171</td><td>156</td><td>/</td><td>78</td><td>8</td><td>93</td><td>148</td><td>46</td><td>95</td></tr><tr><td>Zanotti L <i>et al</i>. [6]</td><td>Italy</td><td>2012</td><td>retrospective</td><td>193(152 + 41)</td><td>125</td><td>51</td><td>152</td><td>19</td><td>41</td><td>106</td><td>79</td><td>85</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>64</td><td>127</td><td>6</td><td>66</td><td>119</td><td>66</td><td>95</td></tr><tr><td>Angioli R <i>et al</i>. [7]</td><td>Italy</td><td>2013</td><td>prospective</td><td>101(95 + 6)</td><td>103</td><td>70</td><td>60</td><td>0</td><td>41</td><td>103</td><td>59</td><td>100</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>150</td><td>36</td><td>0</td><td>65</td><td>103</td><td>36</td><td>100</td></tr><tr><td>Omer B<i>et al</i>. [8]</td><td>Turkey</td><td>2013</td><td>prospective l</td><td>64(54 + 10)</td><td>94(60 + 34)</td><td>60</td><td>48</td><td>32</td><td>16</td><td>62</td><td>75</td><td>66</td></tr><tr><td>Bignotti E <i>et al</i>. [9]</td><td>Italy</td><td>2011</td><td>prospective</td><td>138(109 + 29)</td><td>76</td><td>/</td><td>92</td><td>4</td><td>46</td><td>72</td><td>67</td><td>95</td></tr><tr><td>Zhang, Ai-min <i>et al</i>. [10]</td><td>China</td><td>2012</td><td>prospective</td><td>124</td><td>206(97 + 109)</td><td>/</td><td>51</td><td>10</td><td>73</td><td>196</td><td>41</td><td>95</td></tr><tr><td>Total</td><td> </td><td> </td><td> </td><td>791</td><td>760</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr></table>
<table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td>Moore RG et al. [5]</td><td>USA</td><td>2008</td><td>prospective/retrospective</td><td>171</td><td>156</td><td>/</td><td>78</td><td>8</td><td>93</td><td>148</td><td>46</td><td>95</td></tr><tr><td>Zanotti L et al. [6]</td><td>Italy</td><td>2012</td><td>retrospective</td><td>193(152 + 41)</td><td>125</td><td>51</td><td>152</td><td>19</td><td>41</td><td>106</td><td>79</td><td>85</td></tr></table>
<table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>64</td><td>127</td><td>6</td><td>66</td><td>119</td><td>66</td><td>95</td></tr><tr><td>Angioli R et al. [7]</td><td>Italy</td><td>2013</td><td>prospective</td><td>101(95 + 6)</td><td>103</td><td>70</td><td>60</td><td>0</td><td>41</td><td>103</td><td>59</td><td>100</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>150</td><td>36</td><td>0</td><td>65</td><td>103</td><td>36</td><td>100</td></tr><tr><td>Omer Bet al. [8]</td><td>Turkey</td><td>2013</td><td>prospective l</td><td>64(54 + 10)</td><td>94(60 + 34)</td><td>60</td><td>48</td><td>32</td><td>16</td><td>62</td><td>75</td><td>66</td></tr><tr><td>Bignotti E et al. [9]</td><td>Italy</td><td>2011</td><td>prospective</td><td>138(109 + 29)</td><td>76</td><td>/</td><td>92</td><td>4</td><td>46</td><td>72</td><td>67</td><td>95</td></tr><tr><td>Zhang, Ai-min et al. [10]</td><td>China</td><td>2012</td><td>prospective</td><td>124</td><td>206(97 + 109)</td><td>/</td><td>51</td><td>10</td><td>73</td><td>196</td><td>41</td><td>95</td></tr><tr><td>Total</td><td></td><td></td><td></td><td>791</td><td>760</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
f17e733922aa880bbde08b831fbb173dc9da5b04e63cc94d11b485ea0a897bd9.png
simple
<table><tr><td>Training description</td><td>Related themes</td></tr><tr><td>1. Video: Invite for the workshop and foundational information on <i>Rx for Change</i> and systematic reviews<underline>Delivery:</underline> A video (prezi with audio narration) covering general information about <i>Rx for Change</i> and systematic reviews; the video was sent electronically 1 week prior to the workshop with a request for people to review it prior to attending the workshop; duration was 6 minutes<underline>Content:</underline> Quick facts about the database, information on the type of evidence included, information on when it can be used and how it can help participants in their work; an invitation to attend a free workshop and to explore <i>Rx for Change</i> on-line in a group environment was included</td><td>Need for knowledgeDiversity in delivery</td></tr><tr><td>2. Face-to-face workshop (1 hour)<underline>Delivery:</underline> Didactic presentation (15 min) + hands on skills training (45 min) + discussion (15 min) + handouts<underline>Content of didactic presentation</underline>: <i>Rx for Change</i> was presented as part of the evidence source &#8220;puzzle&#8221; Knowledge users&#8217; questions (as per interviews) partly guided the session&#8217;s themes (e.g. What is <i>Rx for Change</i>? Can I trust the evidence presented? What types of questions are relevant? How is <i>Rx for Change</i> different compared to other evidence sources?); the didactic part of the session focused on emphasizing &#8220;How we turn a research question into a &#8220;searchable question&#8221; in the <i>Rx for Change</i> database&#8221;<underline>Content of hands-on skills training</underline>: A pre-determined example of a research question was used to demonstrate and familiarise participants with strategic navigation strategies for the <i>Rx for Change</i> database; screenshots were used along with an audio or live presentation/demonstration; the three-question framework based on Lavis et al. [21] was used to demonstrate different ways of searching efficiently, the layout of the database, the taxonomy and the layers of the database Participants were then asked to use one of their own work examples and search the database based on the same three-question framework; this was a facilitated exerciseThe session was facilitated by a research team member with expertise in <i>Rx for Change</i> or an external collaborator with knowledge of <i>Rx for Change</i><underline>Content of discussion:</underline> The incorporation and applicability of the evidence in one&#8217;s context as well as the strengths and limitations of the database and the evidence that it includes was discussed<underline>Handouts:</underline> Frequently Asked Questions and a &#8220;map&#8221; of the database layout (screenshots) were given to participants in the form of handouts after the session (for desk use)</td><td>Didactic presentation: Need for knowledgeHands on skills training: Need for skill development in navigating the database and integrating evidence into decision-making, tailoringDiscussion: Knowledge and skillsHandouts: Need for knowledge, variety in delivery methods</td></tr><tr><td>3. Post-training remindersDelivery: Emailed at 1 and 3 months post-workshopContent: Cues and/or reminders regarding the database&#8217;s use, value, updates, and navigation tips</td><td>Routine habits</td></tr></table>
<table><tr><td>Training description</td><td>Related themes</td></tr><tr><td>1. Video: Invite for the workshop and foundational information on Rx for Change and systematic reviewsDelivery: A video (prezi with audio narration) covering general information about Rx for Change and systematic reviews; the video was sent electronically 1 week prior to the workshop with a request for people to review it prior to attending the workshop; duration was 6 minutesContent: Quick facts about the database, information on the type of evidence included, information on when it can be used and how it can help participants in their work; an invitation to attend a free workshop and to explore Rx for Change on-line in a group environment was included</td><td>Need for knowledgeDiversity in delivery</td></tr><tr><td>2. Face-to-face workshop (1 hour)Delivery: Didactic presentation (15 min) + hands on skills training (45 min) + discussion (15 min) + handoutsContent of didactic presentation: Rx for Change was presented as part of the evidence source “puzzle” Knowledge users’ questions (as per interviews) partly guided the session’s themes (e.g. What is Rx for Change? Can I trust the evidence presented? What types of questions are relevant? How is Rx for Change different compared to other evidence sources?); the didactic part of the session focused on emphasizing “How we turn a research question into a “searchable question” in the Rx for Change database”Content of hands-on skills training: A pre-determined example of a research question was used to demonstrate and familiarise participants with strategic navigation strategies for the Rx for Change database; screenshots were used along with an audio or live presentation/demonstration; the three-question framework based on Lavis et al. [21] was used to demonstrate different ways of searching efficiently, the layout of the database, the taxonomy and the layers of the database Participants were then asked to use one of their own work examples and search the database based on the same three-question framework; this was a facilitated exerciseThe session was facilitated by a research team member with expertise in Rx for Change or an external collaborator with knowledge of Rx for ChangeContent of discussion: The incorporation and applicability of the evidence in one’s context as well as the strengths and limitations of the database and the evidence that it includes was discussedHandouts: Frequently Asked Questions and a “map” of the database layout (screenshots) were given to participants in the form of handouts after the session (for desk use)</td><td>Didactic presentation: Need for knowledgeHands on skills training: Need for skill development in navigating the database and integrating evidence into decision-making, tailoringDiscussion: Knowledge and skillsHandouts: Need for knowledge, variety in delivery methods</td></tr></table>
<table><tr><td>3. Post-training remindersDelivery: Emailed at 1 and 3 months post-workshopContent: Cues and/or reminders regarding the database’s use, value, updates, and navigation tips</td><td>Routine habits</td></tr></table>
ebafea3f86882c03d4a523702e9b74832a556fc0bab58ed0919c1a8691b6e81c.png
simple
<table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td><i>P. pastoris</i> AT-ACS</td><td>15</td></tr><tr><td><i>P. pastoris</i> GC-ACS</td><td>1</td></tr><tr><td><i>S. cerevisiae</i> 11 bp ACS</td><td>11</td></tr><tr><td><i>S. cerevisiae</i> 17 bp ACS</td><td>6</td></tr></table>
<table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td>P. pastoris AT-ACS</td><td>15</td></tr><tr><td>P. pastoris GC-ACS</td><td>1</td></tr><tr><td>S. cerevisiae 11 bp ACS</td><td>11</td></tr></table>
<table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td>S. cerevisiae 17 bp ACS</td><td>6</td></tr></table>
ab9282df63ff6f01700ce866b137e0b29fb790f81692eb9c7db23401b9fa5b5f.png
complex
<table><tr><td rowspan="2">Characteristic</td><td colspan="2">Overall</td><td colspan="2">AKI</td><td colspan="2">No AKI</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>N</td><td>14,651</td><td></td><td>1966</td><td>(13.4% of cohort)</td><td>12,685</td><td>(86.6% of cohort)</td></tr><tr><td>Age in years (median &amp; IQR)</td><td>69</td><td>(54&#8211;78)</td><td>73</td><td>(63&#8211;81)</td><td>68</td><td>(53&#8211;78)</td></tr><tr><td>Female</td><td>8317</td><td>(56.8)</td><td>1011</td><td>(51.4)</td><td>7306</td><td>(57.6)</td></tr><tr><td>Residential care</td><td>433</td><td>(3.0)</td><td>111</td><td>(5.6)</td><td>322</td><td>(2.5)</td></tr><tr><td>Deprived home locationa</td><td>1215</td><td>(8.3)</td><td>169</td><td>(8.6)</td><td>1046</td><td>(8.2)</td></tr><tr><td>Rural home location</td><td>4014</td><td>(27.4)</td><td>551</td><td>(28.0)</td><td>3463</td><td>(27.3)</td></tr><tr><td>Emergency hospital admission</td><td>8689</td><td>(59.3)</td><td>1580</td><td>(80.4)</td><td>7109</td><td>(56.0)</td></tr><tr><td>Medical specialty admission</td><td>7203</td><td>(49.2)</td><td>1336</td><td>(68.0)</td><td>5867</td><td>(46.3)</td></tr><tr><td>Critical care admission</td><td>1288</td><td>(8.8)</td><td>529</td><td>(26.9)</td><td>759</td><td>(6.0)</td></tr><tr><td>Intensive care admission</td><td>428</td><td>(2.9)</td><td>276</td><td>(14.0)</td><td>152</td><td>(1.2)</td></tr><tr><td>Length of hospital stay in days (median &amp; IQR)</td><td>3</td><td>(1&#8211;9)</td><td>14</td><td>(7&#8211;31)</td><td>2</td><td>(1&#8211;7)</td></tr><tr><td>Cancer</td><td>1011</td><td>(6.9)</td><td>201</td><td>(10.2)</td><td>810</td><td>(6.4)</td></tr><tr><td>Cardiac failure</td><td>668</td><td>(4.6)</td><td>181</td><td>(9.2)</td><td>487</td><td>(3.8)</td></tr><tr><td>Cerebrovascular disease</td><td>613</td><td>(4.2)</td><td>124</td><td>(6.3)</td><td>489</td><td>(3.9)</td></tr><tr><td>Dementia</td><td>150</td><td>(1.0)</td><td>30</td><td>(1.5)</td><td>120</td><td>(0.9)</td></tr><tr><td>Diabetes</td><td>917</td><td>(6.3)</td><td>255</td><td>(13.0)</td><td>662</td><td>(5.2)</td></tr><tr><td>Liver disease</td><td>189</td><td>(1.3)</td><td>49</td><td>(2.5)</td><td>140</td><td>(1.1)</td></tr><tr><td>Myocardial infarction</td><td>735</td><td>(5.0)</td><td>182</td><td>(9.3)</td><td>553</td><td>(4.4)</td></tr><tr><td>Neurologic disease</td><td>76</td><td>(0.5)</td><td>20</td><td>(1.0)</td><td>56</td><td>(0.4)</td></tr><tr><td>Peptic disease</td><td>304</td><td>(2.1)</td><td>66</td><td>(3.4)</td><td>238</td><td>(1.9)</td></tr><tr><td>Peripheral vascular disease</td><td>487</td><td>(3.3)</td><td>140</td><td>(7.1)</td><td>347</td><td>(2.7)</td></tr><tr><td>Pulmonary disease</td><td>836</td><td>(5.7)</td><td>199</td><td>(10.1)</td><td>637</td><td>(5.0)</td></tr><tr><td>Rheumatic disease</td><td>312</td><td>(2.1)</td><td>68</td><td>(3.5)</td><td>244</td><td>(1.9)</td></tr><tr><td>Baseline (pre-episode) eGFR (median &amp; IQR)</td><td>66.8</td><td>(53.0&#8211;88.2)</td><td>75.3</td><td>(53.9&#8211;91.8)</td><td>65.8</td><td>(52.9&#8211;87.3)</td></tr><tr><td>Post-episode eGFRb</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&#8805;60</td><td>9004</td><td>(61.5)</td><td>955</td><td>(48.6)</td><td>8049</td><td>(63.5)</td></tr><tr><td>45&#8211;59</td><td>3369</td><td>(23.0)</td><td>444</td><td>(22.6)</td><td>2925</td><td>(23.1)</td></tr><tr><td>30&#8211;44</td><td>1733</td><td>(11.8)</td><td>374</td><td>(19.0)</td><td>1359</td><td>(10.7)</td></tr><tr><td>&lt;30</td><td>545</td><td>(3.7)</td><td>193</td><td>(9.8)</td><td>352</td><td>(2.8)</td></tr><tr><td>Intra-episode background change in eGFRc</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&gt;30% rise</td><td>1135</td><td>(7.7)</td><td>67</td><td>(3.4)</td><td>1068</td><td>(8.4)</td></tr><tr><td>10%&#8211;30% rise</td><td>2069</td><td>(14.1)</td><td>120</td><td>(6.1)</td><td>1949</td><td>(15.4)</td></tr><tr><td>No change</td><td>7654</td><td>(52.2)</td><td>517</td><td>(26.3)</td><td>7137</td><td>(56.3)</td></tr><tr><td>10%&#8211;30% fall</td><td>2990</td><td>(20.4)</td><td>757</td><td>(38.5)</td><td>2233</td><td>(17.6)</td></tr><tr><td>&gt;30% fall</td><td>803</td><td>(5.5)</td><td>505</td><td>(25.7)</td><td>298</td><td>(2.3)</td></tr><tr><td>Post-episode proteinuriad</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Untested</td><td>13069</td><td>(89.2)</td><td>1550</td><td>(78.8)</td><td>11519</td><td>(90.8)</td></tr><tr><td>Normal</td><td>753</td><td>(5.1)</td><td>136</td><td>(6.9)</td><td>617</td><td>(4.9)</td></tr><tr><td>Abnormal</td><td>829</td><td>(5.7)</td><td>280</td><td>(14.2)</td><td>549</td><td>(4.3)</td></tr><tr><td>AKI stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0</td><td>12685</td><td>(86.6)</td><td>n/a</td><td>&#8211;</td><td>12685</td><td>(100.0)</td></tr><tr><td>1</td><td>1355</td><td>(9.2)</td><td>1355</td><td>(68.9)</td><td>n/a</td><td>&#8211;</td></tr><tr><td>2</td><td>410</td><td>(2.8)</td><td>410</td><td>(20.9)</td><td>n/a</td><td>&#8211;</td></tr><tr><td>3</td><td>201</td><td>(1.4)</td><td>201</td><td>(10.2)</td><td>n/a</td><td>&#8211;</td></tr><tr><td>Prior AKI episodes</td><td>1358</td><td>(9.3)</td><td>356</td><td>(18.1)</td><td>1002</td><td>(7.9)</td></tr></table>
<table><tr><td rowspan="2">Characteristic</td><td>Overall</td></tr><tr><td>N</td></tr><tr><td>N</td><td>14,651</td></tr><tr><td>Age in years (median & IQR)</td><td>69</td></tr><tr><td>Female</td><td>8317</td></tr><tr><td>Residential care</td><td>433</td></tr><tr><td>Deprived home locationa</td><td>1215</td></tr><tr><td>Rural home location</td><td>4014</td></tr><tr><td>Emergency hospital admission</td><td>8689</td></tr><tr><td>Medical specialty admission</td><td>7203</td></tr><tr><td>Critical care admission</td><td>1288</td></tr><tr><td>Intensive care admission</td><td>428</td></tr><tr><td>Length of hospital stay in days (median & IQR)</td><td>3</td></tr><tr><td>Cancer</td><td>1011</td></tr><tr><td>Cardiac failure</td><td>668</td></tr><tr><td>Cerebrovascular disease</td><td>613</td></tr><tr><td>Dementia</td><td>150</td></tr><tr><td>Diabetes</td><td>917</td></tr><tr><td>Liver disease</td><td>189</td></tr><tr><td>Myocardial infarction</td><td>735</td></tr><tr><td>Neurologic disease</td><td>76</td></tr><tr><td>Peptic disease</td><td>304</td></tr><tr><td>Peripheral vascular disease</td><td>487</td></tr><tr><td>Pulmonary disease</td><td>836</td></tr><tr><td>Rheumatic disease</td><td>312</td></tr><tr><td>Baseline (pre-episode) eGFR (median & IQR)</td><td>66.8</td></tr><tr><td>Post-episode eGFRb</td><td></td></tr><tr><td>≥60</td><td>9004</td></tr><tr><td>45–59</td><td>3369</td></tr><tr><td>30–44</td><td>1733</td></tr><tr><td><30</td><td>545</td></tr><tr><td>Intra-episode background change in eGFRc</td><td></td></tr><tr><td>>30% rise</td><td>1135</td></tr><tr><td>10%–30% rise</td><td>2069</td></tr><tr><td>No change</td><td>7654</td></tr><tr><td>10%–30% fall</td><td>2990</td></tr><tr><td>>30% fall</td><td>803</td></tr><tr><td>Post-episode proteinuriad</td><td></td></tr><tr><td>Untested</td><td>13069</td></tr><tr><td>Normal</td><td>753</td></tr><tr><td>Abnormal</td><td>829</td></tr><tr><td>AKI stage</td><td></td></tr><tr><td>0</td><td>12685</td></tr><tr><td>1</td><td>1355</td></tr><tr><td>2</td><td>410</td></tr><tr><td>3</td><td>201</td></tr><tr><td>Prior AKI episodes</td><td>1358</td></tr></table>
<table><tr><td>Overall</td><td colspan="2">AKI</td><td colspan="2">No AKI</td></tr><tr><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td></td><td>1966</td><td>(13.4% of cohort)</td><td>12,685</td><td>(86.6% of cohort)</td></tr><tr><td>(54–78)</td><td>73</td><td>(63–81)</td><td>68</td><td>(53–78)</td></tr><tr><td>(56.8)</td><td>1011</td><td>(51.4)</td><td>7306</td><td>(57.6)</td></tr><tr><td>(3.0)</td><td>111</td><td>(5.6)</td><td>322</td><td>(2.5)</td></tr><tr><td>(8.3)</td><td>169</td><td>(8.6)</td><td>1046</td><td>(8.2)</td></tr><tr><td>(27.4)</td><td>551</td><td>(28.0)</td><td>3463</td><td>(27.3)</td></tr><tr><td>(59.3)</td><td>1580</td><td>(80.4)</td><td>7109</td><td>(56.0)</td></tr><tr><td>(49.2)</td><td>1336</td><td>(68.0)</td><td>5867</td><td>(46.3)</td></tr><tr><td>(8.8)</td><td>529</td><td>(26.9)</td><td>759</td><td>(6.0)</td></tr><tr><td>(2.9)</td><td>276</td><td>(14.0)</td><td>152</td><td>(1.2)</td></tr><tr><td>(1–9)</td><td>14</td><td>(7–31)</td><td>2</td><td>(1–7)</td></tr><tr><td>(6.9)</td><td>201</td><td>(10.2)</td><td>810</td><td>(6.4)</td></tr><tr><td>(4.6)</td><td>181</td><td>(9.2)</td><td>487</td><td>(3.8)</td></tr><tr><td>(4.2)</td><td>124</td><td>(6.3)</td><td>489</td><td>(3.9)</td></tr><tr><td>(1.0)</td><td>30</td><td>(1.5)</td><td>120</td><td>(0.9)</td></tr><tr><td>(6.3)</td><td>255</td><td>(13.0)</td><td>662</td><td>(5.2)</td></tr><tr><td>(1.3)</td><td>49</td><td>(2.5)</td><td>140</td><td>(1.1)</td></tr><tr><td>(5.0)</td><td>182</td><td>(9.3)</td><td>553</td><td>(4.4)</td></tr><tr><td>(0.5)</td><td>20</td><td>(1.0)</td><td>56</td><td>(0.4)</td></tr><tr><td>(2.1)</td><td>66</td><td>(3.4)</td><td>238</td><td>(1.9)</td></tr><tr><td>(3.3)</td><td>140</td><td>(7.1)</td><td>347</td><td>(2.7)</td></tr><tr><td>(5.7)</td><td>199</td><td>(10.1)</td><td>637</td><td>(5.0)</td></tr><tr><td>(2.1)</td><td>68</td><td>(3.5)</td><td>244</td><td>(1.9)</td></tr><tr><td>(53.0–88.2)</td><td>75.3</td><td>(53.9–91.8)</td><td>65.8</td><td>(52.9–87.3)</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(61.5)</td><td>955</td><td>(48.6)</td><td>8049</td><td>(63.5)</td></tr><tr><td>(23.0)</td><td>444</td><td>(22.6)</td><td>2925</td><td>(23.1)</td></tr><tr><td>(11.8)</td><td>374</td><td>(19.0)</td><td>1359</td><td>(10.7)</td></tr><tr><td>(3.7)</td><td>193</td><td>(9.8)</td><td>352</td><td>(2.8)</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(7.7)</td><td>67</td><td>(3.4)</td><td>1068</td><td>(8.4)</td></tr><tr><td>(14.1)</td><td>120</td><td>(6.1)</td><td>1949</td><td>(15.4)</td></tr><tr><td>(52.2)</td><td>517</td><td>(26.3)</td><td>7137</td><td>(56.3)</td></tr><tr><td>(20.4)</td><td>757</td><td>(38.5)</td><td>2233</td><td>(17.6)</td></tr><tr><td>(5.5)</td><td>505</td><td>(25.7)</td><td>298</td><td>(2.3)</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(89.2)</td><td>1550</td><td>(78.8)</td><td>11519</td><td>(90.8)</td></tr><tr><td>(5.1)</td><td>136</td><td>(6.9)</td><td>617</td><td>(4.9)</td></tr><tr><td>(5.7)</td><td>280</td><td>(14.2)</td><td>549</td><td>(4.3)</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(86.6)</td><td>n/a</td><td>–</td><td>12685</td><td>(100.0)</td></tr><tr><td>(9.2)</td><td>1355</td><td>(68.9)</td><td>n/a</td><td>–</td></tr><tr><td>(2.8)</td><td>410</td><td>(20.9)</td><td>n/a</td><td>–</td></tr><tr><td>(1.4)</td><td>201</td><td>(10.2)</td><td>n/a</td><td>–</td></tr><tr><td>(9.3)</td><td>356</td><td>(18.1)</td><td>1002</td><td>(7.9)</td></tr></table>
f9ab75b18ee973ac4094971069c6d3244dae3ea43401fac83009ce0ec13b234e.png
complex
<table><tr><td>Variables</td><td>Total cohort</td><td>Tsunami group</td><td>Radiation group</td><td>p value<sup>a</sup></td></tr><tr><td>Physical examination</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Body weight (kg)</td><td>58.5 (52.0&#8211;66.0)</td><td>57.9 (52.6&#8211;65.9)</td><td>59.5 (51.9&#8211;66.3)</td><td>n.s.</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24.2 (22.4&#8211;26.1)</td><td>24.2 (22.1&#8211;26.3)</td><td>24.3 (22.6&#8211;26.0)</td><td>n.s.</td></tr><tr><td>High BMI</td><td>32 (16.2)</td><td>17 (15.7)</td><td>15 (16.7)</td><td>n.s.</td></tr><tr><td>Waist circumference (cm)</td><td>86.5 (81.9&#8211;92.5)</td><td>86.0 (81.2&#8211;92.5)</td><td>87.0 (82.3&#8211;92.5)</td><td>n.s.</td></tr><tr><td>High waist circumference</td><td>83 (41.5)</td><td>45 (41.7)</td><td>38 (41.3)</td><td>n.s.</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>132 (124&#8211;146)</td><td>131 (124&#8211;144)</td><td>134 (126&#8211;148)</td><td>n.s.</td></tr><tr><td>High systolic blood pressure</td><td>102 (51.0)</td><td>54 (50.0)</td><td>48 (52.2)</td><td>n.s.</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>80 (70&#8211;84)</td><td>76 (70&#8211;84)</td><td>80 (76&#8211;86)</td><td>0.002</td></tr><tr><td>High diastolic blood pressure</td><td>48 (24.0)</td><td>22 (20.4)</td><td>26 (28.3)</td><td>n.s.</td></tr><tr><td>Laboratory examination</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>5.5 (5.4&#8211;5.9)</td><td>5.5 (5.4&#8211;5.9)</td><td>5.5 (5.2&#8211;5.8)</td><td>n.s.</td></tr><tr><td>High HbA<sub>1c</sub></td><td>62 (31.0)</td><td>37 (34.3)</td><td>25 (27.2)</td><td>n.s.</td></tr><tr><td>HDL cholesterol (mmol/L)</td><td>1.47 (1.22&#8211;1.76)</td><td>1.53 (1.27&#8211;1.81)</td><td>1.42 (1.14&#8211;1.69)</td><td>0.02</td></tr><tr><td>Low HDL cholesterol</td><td>19 (9.5)</td><td>6 (5.6)</td><td>13 (14.3)</td><td>0.04</td></tr><tr><td>LDL cholesterol (mmol/L)</td><td>3.08 (2.64&#8211;3.62)</td><td>3.05 (2.59&#8211;3.59)</td><td>3.13 (2.57&#8211;3.66)</td><td>n.s.</td></tr><tr><td>High LDL cholesterol</td><td>48 (24.1)</td><td>23 (21.3)</td><td>25 (27.5)</td><td>n.s.</td></tr><tr><td>Triglyceride (mmol/L)</td><td>1.00 (0.75&#8211;1.57)</td><td>1.02 (0.72&#8211;1.54)</td><td>1.00 (0.78&#8211;1.69)</td><td>n.s.</td></tr><tr><td>High triglyceride</td><td>46 (23.1)</td><td>23 (21.3)</td><td>23 (25.3)</td><td>n.s.</td></tr><tr><td>Treatment status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Periodic clinic visits for chronic metabolic diseases</td><td>102 (51.0)</td><td>50 (46.3)</td><td>52 (56.5)</td><td>n.s.</td></tr><tr><td>Disease for periodic clinic visits</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Hypertension</td><td>89 (44.5)</td><td>43 (39.8)</td><td>46 (50.0)</td><td rowspan="5">n.s.</td></tr><tr><td>Dyslipidemia</td><td>16 (8.0)</td><td>7 (6.5)</td><td>9 (9.8)</td></tr><tr><td>Diabetes</td><td>12 (6.0)</td><td>4 (3.7)</td><td>8 (8.7)</td></tr><tr><td>Hyperuricemia</td><td>3 (1.5)</td><td>0 (0.0)</td><td>3 (3.3)</td></tr><tr><td>Cardiovascular</td><td>11 (5.5)</td><td>4 (3.7)</td><td>7 (7.6)</td></tr><tr><td>Medication for chronic metabolic diseases</td><td>97 (48.5)</td><td>45 (41.7)</td><td>52 (56.5)</td><td>0.04</td></tr></table>
<table><tr><td>Variables</td><td>Total cohort</td><td>Tsunami group</td><td>Radiation group</td></tr><tr><td>Physical examination</td><td></td><td></td><td></td></tr><tr><td>Body weight (kg)</td><td>58.5 (52.0–66.0)</td><td>57.9 (52.6–65.9)</td><td>59.5 (51.9–66.3)</td></tr><tr><td>BMI (kg/m2)</td><td>24.2 (22.4–26.1)</td><td>24.2 (22.1–26.3)</td><td>24.3 (22.6–26.0)</td></tr><tr><td>High BMI</td><td>32 (16.2)</td><td>17 (15.7)</td><td>15 (16.7)</td></tr><tr><td>Waist circumference (cm)</td><td>86.5 (81.9–92.5)</td><td>86.0 (81.2–92.5)</td><td>87.0 (82.3–92.5)</td></tr><tr><td>High waist circumference</td><td>83 (41.5)</td><td>45 (41.7)</td><td>38 (41.3)</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>132 (124–146)</td><td>131 (124–144)</td><td>134 (126–148)</td></tr><tr><td>High systolic blood pressure</td><td>102 (51.0)</td><td>54 (50.0)</td><td>48 (52.2)</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>80 (70–84)</td><td>76 (70–84)</td><td>80 (76–86)</td></tr><tr><td>High diastolic blood pressure</td><td>48 (24.0)</td><td>22 (20.4)</td><td>26 (28.3)</td></tr><tr><td>Laboratory examination</td><td></td><td></td><td></td></tr><tr><td>HbA1c (%)</td><td>5.5 (5.4–5.9)</td><td>5.5 (5.4–5.9)</td><td>5.5 (5.2–5.8)</td></tr><tr><td>High HbA1c</td><td>62 (31.0)</td><td>37 (34.3)</td><td>25 (27.2)</td></tr><tr><td>HDL cholesterol (mmol/L)</td><td>1.47 (1.22–1.76)</td><td>1.53 (1.27–1.81)</td><td>1.42 (1.14–1.69)</td></tr><tr><td>Low HDL cholesterol</td><td>19 (9.5)</td><td>6 (5.6)</td><td>13 (14.3)</td></tr><tr><td>LDL cholesterol (mmol/L)</td><td>3.08 (2.64–3.62)</td><td>3.05 (2.59–3.59)</td><td>3.13 (2.57–3.66)</td></tr><tr><td>High LDL cholesterol</td><td>48 (24.1)</td><td>23 (21.3)</td><td>25 (27.5)</td></tr><tr><td>Triglyceride (mmol/L)</td><td>1.00 (0.75–1.57)</td><td>1.02 (0.72–1.54)</td><td>1.00 (0.78–1.69)</td></tr><tr><td>High triglyceride</td><td>46 (23.1)</td><td>23 (21.3)</td><td>23 (25.3)</td></tr><tr><td>Treatment status</td><td></td><td></td><td></td></tr><tr><td>Periodic clinic visits for chronic metabolic diseases</td><td>102 (51.0)</td><td>50 (46.3)</td><td>52 (56.5)</td></tr><tr><td>Disease for periodic clinic visits</td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td>89 (44.5)</td><td>43 (39.8)</td><td>46 (50.0)</td></tr><tr><td>Dyslipidemia</td><td>16 (8.0)</td><td>7 (6.5)</td><td>9 (9.8)</td></tr><tr><td>Diabetes</td><td>12 (6.0)</td><td>4 (3.7)</td><td>8 (8.7)</td></tr><tr><td>Hyperuricemia</td><td>3 (1.5)</td><td>0 (0.0)</td><td>3 (3.3)</td></tr><tr><td>Cardiovascular</td><td>11 (5.5)</td><td>4 (3.7)</td><td>7 (7.6)</td></tr><tr><td>Medication for chronic metabolic diseases</td><td>97 (48.5)</td><td>45 (41.7)</td><td>52 (56.5)</td></tr></table>
<table><tr><td>p valuea</td></tr><tr><td></td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>0.002</td></tr><tr><td>n.s.</td></tr><tr><td></td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>0.02</td></tr><tr><td>0.04</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td></td></tr><tr><td>n.s.</td></tr><tr><td></td></tr><tr><td rowspan="5">n.s.</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td>0.04</td></tr></table>
dc3be347dbe2e3686f145b59300266612222e681157682f51c67596b34c00e14.png
complex
<table><tr><td>Chromosomal arm</td><td>Total no. informative SNPs with LOH</td><td>No. informative SNPs with LOH and CN = 1 (fraction)</td><td>No. informative SNPs with LOH and CN = 2 (fraction)</td><td>No. informative SNPs with LOH and CN = 3 or 4 (fraction)</td></tr><tr><td>1p</td><td>10,576</td><td>2,930 (0.28)</td><td>6,522 (0.62)</td><td>1,124 (0.11)</td></tr><tr><td>1q</td><td>8,366</td><td>459 (0.05)</td><td>7,674 (0.92)</td><td>233 (0.03)</td></tr><tr><td>2p</td><td>11,321</td><td>371 (0.03)</td><td>10,770 (0.95)</td><td>180 (0.02)</td></tr><tr><td>2q</td><td>23,115</td><td>3,015 (0.13)</td><td>18,939 (0.82)</td><td>1,161 (0.05)</td></tr><tr><td>3p</td><td>27,593</td><td>15,335 (0.56)</td><td>12,064 (0.44)</td><td>194 (0.01)</td></tr><tr><td>3q</td><td>7,256</td><td>41 (0.01)</td><td>4,168 (0.57)</td><td>3,047 (0.42)</td></tr><tr><td>4p</td><td>12,223</td><td>4,771 (0.39)</td><td>7,452 (0.61)</td><td>0 (0)</td></tr><tr><td>4q</td><td>28,105</td><td>9,142 (0.33)</td><td>17,905 (0.64)</td><td>1,958 (0.04)</td></tr><tr><td>5p</td><td>1,315</td><td>0 (0)</td><td>1,259 (0.96)</td><td>56 (0.04)</td></tr><tr><td>5q</td><td>16,537</td><td>7,744 (0.47)</td><td>8,777 (0.53)</td><td>16 (0)</td></tr><tr><td>6p</td><td>5,622</td><td>342 (0.06)</td><td>4,870 (0.87)</td><td>410 (0.07)</td></tr><tr><td>6q</td><td>3,365</td><td>165 (0.05)</td><td>2,773 (0.82)</td><td>427 (0.13)</td></tr><tr><td>7p</td><td>7,389</td><td>9 (0)</td><td>5,491 (0.74)</td><td>1,889 (0.26)</td></tr><tr><td>7q</td><td>8,001</td><td>151 (0.02)</td><td>6,452 (0.74)</td><td>1,398 (0.17)</td></tr><tr><td>8p</td><td>8,803</td><td>1,580 (0.18)</td><td>6,234 (0.71)</td><td>989 (0.11)</td></tr><tr><td>8q</td><td>17,321</td><td>47 (0)</td><td>4,633 (0.27)</td><td>12,641 (0.74)</td></tr><tr><td>9p</td><td>18,292</td><td>2,772 (0.15)</td><td>13,333 (0.73)</td><td>2,187 (0.12)</td></tr><tr><td>9q</td><td>31,400</td><td>1,965 (0.06)</td><td>27,212 (0.87)</td><td>2,223 (0.07)</td></tr><tr><td>10p</td><td>2,739</td><td>472 (0.17)</td><td>2,063 (0.75)</td><td>204 (0.07)</td></tr><tr><td>10q</td><td>14,651</td><td>1,728 (0.12)</td><td>12,075 (0.82)</td><td>848 (0.06)</td></tr><tr><td>11p</td><td>9,391</td><td>2,367 (0.25)</td><td>6,902 (0.73)</td><td>122 (0.01)</td></tr><tr><td>11q</td><td>17,377</td><td>5,116 (0.29)</td><td>10,422 (0.60)</td><td>1,839 (0.11)</td></tr><tr><td>12p</td><td>5,229</td><td>156 (0.03)</td><td>3,251 (0.62)</td><td>1,822 (0.34)</td></tr><tr><td>12q</td><td>6,794</td><td>67 (0.01)</td><td>5,980 (0.88)</td><td>747 (0.11)</td></tr><tr><td>13q</td><td>35,648</td><td>5,897 (0.17)</td><td>25,964 (0.73)</td><td>3,787 (0.11)</td></tr><tr><td>14q</td><td>10,931</td><td>1,484 (0.14)</td><td>7,446 (0.68)</td><td>2,001 (0.18)</td></tr><tr><td>15q</td><td>10,194</td><td>685 (0.07)</td><td>8,313 (0.82)</td><td>1,196 (0.12)</td></tr><tr><td>16p</td><td>1,395</td><td>111 (0.08)</td><td>1,284 (0.92)</td><td>0 (0)</td></tr><tr><td>16q</td><td>3,127</td><td>1 (0)</td><td>2,832 (0.91)</td><td>294 (0.09)</td></tr><tr><td>17p</td><td>7,719</td><td>324 (0.04)</td><td>6,939 (0.90)</td><td>456 (0.06)</td></tr><tr><td>17q</td><td>16,328</td><td>38 (0)</td><td>14,754 (0.90)</td><td>1,536 (0.09)</td></tr><tr><td>18p</td><td>2,596</td><td>488 (0.19)</td><td>1,147 (0.44)</td><td>961 (0.37)</td></tr><tr><td>18q</td><td>9,978</td><td>3,108 (0.31)</td><td>6,838 (0.69)</td><td>32 (0)</td></tr><tr><td>19p</td><td>1,069</td><td>1 (0)</td><td>1,065 (1.00)</td><td>3 (0)</td></tr><tr><td>19q</td><td>3,505</td><td>932 (0.27)</td><td>2,482 (0.71)</td><td>91 (0.03)</td></tr><tr><td>20p</td><td>1,278</td><td>0 (0)</td><td>229 (0.18)</td><td>1,049 (0.82)</td></tr><tr><td>20q</td><td>1,773</td><td>60 (0.03)</td><td>1,677 (0.95)</td><td>36 (0.02)</td></tr><tr><td>21q</td><td>9,444</td><td>3,825 (0.41)</td><td>5,599 (0.59)</td><td>20 (0)</td></tr><tr><td>22q</td><td>4,177</td><td>621 (0.15)</td><td>3,274 (0.80)</td><td>222 (0.05)</td></tr><tr><td colspan="2">Range (fraction SNPs with LOH)</td><td>0-0.56</td><td>0.18-1.00</td><td>0-0.82</td></tr><tr><td colspan="2">Median (fraction SNPs with LOH)</td><td>0.05</td><td>0.71</td><td>0.05</td></tr><tr><td colspan="2">Global average (fraction SNPs with LOH)</td><td>0.19</td><td>0.70</td><td>0.11</td></tr></table>
<table><tr><td>Chromosomal arm</td><td>Total no. informative SNPs with LOH</td><td>No. informative SNPs with LOH and CN = 1 (fraction)</td><td>No. informative SNPs with LOH and CN = 2 (fraction)</td><td>No. informative SNPs with LOH and CN = 3 or 4 (fraction)</td></tr><tr><td>1p</td><td>10,576</td><td>2,930 (0.28)</td><td>6,522 (0.62)</td><td>1,124 (0.11)</td></tr><tr><td>1q</td><td>8,366</td><td>459 (0.05)</td><td>7,674 (0.92)</td><td>233 (0.03)</td></tr><tr><td>2p</td><td>11,321</td><td>371 (0.03)</td><td>10,770 (0.95)</td><td>180 (0.02)</td></tr><tr><td>2q</td><td>23,115</td><td>3,015 (0.13)</td><td>18,939 (0.82)</td><td>1,161 (0.05)</td></tr><tr><td>3p</td><td>27,593</td><td>15,335 (0.56)</td><td>12,064 (0.44)</td><td>194 (0.01)</td></tr><tr><td>3q</td><td>7,256</td><td>41 (0.01)</td><td>4,168 (0.57)</td><td>3,047 (0.42)</td></tr></table>
<table><tr><td>4p</td><td>12,223</td><td>4,771 (0.39)</td><td>7,452 (0.61)</td><td>0 (0)</td></tr><tr><td>4q</td><td>28,105</td><td>9,142 (0.33)</td><td>17,905 (0.64)</td><td>1,958 (0.04)</td></tr><tr><td>5p</td><td>1,315</td><td>0 (0)</td><td>1,259 (0.96)</td><td>56 (0.04)</td></tr><tr><td>5q</td><td>16,537</td><td>7,744 (0.47)</td><td>8,777 (0.53)</td><td>16 (0)</td></tr><tr><td>6p</td><td>5,622</td><td>342 (0.06)</td><td>4,870 (0.87)</td><td>410 (0.07)</td></tr><tr><td>6q</td><td>3,365</td><td>165 (0.05)</td><td>2,773 (0.82)</td><td>427 (0.13)</td></tr><tr><td>7p</td><td>7,389</td><td>9 (0)</td><td>5,491 (0.74)</td><td>1,889 (0.26)</td></tr><tr><td>7q</td><td>8,001</td><td>151 (0.02)</td><td>6,452 (0.74)</td><td>1,398 (0.17)</td></tr><tr><td>8p</td><td>8,803</td><td>1,580 (0.18)</td><td>6,234 (0.71)</td><td>989 (0.11)</td></tr><tr><td>8q</td><td>17,321</td><td>47 (0)</td><td>4,633 (0.27)</td><td>12,641 (0.74)</td></tr><tr><td>9p</td><td>18,292</td><td>2,772 (0.15)</td><td>13,333 (0.73)</td><td>2,187 (0.12)</td></tr><tr><td>9q</td><td>31,400</td><td>1,965 (0.06)</td><td>27,212 (0.87)</td><td>2,223 (0.07)</td></tr><tr><td>10p</td><td>2,739</td><td>472 (0.17)</td><td>2,063 (0.75)</td><td>204 (0.07)</td></tr><tr><td>10q</td><td>14,651</td><td>1,728 (0.12)</td><td>12,075 (0.82)</td><td>848 (0.06)</td></tr><tr><td>11p</td><td>9,391</td><td>2,367 (0.25)</td><td>6,902 (0.73)</td><td>122 (0.01)</td></tr><tr><td>11q</td><td>17,377</td><td>5,116 (0.29)</td><td>10,422 (0.60)</td><td>1,839 (0.11)</td></tr><tr><td>12p</td><td>5,229</td><td>156 (0.03)</td><td>3,251 (0.62)</td><td>1,822 (0.34)</td></tr><tr><td>12q</td><td>6,794</td><td>67 (0.01)</td><td>5,980 (0.88)</td><td>747 (0.11)</td></tr><tr><td>13q</td><td>35,648</td><td>5,897 (0.17)</td><td>25,964 (0.73)</td><td>3,787 (0.11)</td></tr><tr><td>14q</td><td>10,931</td><td>1,484 (0.14)</td><td>7,446 (0.68)</td><td>2,001 (0.18)</td></tr><tr><td>15q</td><td>10,194</td><td>685 (0.07)</td><td>8,313 (0.82)</td><td>1,196 (0.12)</td></tr><tr><td>16p</td><td>1,395</td><td>111 (0.08)</td><td>1,284 (0.92)</td><td>0 (0)</td></tr><tr><td>16q</td><td>3,127</td><td>1 (0)</td><td>2,832 (0.91)</td><td>294 (0.09)</td></tr><tr><td>17p</td><td>7,719</td><td>324 (0.04)</td><td>6,939 (0.90)</td><td>456 (0.06)</td></tr><tr><td>17q</td><td>16,328</td><td>38 (0)</td><td>14,754 (0.90)</td><td>1,536 (0.09)</td></tr><tr><td>18p</td><td>2,596</td><td>488 (0.19)</td><td>1,147 (0.44)</td><td>961 (0.37)</td></tr><tr><td>18q</td><td>9,978</td><td>3,108 (0.31)</td><td>6,838 (0.69)</td><td>32 (0)</td></tr><tr><td>19p</td><td>1,069</td><td>1 (0)</td><td>1,065 (1.00)</td><td>3 (0)</td></tr><tr><td>19q</td><td>3,505</td><td>932 (0.27)</td><td>2,482 (0.71)</td><td>91 (0.03)</td></tr><tr><td>20p</td><td>1,278</td><td>0 (0)</td><td>229 (0.18)</td><td>1,049 (0.82)</td></tr><tr><td>20q</td><td>1,773</td><td>60 (0.03)</td><td>1,677 (0.95)</td><td>36 (0.02)</td></tr><tr><td>21q</td><td>9,444</td><td>3,825 (0.41)</td><td>5,599 (0.59)</td><td>20 (0)</td></tr><tr><td>22q</td><td>4,177</td><td>621 (0.15)</td><td>3,274 (0.80)</td><td>222 (0.05)</td></tr><tr><td colspan="2">Range (fraction SNPs with LOH)</td><td>0-0.56</td><td>0.18-1.00</td><td>0-0.82</td></tr><tr><td colspan="2">Median (fraction SNPs with LOH)</td><td>0.05</td><td>0.71</td><td>0.05</td></tr><tr><td colspan="2">Global average (fraction SNPs with LOH)</td><td>0.19</td><td>0.70</td><td>0.11</td></tr></table>
6a35034fd9bbab8693d4652b1c24b6602ea4a36e3440c927ae47068adaaf01f7.png
simple
<table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1&#8211;30 days)</td></tr><tr><td>Plastic</td><td>Attractive</td><td>Pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Good</td><td>Moderate</td><td>Long</td></tr><tr><td>Mosquito net</td><td>Attractive</td><td>Pleasant</td><td>Good</td><td>Good</td><td>Very hard</td><td>Good</td><td>High</td><td>Long</td></tr><tr><td>Glass</td><td>Very attractive</td><td>Pleasant</td><td>Very good</td><td>Very good</td><td>Very hard</td><td>Good</td><td>Very high</td><td>Longer</td></tr><tr><td>Aluminum</td><td>Attractive</td><td>Pleasant</td><td>Good</td><td>Good</td><td>Very hard</td><td>Good</td><td>High</td><td>Longer</td></tr><tr><td>Glass with black stone</td><td>Very attractive</td><td>Very pleasant</td><td>Very good</td><td>Very good</td><td>Very hard</td><td>Very good</td><td>Very high</td><td>Longest</td></tr><tr><td>Open-sun drying (control)</td><td>Not attractive</td><td>Not pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Fair</td><td>Low</td><td>Not long</td></tr></table>
<table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1–30 days)</td></tr><tr><td>Plastic</td><td>Attractive</td><td>Pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Good</td><td>Moderate</td><td>Long</td></tr><tr><td>Mosquito net</td><td>Attractive</td><td>Pleasant</td><td>Good</td><td>Good</td><td>Very hard</td><td>Good</td><td>High</td><td>Long</td></tr><tr><td>Glass</td><td>Very attractive</td><td>Pleasant</td><td>Very good</td><td>Very good</td><td>Very hard</td><td>Good</td><td>Very high</td><td>Longer</td></tr><tr><td>Aluminum</td><td>Attractive</td><td>Pleasant</td><td>Good</td><td>Good</td><td>Very hard</td><td>Good</td><td>High</td><td>Longer</td></tr></table>
<table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1–30 days)</td></tr><tr><td>Glass with black stone</td><td>Very attractive</td><td>Very pleasant</td><td>Very good</td><td>Very good</td><td>Very hard</td><td>Very good</td><td>Very high</td><td>Longest</td></tr><tr><td>Open-sun drying (control)</td><td>Not attractive</td><td>Not pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Fair</td><td>Low</td><td>Not long</td></tr></table>
d97c9fa4960ecf7d004a6cb7df773b91033af0a3b9e92542e463c5af5cd11820.png
simple
<table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>correct</td><td>94.7 (0.9)</td><td>92.0 (1.2)</td><td>82.5 (2.6)</td><td>92.0 (1.6)</td><td>82.1 (3.5)</td></tr><tr><td>semantics</td><td>97.6 (0.8)</td><td>94.2 (1.2)</td><td>94.5 (1.8)</td><td>93.1 (3.4)</td><td>84.1 (5.9)</td></tr><tr><td>syntax</td><td>95.5 (1.9)</td><td>77.3 (4.2)</td><td>80.5 (4.5)</td><td>27.8 (11.6)</td><td>34.3 (10.6)</td></tr></table>
<table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>correct</td><td>94.7 (0.9)</td><td>92.0 (1.2)</td><td>82.5 (2.6)</td><td>92.0 (1.6)</td><td>82.1 (3.5)</td></tr><tr><td>semantics</td><td>97.6 (0.8)</td><td>94.2 (1.2)</td><td>94.5 (1.8)</td><td>93.1 (3.4)</td><td>84.1 (5.9)</td></tr></table>
<table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>syntax</td><td>95.5 (1.9)</td><td>77.3 (4.2)</td><td>80.5 (4.5)</td><td>27.8 (11.6)</td><td>34.3 (10.6)</td></tr></table>